

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 21, 2004, 09:14:54 ; Search time 2.63862 Seconds
(without alignments)
601.551 Million cell updates/sec

Title: US-09-869-414A-64
Perfect score: 49
Sequence: 1 SEVKMDAEFR 10

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_19Jun03:*

- 1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
- 2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
- 3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
- 4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
- 5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
- 6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
- 7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
- 8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
- 9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
- 10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
- 11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
- 12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
- 13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
- 14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
- 15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
- 16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
- 17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
- 18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
- 19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
- 20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
- 21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
- 22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
- 23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
- 24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed,

and is derived by analysis of the total score distribution.

SUMMARIES

Result	% Query					Description
	No.	Score	Match	Length	ID	
1	49	100.0	10	13	AAR24261	Human amyloidin pr
2	49	100.0	10	21	AAY69703	Beta-APP alpha-sec
3	49	100.0	10	22	AAE10654	Human wild-type AP
4	49	100.0	10	22	AAE06899	Human amyloid prec
5	49	100.0	10	22	AAU06628	Asp2 recognition s
6	49	100.0	10	22	AAU07227	Human beta-amyloid
7	49	100.0	10	22	AAE02606	Human wild-type AP
8	49	100.0	10	22	AAB66574	Synthetic peptide
9	49	100.0	10	22	AAB46208	Human APP derived
10	49	100.0	10	22	AAB61336	Sythetic peptide f
11	49	100.0	10	23	ABG78375	Human beta amyloid
12	49	100.0	10	23	ABG30940	Nogo/BACE method c
13	49	100.0	10	23	AAU99490	Peptide #1 used as
14	49	100.0	10	23	ABB78615	Beta-secretase spe
15	49	100.0	10	23	ABB06426	Human APP beta-sec
16	49	100.0	10	24	ABG76103	Amyloid precursor
17	49	100.0	11	22	AAB75143	APP beta-secretase
18	49	100.0	11	22	AAB75144	Asp 1 substrate se
19	49	100.0	11	22	AAB97468	Asp2 substrate wil
20	49	100.0	12	23	ABB08997	Amyloid precursor
21	49	100.0	12	23	ABB07592	Biotinylated synth
22	49	100.0	12	23	AAE16657	APP substrate pept
23	49	100.0	12	23	AAU74831	Synthetic amyloid
24	49	100.0	12	24	AAO26795	Beta-secretase sub
25	49	100.0	13	19	AAW70869	Beta-amyloid pepti
26	49	100.0	13	23	AAM50891	Fluorescent substr
27	49	100.0	13	24	ABP71624	Beta-secretase act
28	49	100.0	13	24	ABG75934	Synthetic Amyloid
29	49	100.0	13	24	ABP71462	Beta-secretase act
30	49	100.0	13	24	ABP71263	Synthetic APP subs
31	49	100.0	13	24	AAO16443	Beta-secretase syn
32	49	100.0	13	24	ABP57078	Synthetic amyloid
33	49	100.0	13	24	ABP58369	Synthetic amyloid
34	49	100.0	16	21	AAB06315	Human beta-amyloid
35	49	100.0	16	21	AAB06317	Human beta-amyloid
36	49	100.0	18	22	AAE00608	Beta-amyloid precu
37	49	100.0	20	21	AAY69713	Beta-APP alpha-sec
38	49	100.0	23	22	AAB75147	Asp 1 substrate se
39	49	100.0	23	22	AAB97473	Asp2 substrate wil
40	49	100.0	33	20	AAW98002	Amyloid precursor
41	49	100.0	39	21	AAY69717	Beta-APP alpha-sec
42	49	100.0	45	18	AAW26512	Amyloid precursor
43	49	100.0	45	18	AAW26392	Amyloid precursor
44	49	100.0	45	19	AAW44748	APP-REP 751 [BAP d
45	49	100.0	45	19	AAW42977	Deletion beta-amyl

ALIGNMENTS

RESULT 1

AAR24261

ID AAR24261 standard; Protein; 10 AA.

XX

AC AAR24261;

XX

DT 25-MAR-2003 (updated)

DT 09-NOV-1992 (first entry)

XX

DE Human amyloidin protease substrate sequence #1.

XX

KW Alzheimer's disease; beta amyloid precursor protein; APP; zinc;

KW metalloprotease; hAP; protease inhibitor; APP592-601

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "Acetylated-Ser"

XX

PN WO9207068-A1.

XX

PD 30-APR-1992.

XX

PF 04-OCT-1991; 91WO-US07290.

XX

PR 05-OCT-1990; 90US-0594122.

PR 30-SEP-1991; 91US-0766351.

XX

PA (ATHE-) ATHENA NEUROSCIENCES INC.

PA (ELIL) LILLY & CO ELI.

XX

PI Dovey HF, Johnstone EM, Little SP, McConlogue L, Seubert PA;

PI Sinha S;

XX

DR WPI; 1992-167148/20.

XX

PT Human amyloidin protease - used for cleaving Met-Asp bond in

PT amyloid-like substrate for identifying protease inhibitors

XX

PS Claim 1; Page 52; 62pp; English.

XX

CC Claimed human amyloidin protease is defined by its ability to
 CC cleave the Met-Asp bond of this synthetic substrate. The substrate,
 CC which corresponds to residues 592 to 601 of the 695 amino acid APP,
 CC can be used in an assay for identifying inhibitors of proteases
 CC which cleave Met-Asp bonds, e.g. amyloidin, human skin chymase or
 CC rat mast cell protease I or II.

CC See AAR24260-3, AAR24266-7 and AAQ24875-Q24887.

CC (Updated on 25-MAR-2003 to correct PN field.)

XX

SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 13; Length 10;

Best Local Similarity 100.0%; Pred. No. 0.00059;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 1 SEVKMDAEFR 10

RESULT 2

AA69703

ID AAY69703 standard; peptide; 10 AA.
XX
AC AAY69703;
XX
DT 11-APR-2000 (first entry)
XX
DE Beta-APP alpha-secretase substrate [KMD]-APP(-5,+5).
XX
KW Nootropic; neuroprotective; beta-amyloid precursor protein; metabolism;
KW cleavage site; beta-secretase; neurodegenerative disease;
KW Alzheimer's disease.
XX
OS Homo sapiens.
XX
PN WO9964587-A1.
XX
PD 16-DEC-1999.
XX
PF 04-JUN-1999; 99WO-FR01326.
XX
PR 05-JUN-1998; 98FR-0007068.
PR 31-MAR-1999; 99US-0122599.
XX
PA (RHON) RHONE-POULENC RORER SA.
PA (UYPA-) UNIV CURIE PARIS VI P & M.
XX
PI Rholam M, Munoz-Gimenez N, Moutaouakil M, Cohen P, Bertrand P;
XX
DR WPI; 2000-097537/08.
XX
PT Polypeptide with beta-secretase activity, specific for wild-type
PT amyloid precursor protein, useful in treating Alzheimer's disease -
XX
PS Example 3; Page 24; 44pp; French.
XX
CC Peptides AAY69702-Y69718 represent synthetic peptide substrates for a
CC novel polypeptide with beta-secretase activity that can cleave
CC specifically the natural beta-amyloid precursor protein (bAPP). Normal
CC cleavage of the protein occurs between amino acids Met596-Asp597 and
CC Val636-Ile637 (positions 4-5 and 44-45 of AAY69701). The novel
CC polypeptide is used to identify agents that interact specifically with
CC it. These agents regulate metabolism of APP, particularly they slow down
CC or reduce production of beta-amyloid, so can be used to treat
CC neurodegenerative diseases, particularly Alzheimer's disease.
XX
SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00059;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | |
Db 1 SEVKMDAEFR 10

RESULT 3

AAE10654

ID AAE10654 standard; peptide; 10 AA.
XX
AC AAE10654;
XX
DT 10-DEC-2001 (first entry)
XX
DE Human wild-type APP beta-secretase peptide, PHA-95812E.
XX
KW Human; aspartyl protease 1; Aspl; amyloid precursor protein;
KW Alzheimer's disease; AD; dementia; neurofibrillary tangle; gliosis;
KW amyloid plaque; neuronal loss; proteolytic; nootropic; neuroprotective;
KW APP beta-secretase peptide.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Cleavage-site 5..6
XX
PN GB2357767-A.
XX
PD 04-JUL-2001.
XX
PF 22-SEP-2000; 2000GB-0023315.
XX
PR 23-SEP-1999; 99US-0155493.
PR 23-SEP-1999; 99US-0404133.
PR 23-SEP-1999; 99WO-US20881.
PR 13-OCT-1999; 99US-0416901.
PR 06-DEC-1999; 99US-0169232.
XX
PA (PHAA) PHARMACIA & UPJOHN CO.
XX
PI Bienkowski MJ, Gurney M;
XX
DR WPI; 2001-444208/48.
XX
PT Polypeptide comprising fragments of human aspartyl protease with
PT amyloid precursor protein processing activity and alpha-secretase
PT activity, for identifying modulators useful in treating Alzheimer's
PT disease -
XX
PS Example 12; Page 84; 187pp; English.
XX
CC The patent discloses human aspartyl protease 1 (hu-Aspl) or modified
CC Aspl proteins which lack transmembrane domain or amino terminal
CC domain or cytoplasmic domain and retains alpha-secretase activity
CC and amyloid protein precursor (APP) processing activity. The proteins
CC of the invention are useful for assaying hu-Aspl alpha-secretase
CC activity, which in turn is useful for identifying modulators of

CC hu-Asp1 alpha-secretase activity, where modulators that increase
 CC hu-Asp1 alpha-secretase activity are useful for treating Alzheimer's
 CC disease (AD) which causes progressive dementia with consequent
 CC formation of amyloid plaques, neurofibrillary tangles, gliosis and
 CC neuronal loss. Hu-Asp1 protease substrate is useful for assaying
 CC hu-Asp1 proteolytic activity, by contacting hu-Asp1 protein with
 CC the substrate under acidic conditions and determining the level of
 CC hu-Asp1 proteolytic activity. The present sequence is wild-type
 CC human amyloid precursor protein (APP) beta-secretase specific
 CC substrate peptide, PHA-95812E. This peptide is used for assaying
 CC the beta-secretase activity of human Aspartyl protease 2a (Asp2a)
 CC protein. The peptide is also used for determining the relationship
 CC between Aspartyl protease 1 (Asp1) and APP protein.

XX

SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 22; Length 10;

Best Local Similarity 100.0%; Pred. No. 0.00059;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SEVKMDAEFR 10

|||||

Db 1 SEVKMDAEFR 10

RESULT 4

AAE06899

ID AAE06899 standard; peptide; 10 AA.

XX

AC AAE06899;

XX

DT 23-OCT-2001 (first entry)

XX

DE Human amyloid precursor protein wild-type beta-secretase peptide.

XX

KW Human; aspartyl protease 2; Asp 2; beta-amyloid precursor protein; APP;

KW beta-secretase; Alzheimer's disease; dementia; amyloid plaque; gliosis;

KW neurofibrillary tangle; neuronal loss; amyloid-beta peptide; nootropic;

KW neuroprotective; antisense therapy; gene therapy.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Cleavage-site 5..6

XX

PN WO200150829-A2.

XX

PD 19-JUL-2001.

XX

PF 09-MAY-2001; 2001WO-IB00799.

XX

PR 09-MAY-2001; 2001WO-IB00799.

XX

PA (BIEN/) BIENKOWSKI M J.

PA (GURN/) GURNEY M E.

PA (HEIN/) HEINRIKSON R L.

PA (PARO/) PARODI L A.

PA (YANR/) YAN R.
 XX
 PI Bienkowski MJ, Gurney ME, Heinrikson RL, Parodi LA, Yan R;
 XX
 DR WPI; 2001-483072/52.
 XX
 PT Novel purified polypeptide comprising fragment of mammalian aspartyl
 PT protease 2, lacking Asp2 transmembrane domain and retaining beta
 PT secretase activity of Asp2 useful for identifying inhibitors of Asp2
 PT activity -
 XX
 PS Claim 127; Page 80; 185pp; English.
 XX
 CC The invention relates to human aspartyl proteases (Hu-Asp), beta-amyloid
 CC precursor protein (APP) isoforms and their corresponding DNA molecules.
 CC Human aspartyl proteases can act as beta-secretase proteases useful for
 CC treating Alzheimer's disease. APP isoforms are useful for identifying
 CC modulators of amyloid-beta peptide production, for use in designing
 CC therapeutics for the treatment and prevention of Alzheimer's disease,
 CC dementia, formation of amyloid plaques, neurofibrillary tangles, gliosis
 CC and neuronal loss. APP isoforms are also used in methods for identifying
 CC inhibitors and modulators of human Asp2 activity. The invention relates
 CC to a method for identifying agents that modulate the activity of human
 CC aspartyl protease Asp2. Amyloid-beta peptides obtained from APP are used
 CC as a means to screen in cellular assays for the inhibitors of beta- and
 CC gamma- secretase. Hu-Asp DNA fragments are useful as probes or primers in
 CC polymerase chain reactions (PCR). The probes are useful for detecting
 CC Hu-Asp nucleic acids in in vitro assays and in Northern and Southern
 CC blots. The present sequence is human amyloid precursor protein (APP)
 CC wild type beta-secretase peptide used in beta-secretase assay.
 XX
 SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 22; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.00059;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 1 SEVKMDAEFR 10

RESULT 5

AAU06628

ID AAU06628 standard; Peptide; 10 AA.

XX

AC AAU06628;

XX

DT 24-OCT-2001 (first entry)

XX

DE Asp2 recognition site from wild-type APP.

XX

KW Aspartyl protease; Asp2; beta-secretase; nootropic;

KW neuroprotective; amyloid protein precursor; APP; Alzheimer's disease;

KW amyloid-beta; Abeta.

XX

OS Homo sapiens.

XX
 FH Key Location/Qualifiers
 FT Cleavage-site 5
 FT /label= Asp2_protease_cleavage_site
 XX
 PN WO200149098-A2.
 XX
 PD 12-JUL-2001.
 XX
 PF 09-MAY-2001; 2001WO-IB00798.
 XX
 PR 09-MAY-2001; 2001WO-IB00798.
 XX
 PA (BIEN/) BIENKOWSKI M J.
 PA (GURN/) GURNEY M E.
 PA (HEIN/) HEINRIKSON R L.
 PA (PARO/) PARODI L A.
 PA (YANR/) YAN R.
 XX
 PI Bienkowski MJ, Gurney ME, Heinrikson RL, Parodi LA, Yan R;
 XX
 DR WPI; 2001-502549/55.
 XX
 PT Novel purified polypeptide comprising fragment of mammalian aspartyl
 PT protease 2, lacking Asp2 transmembrane domain and retaining beta
 PT secretase activity of Asp2 useful for identifying inhibitors of Asp2
 PT activity -
 XX
 PS Claim 127; Page 101; 185pp; English.
 XX
 CC The invention relates to a purified polypeptide comprising a fragment of
 CC mammalian aspartyl protease (Asp)2 protein which lacks the Asp2
 CC transmembrane domain and the Asp2 protein, and where the polypeptide and
 CC the fragment retain the beta-secretase activity of the mammalian Asp2
 CC protein. The invention also details polynucleotides for the Asp
 CC proteins and vectors expressing them, and a polypeptide (isoform of
 CC amyloid protein precursor (APP)) comprising the amino acid sequence of an
 CC APP or its fragment containing an APP cleavage site recognizable by a
 CC mammalian beta-secretase, and further comprising two lysine residues at
 CC the carboxyl terminus of the amino acid sequence of the mammalian APP or
 CC APP fragment. Also included in the invention are methods of identifying
 CC modulators or inhibitors of Asp2. Modulators and inhibitors of Asp2 are
 CC useful for treating Alzheimer's disease. APP is useful in methods for
 CC identifying inhibitors or modulators of human Asp2 activity and
 CC amyloid-beta (Abeta) peptide production. APP is also useful in designing
 CC therapeutics for the treatment or prevention of Alzheimer's disease.
 CC APP comprising the APP-Sw-beta-secretase peptide sequence (NLDA), which
 CC is associated with increased levels of Abeta processing is useful in
 CC assays relating the Alzheimer's research. The expression vector is useful
 CC for recombinantly expressing APP. Nucleic acids that hybridise to
 CC Asp oligonucleotides are useful as probes or primers. The probes are
 CC useful for detecting Hu-Asp nucleic acids in in vitro assays and in
 CC Northern and Southern blots. The present sequence is a peptide substrate
 CC for Asp2 corresponding to the wild-type APP beta-secretase site.
 XX
 SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 22; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00059;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||||
Db 1 SEVKMDAEFR 10

RESULT 6

AAU07227

ID AAU07227 standard; Peptide; 10 AA.

XX

AC AAU07227;

XX

DT 24-OCT-2001 (first entry)

XX

DE Human beta-amyloid protein precursor, APP-beta40 and 42 secretase site.

XX

KW Human; aspartyl protease 1; Asp-1; nootropic; neuroprotective;

KW aspartyl protease 2; Asp2; amyloid protein precursor; APP;

KW beta-secretase; Alzheimer's disease; APP-beta40; APP-beta42.

XX

OS Homo sapiens.

XX

PN WO200149097-A2.

XX

PD 12-JUL-2001.

XX

PF 09-MAY-2001; 2001WO-IB00797.

XX

PR 09-MAY-2001; 2001WO-IB00797.

XX

PA (BIEN/) BIENKOWSKI M J.

PA (GURN/) GURNEY M E.

PA (HEIN/) HEINRIKSON R L.

PA (PARO/) PARODI L A.

PA (YANR/) YAN R.

XX

PI Bienkowski MJ, Gurney ME, Heinrikson RL, Parodi LA, Yan R;

XX

DR WPI; 2001-502548/55.

XX

PT Novel purified polypeptide comprising fragment of mammalian aspartyl
PT protease 2, lacking Asp2 transmembrane domain and retaining beta
PT secretase activity of Asp2 useful for identifying inhibitors of Asp2
PT activity -

XX

PS Claim 127; Page 101; 185pp; English.

XX

CC The invention relates to a novel purified polypeptide comprising a
CC fragment of mammalian aspartyl protease 2 (Asp2) protein which lacks the
CC Asp2 transmembrane domain and the Asp2 protein, and where the polypeptide
CC and the fragment retain the beta-secretase activity of the mammalian Asp2
CC protein. Also included is an isoform of amyloid protein precursor (APP)
CC comprising the amino acid sequence of a APP or its fragment containing
CC an APP cleavage site recognisable by a mammalian beta-secretase, and

CC further comprising two lysine residues at the carboxyl terminus of the
 CC amino acid sequence of the mammalian APP or APP fragment. The
 CC polypeptides are used for assaying for modulators of beta-secretase
 CC activity; identifying agents that inhibit the APP processing activity
 CC of human Asp2 aspartyl protease (Hu-Asp2); identifying agents that
 CC modulate the activity of Asp2; and for reducing cellular production of
 CC amyloid beta (Abeta) from APP. Agents identified by the above methods
 CC are useful for treating Alzheimer's disease; and for identifying
 CC modulators of amyloid-beta (Abeta) peptide production, for use in
 CC designing therapeutics for the treatment or prevention of Alzheimer's
 CC disease. Probes and primers derived from Asp nucleic acid sequences
 CC are useful for detecting Hu-Asp nucleic acids in in vitro assays and in
 CC Northern and Southern blots. The present sequence represents the
 CC amino acid sequence of human amyloid protein precursor, APP-beta40
 CC and APP-beta42 secretase sites.

XX

SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 22; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.00059;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 1 SEVKMDAEFR 10

RESULT 7

AAE02606

ID AAE02606 standard; peptide; 10 AA.

XX

AC AAE02606;

XX

DT 10-AUG-2001 (first entry)

XX

DE Human wild-type APP beta-secretase substrate peptide, PHA-95812E.

XX

KW Human; alpha-secretase; amyloid precursor protein; APP; therapy;

KW Alzheimer's disease; antialzheimer's; aspartyl protease 2a; Asp2a;

KW beta-secretase.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Cleavage-site 5..6

XX

PN WO200123533-A2.

XX

PD 05-APR-2001.

XX

PF 22-SEP-2000; 2000WO-US26080.

XX

PR 23-SEP-1999; 99US-0155493.

PR 23-SEP-1999; 99WO-US20881.

PR 13-OCT-1999; 99US-0416901.

PR 06-DEC-1999; 99US-0169232.

XX

PA (PHAA) PHARMACIA & UPJOHN CO.
 XX
 PI Gurney M, Bienkowski MJ;
 XX
 DR WPI; 2001-290516/30.
 XX
 PT Enzymes that cleave the alpha-secretase site of the amyloid precursor
 PT protein, useful for the treatment of Alzheimer's disease -
 XX
 PS Example 12; Page 85; 189pp; English.
 XX
 CC The present invention relates to enzymes for cleaving the alpha-
 CC secretase site of the amyloid precursor protein (APP) and methods of
 CC identifying those enzymes. The methods may be used to identify enzymes
 CC that may be used to cleave the alpha-secretase cleavage site of the APP
 CC protein. The enzymes may be used to treat or modulate the progress of
 CC Alzheimer's disease. The present sequence is human wild-type amyloid
 CC precursor protein (APP) beta-secretase specific substrate peptide,
 CC PHA-95812E. This peptide is used for assaying the beta-secretase activity
 CC of human Aspartyl protease 2a (Asp2a) protein. The peptide is also used
 CC for determining the relationship between Aspartyl protease 1 (Asp1) and
 CC APP protein.
 XX
 SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 22; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.00059;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 1 SEVKMDAEFR 10

RESULT 8

AAB66574

ID AAB66574 standard; Peptide; 10 AA.

XX

AC AAB66574;

XX

DT 12-APR-2001 (first entry)

XX

DE Synthetic peptide derived from APP beta-secretase site.

XX

KW Memapsin 2; nootropic; neuroprotective; amyloid precursor protein;

KW APP; memapsin 2 inhibitor; Alzheimer's disease.

XX

OS Synthetic.

XX

PN WO200100665-A2.

XX

PD 04-JAN-2001.

XX

PF 27-JUN-2000; 2000WO-US17742.

XX

PR 28-JUN-1999; 99US-0141363.

PR 30-NOV-1999; 99US-0168060.

PR 25-JAN-2000; 2000US-0177836.
 PR 27-JAN-2000; 2000US-0178368.
 PR 08-JUN-2000; 2000US-0210292.
 XX
 PA (OKLA-) OKLAHOMA MEDICAL RES FOUND.
 PA (UNII) UNIV ILLINOIS FOUND.
 XX
 PI Tang JJN, Hong L, Ghosh AK;
 XX
 DR WPI; 2001-137933/14.
 XX
 PT Novel memapsin 2 inhibitors which bind to active site of memapsin 2
 PT having 2 catalytic aspartic residues and substrate binding cleft, used
 PT to treat Alzheimer's disease by blocking amyloid precursor protein
 PT cleavage -
 XX
 PS Disclosure; Page 11; 86pp; English.
 XX
 CC The present sequence is given in a specification relating to an inhibitor
 CC of catalytically active memapsin 2. The inhibitor binds to the memapsin 2
 CC active site, which is defined by the presence of two catalytic aspartic
 CC residues and a substrate binding cleft. The inhibitor is useful for
 CC the treatment and diagnosis of Alzheimer's disease. It is useful in
 CC screens for individuals with a genetic predisposition to Alzheimer's
 CC disease. The inhibitor is useful as a reagent for specifically binding to
 CC memapsin 2 or memapsin 2 analogues and for aiding in memapsin 2
 CC isolation, purification and characterisation.
 XX
 SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 22; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.00059;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 1 SEVKMDAEFR 10

RESULT 9

AAB46208

ID AAB46208 standard; peptide; 10 AA.

XX

AC AAB46208;

XX

DT 04-APR-2001 (first entry)

XX

DE Human APP derived immunogenic peptide #4.

XX

KW Amyloid deposit; APP; Abeta; brain; human; clearing response; nootropic;

KW Fc receptor mediated phagocytosis; immunogenic response; neuroprotective;

KW amyloid precursor protein; Alzheimer's disease.

XX

OS Homo sapiens.

XX

PN WO200072880-A2.

XX

PD 07-DEC-2000.
 XX
 PF 26-MAY-2000; 2000WO-US14810.
 XX
 PR 28-MAY-1999; 99US-0322289.
 XX
 PA (NEUR-) NEURALAB LTD.
 XX
 PI Schenk DB, Bard F, Vasquez NJ, Yednock T;
 XX
 DR WPI; 2001-032104/04.
 XX
 PT Preventing or treating a disease associated with amyloid deposits,
 PT especially Alzheimer's disease, comprises administering amyloid
 PT specific antibody -
 XX
 PS Disclosure; Figure 19; 143pp; English.
 XX
 CC This invention describes a novel method of preventing or treating a
 CC disease associated with amyloid deposits of amyloid precursor protein
 CC (APP) Abeta fragments in the brain of a patient, which comprises
 CC administering to the patient: (a) an antibody that binds to Abeta, the
 CC antibody binds to an amyloid deposit and induces a clearing response (Fc
 CC receptor mediated phagocytosis) against it (b) a polypeptide containing
 CC an N-terminal segment of at least residues 1-5 of Abeta; or (c) an agent
 CC that induces an immunogenic response against residues 1-3 to 7-11 of
 CC Abeta. The products of the invention have nootropic and neuroprotective
 CC activity. The method is also useful for monitoring a course of treatment
 CC being administered to a patient e.g. active and passive immunization. The
 CC methods are useful for prophylactic and therapeutic treatment of
 CC Alzheimer's disease.
 XX
 SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 22; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.00059;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 1 SEVKMDAEFR 10

RESULT 10

AAB61336

ID AAB61336 standard; peptide; 10 AA.

XX

AC AAB61336;

XX

DT 02-APR-2001 (first entry)

XX

DE Synthetic peptide from beta amyloid precursor protein.

XX

KW Memapsin 2; catalyst; Alzheimer's.

XX

OS Unidentified.

XX

PN WO200100663-A2.
 XX
 PD 04-JAN-2001.
 XX
 PF 27-JUN-2000; 2000WO-US17661.
 XX
 PR 28-JUN-1999; 99US-0141363.
 PR 30-NOV-1999; 99US-0168060.
 PR 25-JAN-2000; 2000US-0177836.
 PR 27-JAN-2000; 2000US-0178368.
 PR 08-JUN-2000; 2000US-0210292.
 XX
 PA (OKLA-) OKLAHOMA MEDICAL RES FOUND.
 XX
 PI Tang JJN, Lin X, Koelsch G;
 XX
 DR WPI; 2001-102885/11.
 XX
 PT Purified recombinant catalytically active memapsin 2, used to screen
 PT inhibitors of it, which are used to treat and prevent Alzheimer's
 PT disease -
 XX
 PS Claim 6; Page 11; 86pp; English.
 XX
 CC The present invention relates to a purified recombinant
 CC catalytically active memapsin 2. The invention may be used for
 CC isolating inhibitors which are used to treat or prevent
 CC Alzheimer's disease. The invention may also be used to screen
 CC for individuals more genetically prone to develop Alzheimer's
 CC disease.
 XX
 SQ Sequence 10 AA;

 Query Match 100.0%; Score 49; DB 22; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.00059;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 1 SEVKMDAEFR 10

RESULT 11

ABG78375

ID ABG78375 standard; Peptide; 10 AA.

XX

AC ABG78375;

XX

DT 15-NOV-2002 (first entry)

XX

DE Human beta amyloid precursor protein beta secretase site #1.

XX

KW Human; memapsin 2; aspartic protease; beta secretase;

KW degenerative disease; Alzheimer's disease; amyloid precursor protein;

KW APP; neuroprotective; nootropic; inhibitor; cleavage site;

KW substrate side-chain preference.

XX

OS Homo sapiens.
 XX
 PN WO200253594-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 28-DEC-2001; 2001WO-US50826.
 XX
 PR 28-DEC-2000; 2000US-258705P.
 PR 14-MAR-2001; 2001US-275756P.
 XX
 PA (OKLA-) OKLAHOMA MEDICAL RES FOUND.
 PA (UNII) UNIV ILLINOIS FOUND.
 XX
 PI Tang JJN, Koelsch G, Ghosh AK;
 XX
 DR WPI; 2002-619088/66.
 XX
 PT New memapsin 2 activity inhibitor useful in treatment of e.g.
 PT Alzheimer's disease -
 XX
 PS Disclosure; Page 23; 74pp; English.
 XX
 CC The invention relates to an inhibitor of catalytically active memapsin 2
 CC (an aspartic protease which can cleave at beta secretase sites), which
 CC binds to the active site of memapsin 2 defined by the presence of two
 CC catalytic aspartic residues and substrate binding cleft. Also
 CC included is a method of determination of the substrate side-chain
 CC preference in memapsin 2 sub-sites comprising: (a) reacting a mixture of
 CC memapsin 2 substrates with memapsin 2, and determining the sub-site
 CC preference of memapsin 2 by determining relative initial hydrolysis rates
 CC of the mixture of memapsin 2 substrates; or (b) preparing a combinatorial
 CC library of memapsin 2 inhibitors containing a base sequence taken from
 CC OM99-2 (Glu-Val-Asn-Leu-Ala-Ala-Glu-phe), probing the library of
 CC inhibitors with memapsin 2 which binds to several inhibitors to generate
 CC several bound memapsin 2, and detecting the bound memapsin 2 with an
 CC antibody raised to memapsin 2 and an alkaline phosphatase conjugated
 CC secondary antibody. The inhibitors may be used in the manufacture of a
 CC medicament for the treatment of Alzheimer's disease since memapsin 2 may
 CC be involved in the cleavage of amyloid precursor protein (APP), and for
 CC determining the substrate side-chain preference in memapsin 2 sub-sites.
 CC The present sequence represents a beta secretase cleavage site used
 CC to determine the substrate specificity of human memapsin 2.
 XX
 SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 23; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.00059;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 1 SEVKMDAEFR 10

RESULT 12
 ABG30940

ID ABG30940 standard; Peptide; 10 AA.
XX
AC ABG30940;
XX
DT 21-OCT-2002 (first entry)
XX
DE Nogo/BACE method cleavage peptide #1.
XX
KW Human; Nogo; BACE; acute neuronal injury; spinal injury; head injury;
KW stroke; peripheral nerve damage; neoplastic disorder; glioblastoma;
KW neuroblastoma; hyperproliferative disorder; dysproliferative disorder;
KW cirrhosis; psoriasis; keloid formation; fibrocystic condition; cancer;
KW tissue hypertrophy; central nervous system; axon regeneration;
KW Nogo-associated disease; metastasis; cleavage peptide.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
FT Cleavage-site 5..6
FT /note= "Beta-secretase cleavage site"
XX
PN WO200257483-A2.
XX
PD 25-JUL-2002.
XX
PF 18-JAN-2002; 2002WO-GB00228.
XX
PR 18-JAN-2001; 2001GB-0001312.
XX
PA (GLAX) GLAXO GROUP LTD.
PA (SMIK) SMITHKLINE BEECHAM PLC.
XX
PI Blackstock WP, Hale RS, Prinjha R, Rowley A;
XX
DR WPI; 2002-599722/64.
XX
PT Identifying modulators of Nogo or BACE activity for treating acute
PT neuronal injuries, neoplastic or dysproliferative disorders, comprises
PT providing and monitoring interaction between Nogo and BACE polypeptides
PT -
XX
PS Disclosure; Page 14; 68pp; English.
XX
CC The present invention relates to a new method of identifying modulators
CC of Nogo function or BACE activity. The method involves providing Nogo and
CC BACE polypeptides capable of binding with each other, monitoring the
CC interaction between these polypeptides, and determining if the test agent
CC is a modulator of Nogo or BACE activity. The method is useful in treating
CC acute neuronal injuries, such as spinal or head injury, stroke,
CC peripheral nerve damage, and in neoplastic (e.g. glioblastomas,
CC neuroblastomas), hyperproliferative or dysproliferative disorders (e.g.
CC cirrhosis, psoriasis, keloid formation, fibrocystic conditions, tissue
CC hypertrophy) of the central nervous system. The BACE polypeptide is
CC useful in screening methods to identify agents that may act as modulators
CC of BACE activity and in particular agents that may be useful in treating
CC Nogo-associated diseases. The modulators of Nogo or BACE polypeptides,
CC and the polynucleotide encoding the BACE polypeptide are useful in

CC manufacturing a medicament for the treatment or prevention of disorders
 CC responsive to the modulation of Nogo activity, in alleviating the
 CC symptoms or improving the condition of a patient suffering from this
 CC disorder, in axon regeneration, or in preventing metastasis or spreading
 CC of a cancer. The polynucleotide may also be an essential component in
 CC assays, a probe, in recombinant protein synthesis, and in gene therapy
 CC techniques. The present amino acid sequence represents a cleavage peptide
 CC that was used in the methods of the invention.
 XX
 SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 23; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.00059;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 1 SEVKMDAEFR 10

RESULT 13

AAU99490

ID AAU99490 standard; peptide; 10 AA.

XX

AC AAU99490;

XX

DT 07-OCT-2002 (first entry)

XX

DE Peptide #1 used as substrate for human memapsin 2.

XX

KW Human; memapsin 2; beta secretase; aspartic protease; APP;

KW beta-amyloid precursor protein; amyloid plaque; Alzheimer's disease;

KW neuroprotective; nootropic.

XX

OS Homo sapiens.

OS Synthetic.

XX

PN US2002049303-A1.

XX

PD 25-APR-2002.

XX

PF 28-FEB-2001; 2001US-0796264.

XX

PR 28-JUN-1999; 99US-141363P.

PR 30-NOV-1999; 99US-168060P.

PR 25-JAN-2000; 2000US-177836P.

PR 27-JAN-2000; 2000US-178368P.

PR 27-JUN-2000; 2000US-0604608.

XX

PA (TANG/) TANG J J N.

PA (LINX/) LIN X.

PA (KOEL/) KOELSCH G.

PA (HONG/) HONG L.

XX

PI Tang JJN, Lin X, Koelsch G, Hong L;

XX

DR WPI; 2002-507280/54.

XX
PT New recombinant catalytically active memapsin 2, useful to screen for
PT inhibitors of memapsin 2 which can be used to prevent and treat
PT Alzheimer's disease -
XX
PS Claim 6; Page 30; 44pp; English.
XX
CC The present invention relates to methods for the production of
CC purified, recombinant catalytically active, memapsin 2 (beta
CC secretase). Memapsin 2, a member of the aspartic protease family,
CC cleaves beta-amyloid precursor protein (APP) found in amyloid plaques.
CC The recombinant memapsin 2 is useful for identifying inhibitors of
CC memapsin 2 in the design of drugs for the treatment and/or prevention
CC of Alzheimer's disease. The recombinant memapsin 2 can be used to
CC immunise against Alzheimer's disease. The present sequence represents
CC a peptide used as a substrate for human memapsin 2.
XX
SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 23; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00059;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 1 SEVKMDAEFR 10

RESULT 14

ABB78615

ID ABB78615 standard; Peptide; 10 AA.

XX

AC ABB78615;

XX

DT 16-JUL-2002 (first entry)

XX

DE Beta-secretase specific substrate PHA-95812E SEQ ID NO:64.

XX

KW Human; Asp-1; Asp-2; aspartyl protease; Alzheimer's disease;
KW proteolytic.

XX

OS Synthetic.

XX

PN GB2367060-A.

XX

PD 27-MAR-2002.

XX

PF 29-OCT-2001; 2001GB-0025934.

XX

PR 23-SEP-1999; 99US-155493P.

PR 23-SEP-1999; 99US-0404133.

PR 23-SEP-1999; 99WO-US20881.

PR 13-OCT-1999; 99US-0416901.

PR 06-DEC-1999; 99US-169232P.

PR 22-SEP-2000; 2000GB-0023315.

XX

PA (PHAA) PHARMACIA & UPJOHN CO.

XX
 PI Bienkowski MJ, Gurney M;
 XX
 DR WPI; 2002-396337/43.
 XX
 PT Human aspartyl protease 1 substrates useful in assays to detect
 PT aspartyl protease activity, e.g. for the diagnosis of Alzheimer's
 PT disease -
 XX
 PS Example 15; Page 92; 182pp; English.
 XX
 CC The present invention describes a human aspartyl protease 1 (hu-Aspl)
 CC substrate (I) which comprises a peptide of no more than 50 amino acids,
 CC and which comprises the 8 amino acid sequence Gly-Leu-Ala-Leu-Ala-Leu-
 CC Glu-Pro. Also described are: (1) a method (II) for assaying hu-Aspl
 CC proteolytic activity, comprising: (a) contacting a hu-Aspl protein with
 CC (I) under acidic conditions; and (b) determining the level of hu-Aspl
 CC proteolytic activity; (2) a purified polynucleotide (III) comprising a
 CC nucleotide sequence that hybridises under stringent conditions to the
 CC non-coding strand complementary to a defined 1804 nucleotide sequence
 CC (see ABL52456) where the nucleotide sequence encodes a polypeptide having
 CC Aspl proteolytic activity and lacks nucleotides encoding a transmembrane
 CC domain); (3) a purified polynucleotide (III') comprising a sequence that
 CC hybridises under stringent conditions to (III) (the nucleotide sequence
 CC encodes a polypeptide further lacking a pro-peptide domain corresponding
 CC to amino acids 23-62 of hu-Aspl (see ABB78589)); (4) a vector (IV)
 CC comprising (III) or (III'); and (5) a host cell (V) transformed or
 CC transfected with (III), (III') and/or (IV). The hu-Aspl protease
 CC substrate (I) may be used as an enzyme substrate in assays to detect
 CC aspartyl protease activity, (II) and therefore diagnose diseases
 CC associated with aberrant hu-Aspl expression and activity such as
 CC Alzheimer's disease. Hu-Aspl has been localised to chromosome 21, while
 CC hu-Asp2 has been localised to chromosome 11q23.3-24.1. The present
 CC sequence represents a beta-secretase specific substrate peptide which is
 CC used in an example from the present invention.
 XX
 SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 23; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.00059;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 1 SEVKMDAEFR 10

RESULT 15
 ABB06426
 ID ABB06426 standard; Peptide; 10 AA.
 XX
 AC ABB06426;
 XX
 DT 31-MAY-2002 (first entry)
 XX
 DE Human APP beta-secretase cleavage sequence SEQ ID NO:20.
 XX

KW Beta-secretase; enzyme; cleavage site; amyloid protein precursor; APP;
 KW aspartyl protease; neuroprotective; nootropic; beta-secretase inhibitor;
 KW Alzheimer's disease.
 XX
 OS Homo sapiens.
 XX
 PN WO200206306-A2.
 XX
 PD 24-JAN-2002.
 XX
 PF 19-JUL-2001; 2001WO-US23035.
 XX
 PR 19-JUL-2000; 2000US-219795P.
 PR 12-MAR-2001; 2001US-275251P.
 XX
 PA (PHAA) PHARMACIA & UPJOHN CO.
 XX
 PI Yan R, Tomasselli AG, Gurney ME, Emmons TL, Bienkowski MJ;
 PI Heinrikson RL;
 XX
 DR WPI; 2002-216995/27.
 XX
 PT Novel substrates for human aspartyl protease useful for identifying
 PT modulators of beta secretase activity of aspartyl protease for treating
 PT Alzheimer's disease -
 XX
 PS Claim 18; Page 126; 188pp; English.
 XX
 CC The present invention describes an isolated peptide (I) comprising a
 CC sequence of at least four amino acids, where the peptide is a substrate
 CC for conducting aspartyl protease assays. (I) has neuroprotective and
 CC nootropic activities, and can be used as an inhibitor of beta-secretase
 CC activity. A beta-secretase modulator from the present invention can be
 CC used for inhibiting beta-secretase activity in vivo, and in the
 CC manufacture of a medicament for the treatment of Alzheimer's disease.
 CC Pharmaceutical compositions from the present invention can be used for
 CC treating a disease or condition characterised by an abnormal beta-
 CC secretase activity. (I) is useful for identifying agents that modulate
 CC the activity of human Asp2 aspartyl protease (Hu-Asp2). (I) is useful
 CC as a core structure to construct derivatives. ABL49914 to ABL49925 and
 CC ABB06409 to ABB06593 represent sequences used in the exemplification
 CC of the present invention.
 XX
 SQ Sequence 10 AA;

Query Match 100.0%; Score 49; DB 23; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.00059;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SEVKMDAEFR 10
 | | | | | | | | | |
 Db 1 SEVKMDAEFR 10

Search completed: January 21, 2004, 09:22:25
 Job time : 3.63862 secs

OM protein - protein search, using sw model

Run on: January 21, 2004, 09:19:55 ; Search time 0.898662 Seconds
(without alignments)
470.821 Million cell updates/sec

Title: US-09-869-414A-64
Perfect score: 49
Sequence: 1 SEVKMDAEFR 10

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 328717 seqs, 42310858 residues

Total number of hits satisfying chosen parameters: 328717

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA:*
1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

		%					
Result		Query					
No.	Score	Match	Length	DB	ID	Description	
1	49	100.0	10	4	US-09-548-372D-64	Sequence 64, Appl	
2	49	100.0	10	4	US-09-548-367D-64	Sequence 64, Appl	
3	49	100.0	10	4	US-09-551-853D-64	Sequence 64, Appl	
4	49	100.0	10	4	US-09-604-608-4	Sequence 4, Appli	
5	49	100.0	11	5	PCT-US94-07043A-7	Sequence 7, Appli	
6	49	100.0	12	5	PCT-US94-07043A-2	Sequence 2, Appli	
7	49	100.0	16	5	PCT-US94-07043A-1	Sequence 1, Appli	
8	49	100.0	27	1	US-08-141-324-11	Sequence 11, Appl	
9	49	100.0	27	1	US-08-541-902-11	Sequence 11, Appl	
10	49	100.0	45	1	US-08-462-859A-5	Sequence 5, Appli	
11	49	100.0	45	1	US-08-123-659A-5	Sequence 5, Appli	

12	49	100.0	45	1	US-08-464-247A-5	Sequence 5, Appli
13	49	100.0	45	1	US-08-464-248A-5	Sequence 5, Appli
14	49	100.0	58	1	US-08-371-930-25	Sequence 25, Appl
15	49	100.0	58	5	PCT-US94-01712-25	Sequence 25, Appl
16	49	100.0	63	1	US-08-462-859A-3	Sequence 3, Appli
17	49	100.0	63	1	US-08-462-859A-4	Sequence 4, Appli
18	49	100.0	63	1	US-08-123-659A-3	Sequence 3, Appli
19	49	100.0	63	1	US-08-123-659A-4	Sequence 4, Appli
20	49	100.0	63	1	US-08-464-247A-3	Sequence 3, Appli
21	49	100.0	63	1	US-08-464-247A-4	Sequence 4, Appli
22	49	100.0	63	1	US-08-464-248A-3	Sequence 3, Appli
23	49	100.0	63	1	US-08-464-248A-4	Sequence 4, Appli
24	49	100.0	105	2	US-08-729-345-1	Sequence 1, Appli
25	49	100.0	117	2	US-08-729-345-3	Sequence 3, Appli
26	49	100.0	152	6	5187153-4	Patent No. 5187153
27	49	100.0	162	6	5220013-4	Patent No. 5220013
28	49	100.0	162	6	5223482-4	Patent No. 5223482
29	49	100.0	264	1	US-07-990-893-5	Sequence 5, Appli
30	49	100.0	487	1	US-08-462-859A-9	Sequence 9, Appli
31	49	100.0	487	1	US-08-123-659A-9	Sequence 9, Appli
32	49	100.0	487	1	US-08-464-247A-9	Sequence 9, Appli
33	49	100.0	487	1	US-08-464-248A-9	Sequence 9, Appli
34	49	100.0	492	1	US-08-462-859A-7	Sequence 7, Appli
35	49	100.0	492	1	US-08-123-659A-7	Sequence 7, Appli
36	49	100.0	492	1	US-08-464-247A-7	Sequence 7, Appli
37	49	100.0	492	1	US-08-464-248A-7	Sequence 7, Appli
38	49	100.0	537	1	US-08-453-552-4	Sequence 4, Appli
39	49	100.0	537	2	US-08-710-637-4	Sequence 4, Appli
40	49	100.0	537	5	PCT-US93-00907-4	Sequence 4, Appli
41	49	100.0	656	1	US-08-371-930-23	Sequence 23, Appl
42	49	100.0	656	5	PCT-US94-01712-23	Sequence 23, Appl
43	49	100.0	676	1	US-08-371-930-24	Sequence 24, Appl
44	49	100.0	676	5	PCT-US94-01712-24	Sequence 24, Appl
45	49	100.0	694	1	US-08-339-152A-18	Sequence 18, Appl

ALIGNMENTS

RESULT 1
 US-09-548-372D-64
 ; Sequence 64, Application US/09548372D
 ; Patent No. 6420534
 ; GENERAL INFORMATION:
 ; APPLICANT: GURNEY ET AL.
 ; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR
 AND USES
 ; TITLE OF INVENTION: THEREOF
 ; FILE REFERENCE: 29915/6280I
 ; CURRENT APPLICATION NUMBER: US/09/548,372D
 ; CURRENT FILING DATE: 2000-04-12
 ; PRIOR APPLICATION NUMBER: US 60/155,493
 ; PRIOR FILING DATE: 1999-09-23
 ; PRIOR APPLICATION NUMBER: US 09/404,133
 ; PRIOR FILING DATE: 1999-09-23
 ; PRIOR APPLICATION NUMBER: PCT/US99/20881
 ; PRIOR FILING DATE: 1999-09-23

; PRIOR APPLICATION NUMBER: US 60/101,594
; PRIOR FILING DATE: 1998-09-24
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 64
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-09-548-372D-64

Query Match 100.0%; Score 49; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00061;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 1 SEVKMDAEFR 10

RESULT 2

US-09-548-367D-64

; Sequence 64, Application US/09548367D
; Patent No. 6440698
; GENERAL INFORMATION:
; APPLICANT: GURNEY ET AL.
; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR
AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: 29915/6280H
; CURRENT APPLICATION NUMBER: US/09/548,367D
; CURRENT FILING DATE: 2000-04-12
; PRIOR APPLICATION NUMBER: US 60/155,493
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: US 09/404,133
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: PCT/US99/20881
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: US 60/101,594
; PRIOR FILING DATE: 1998-09-24
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 64
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-09-548-367D-64

Query Match 100.0%; Score 49; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00061;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |

Db 1 SEVKMDAEFR 10

RESULT 3

US-09-551-853D-64
; Sequence 64, Application US/09551853D
; Patent No. 6500667
; GENERAL INFORMATION:
; APPLICANT: GURNEY ET AL.
; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR
AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: 29915/6280L
; CURRENT APPLICATION NUMBER: US/09/551,853D
; CURRENT FILING DATE: 2000-04-18
; PRIOR APPLICATION NUMBER: US 60/155,493
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: US 09/404,133
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: PCT/US99/20881
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: US 60/101,594
; PRIOR FILING DATE: 1998-09-24
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 64
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-09-551-853D-64

Query Match 100.0%; Score 49; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00061;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||
Db 1 SEVKMDAEFR 10

RESULT 4

US-09-604-608-4
; Sequence 4, Application US/09604608
; Patent No. 6545127
; GENERAL INFORMATION:
; APPLICANT: Tang, Jordan J.N.
; APPLICANT: Lin, Xinli
; APPLICANT: Koelsch, Gerald
; TITLE OF INVENTION: Catalytically Active Recombinant Memapsin and Methods
; TITLE OF INVENTION: of Use Thereof
; FILE REFERENCE: OMRF 179
; CURRENT APPLICATION NUMBER: US/09/604,608
; CURRENT FILING DATE: 2000-06-27
; PRIOR APPLICATION NUMBER: 60/141,363
; PRIOR FILING DATE: 1999-06-28

```
; PRIOR APPLICATION NUMBER: 60/168,060
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: 60/177,836
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 60/178,368
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: 60/210,292
; PRIOR FILING DATE: 2000-06-08
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-604-608-4
```

```
Query Match          100.0%; Score 49; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.00061;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 SEVKMDAEFR 10
        |||||
Db      1 SEVKMDAEFR 10
```

RESULT 5

PCT-US94-07043A-7

; Sequence 7, Application PC/TUS9407043A

; GENERAL INFORMATION:

```
; APPLICANT: Tamburini, Paul P.; Benz, G nter; H bich,
; APPLICANT: Dieter; Dreyer, Robert N.; Koenig, Gerhard
; TITLE OF INVENTION: CATHEPSIN D IS AN AMYLOIDOGENIC
; TITLE OF INVENTION: PROTEASE IN ALZHEIMER S DISEASE
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Miles Inc.
; STREET: 400 Morgan Lane
; CITY: West Haven
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06516
```

; COMPUTER READABLE FORM:

```
; MEDIUM TYPE: Diskette, 3.50 inch, 800 kb storage
; COMPUTER: Sharp PC 4600
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
```

; CURRENT APPLICATION DATA:

```
; APPLICATION NUMBER: PCT/US94/07043A
; FILING DATE: June 21, 1994
; CLASSIFICATION:
```

; PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: PCT/US93/10889
; FILING DATE: November 12, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/995,660
```

```
; FILING DATE: December 16, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/880,914
; FILING DATE: May 11, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Pamela A. Simonton
; REGISTRATION NUMBER: 31,060
; REFERENCE/DOCKET NUMBER: MTI 224.3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203) 937-2340
; TELEFAX: (203) 937-2795
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
PCT-US94-07043A-7
```

```
Query Match          100.0%; Score 49; DB 5; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.00067;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 SEVKMDAEFR 10
        |||||
Db      2 SEVKMDAEFR 11
```

RESULT 6

PCT-US94-07043A-2

; Sequence 2, Application PC/TUS9407043A

; GENERAL INFORMATION:

```
; APPLICANT: Tamburini, Paul P.; Benz, G nter; H bich,
; APPLICANT: Dieter; Dreyer, Robert N.; Koenig, Gerhard
; TITLE OF INVENTION: CATHEPSIN D IS AN AMYLOIDOGENIC
; TITLE OF INVENTION: PROTEASE IN ALZHEIMER S DISEASE
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Miles Inc.
; STREET: 400 Morgan Lane
; CITY: West Haven
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06516
```

; COMPUTER READABLE FORM:

```
; MEDIUM TYPE: Diskette, 3.50 inch, 800 kb storage
; COMPUTER: Sharp PC 4600
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
```

; CURRENT APPLICATION DATA:

```
; APPLICATION NUMBER: PCT/US94/07043A
; FILING DATE: June 21, 1994
; CLASSIFICATION:
```

; PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: PCT/US93/10889
; FILING DATE: November 12, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/995,660
```

```
; FILING DATE: December 16, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/880,914
; FILING DATE: May 11, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Pamela A. Simonton
; REGISTRATION NUMBER: 31,060
; REFERENCE/DOCKET NUMBER: MTI 224.3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203) 937-2340
; TELEFAX: (203) 937-2795
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
PCT-US94-07043A-2
```

```
Query Match          100.0%; Score 49; DB 5; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.00073;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 SEVKMDAEFR 10
        |||||
Db      2 SEVKMDAEFR 11
```

RESULT 7

PCT-US94-07043A-1

; Sequence 1, Application PC/TUS9407043A

; GENERAL INFORMATION:

```
; APPLICANT: Tamburini, Paul P.; Benz, G nter; H bich,
; APPLICANT: Dieter; Dreyer, Robert N.; Koenig, Gerhard
; TITLE OF INVENTION: CATHEPSIN D IS AN AMYLOIDOGENIC
; TITLE OF INVENTION: PROTEASE IN ALZHEIMER S DISEASE
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Miles Inc.
; STREET: 400 Morgan Lane
; CITY: West Haven
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06516
```

; COMPUTER READABLE FORM:

```
; MEDIUM TYPE: Diskette, 3.50 inch, 800 kb storage
; COMPUTER: Sharp PC 4600
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
```

; CURRENT APPLICATION DATA:

```
; APPLICATION NUMBER: PCT/US94/07043A
; FILING DATE: June 21, 1994
; CLASSIFICATION:
```

; PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: PCT/US93/10889
; FILING DATE: November 12, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/995,660
```

```
; FILING DATE: December 16, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/880,914
; FILING DATE: May 11, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Pamela A. Simonton
; REGISTRATION NUMBER: 31,060
; REFERENCE/DOCKET NUMBER: MTI 224.3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203) 937-2340
; TELEFAX: (203) 937-2795
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
PCT-US94-07043A-1
```

```
Query Match          100.0%; Score 49; DB 5; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.001;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 SEVKMDAEFR 10
        |||||
Db      2 SEVKMDAEFR 11
```

RESULT 8

US-08-141-324-11

```
; Sequence 11, Application US/08141324
; Patent No. 5475097
; GENERAL INFORMATION:
; APPLICANT: Travis, James
; APPLICANT: Potempa, Jan S.
; APPLICANT: Barr, Philip J.
; APPLICANT: Pavloff, Nadine
; APPLICANT: Pike, Robert N.
; TITLE OF INVENTION: Lysine-specific Porphyromonas gingivalis
; TITLE OF INVENTION: Protease
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Greenlee and Winner, P.C.
; STREET: 5370 Manhattan Circle, Suite 201
; CITY: Boulder
; STATE: CO
; COUNTRY: US
; ZIP: 80303
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/141,324
; FILING DATE: 21-OCT-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
```

; NAME: Ferber, Donna M.
; REGISTRATION NUMBER: 33,878
; REFERENCE/DOCKET NUMBER: 44-93
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 303-499-8080
; TELEFAX: 303-499-8089
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-141-324-11

Query Match 100.0%; Score 49; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 4 SEVKMDAEFR 13

RESULT 9

US-08-541-902-11

; Sequence 11, Application US/08541902
; Patent No. 5707620
; GENERAL INFORMATION:
; APPLICANT: Travis, James
; APPLICANT: Potempa, Jan S.
; APPLICANT: Barr, Philip J.
; APPLICANT: Pavloff, Nadine
; APPLICANT: Pike, Robert N.
; TITLE OF INVENTION: Lysine-specific Porphyromonas gingivalis
; TITLE OF INVENTION: Protease
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Greenlee and Winner, P.C.
; STREET: 5370 Manhattan Circle, Suite 201
; CITY: Boulder
; STATE: CO
; COUNTRY: US
; ZIP: 80303
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/541,902
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/141,324

```

; FILING DATE: 21-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Ferber, Donna M.
; REGISTRATION NUMBER: 33,878
; REFERENCE/DOCKET NUMBER: 44-93
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 303-499-8080
; TELEFAX: 303-499-8089
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-541-902-11

```

```

Query Match          100.0%; Score 49; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 SEVKMDAEFR 10
        |||||
Db      4 SEVKMDAEFR 13

```

RESULT 10

US-08-462-859A-5

```

; Sequence 5, Application US/08462859A
; Patent No. 5652092
; GENERAL INFORMATION:
; APPLICANT: Jacobsen, J. S.
; APPLICANT: Vitek, M. P.
; TITLE OF INVENTION: No. 5652092el Amyloid Precursor and Method of
; TITLE OF INVENTION: Using Same to Access Agents Which Down-Regulate
Formation
; TITLE OF INVENTION: of B-Amyloid Peptide
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: American Cyanamid Company
; STREET: One Cyanamid Plaza
; CITY: Wayne
; STATE: New Jersey
; COUNTRY: United States
; ZIP: 07470-8426
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,859A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:

```

; NAME: Barnhard, Elizabeth M.
; REGISTRATION NUMBER: 31,088
; REFERENCE/DOCKET NUMBER: 31,844-04
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (201)831-3246
; TELEFAX: (201)831-3305
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 45 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-462-859A-5

Query Match 100.0%; Score 49; DB 1; Length 45;
Best Local Similarity 100.0%; Pred. No. 0.003;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||||||
Db 5 SEVKMDAEFR 14

RESULT 11

US-08-123-659A-5

; Sequence 5, Application US/08123659A
; Patent No. 5656477
; GENERAL INFORMATION:
; APPLICANT: Jacobsen, J. S.
; APPLICANT: Vitek, M. P.
; TITLE OF INVENTION: No. 5656477e1 Amyloid Precursor and Method of
; TITLE OF INVENTION: Using Same to Access Agents Which Down-Regulate
Formation
; TITLE OF INVENTION: of B-Amyloid Peptide
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Anne Rosenblum
; STREET: 163 Delaware Avenue, Suite 212
; CITY: Delmar
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 12054
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/123,659A
; FILING DATE: 20-SEP-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Rosenblum, Anne M.
; REGISTRATION NUMBER: 30,419
; REFERENCE/DOCKET NUMBER: 31,844-01
; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (518)475-0611
; TELEFAX: (518)475-0619
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 45 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-123-659A-5

Query Match 100.0%; Score 49; DB 1; Length 45;
Best Local Similarity 100.0%; Pred. No. 0.003;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 5 SEVKMDAEFR 14

RESULT 12

US-08-464-247A-5

; Sequence 5, Application US/08464247A
; Patent No. 5693478
; GENERAL INFORMATION:
; APPLICANT: Jacobsen, J. S.
; APPLICANT: Vitek, M. P.
; TITLE OF INVENTION: No. 5693478el Amyloid Precursor and Method of
; TITLE OF INVENTION: Using Same to Access Agents Which Down-Regulate
Formation
; TITLE OF INVENTION: of B-Amyloid Peptide
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: American Cyanamid Company
; STREET: One Campus Drive
; CITY: Parsippany
; STATE: New Jersey
; COUNTRY: United States
; ZIP: 07054
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/464,247A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Barnhard, Elizabeth M.
; REGISTRATION NUMBER: 31,088
; REFERENCE/DOCKET NUMBER: 31,844-03
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-683-2158
; TELEFAX: 201-683-4117
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 45 amino acids

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 21, 2004, 09:16:55 ; Search time 0.917782 Seconds
(without alignments)
1047.838 Million cell updates/sec

Title: US-09-869-414A-64
Perfect score: 49
Sequence: 1 SEVKMDAEFR 10

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283308 seqs, 96168682 residues

Total number of hits satisfying chosen parameters: 283308

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_76:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query		DB	ID	Description
		Match	Length			
1	49	100.0	57	2	E60045	Alzheimer's diseas
2	49	100.0	57	2	F60045	Alzheimer's diseas
3	49	100.0	57	2	G60045	Alzheimer's diseas
4	49	100.0	57	2	D60045	Alzheimer's diseas
5	49	100.0	57	2	A60045	Alzheimer's diseas
6	49	100.0	57	2	B60045	Alzheimer's diseas
7	49	100.0	82	2	PQ0438	Alzheimer's diseas
8	49	100.0	695	1	A49795	Alzheimer's diseas
9	49	100.0	770	1	QRHUA4	Alzheimer's diseas
10	44	89.8	33	2	S23094	beta-amyloid prote
11	44	89.8	695	2	A27485	Alzheimer's diseas
12	44	89.8	695	2	S00550	Alzheimer's diseas
13	43	87.8	747	2	JH0773	Alzheimer's diseas

14	39	79.6	142	2	E89026	protein F13A2.1 [i
15	35	71.4	774	2	AG1565	autolysin (amidase
16	34	69.4	626	2	AF0358	conserved hypothet
17	34	69.4	3562	2	A47171	chondroitin sulfat
18	34	69.4	4563	1	LPHUB	apolipoprotein B-1
19	33	67.3	927	2	T38127	phosphoprotein - f
20	33	67.3	1245	2	G86404	probable P-glycopr
21	32	65.3	263	2	D84226	hypothetical prote
22	32	65.3	354	2	S51143	FMO-protein - Chlo
23	32	65.3	392	2	T49471	mucin (muc3) relat
24	32	65.3	426	2	G75187	probable trehalose
25	32	65.3	625	2	D86244	protein Ser/Thr pr
26	32	65.3	700	2	E84131	transcription anti
27	32	65.3	929	2	T52517	hypothetical prote
28	32	65.3	1044	2	H97186	glycosyltransferas
29	32	65.3	1265	2	T51498	hypothetical prote
30	32	65.3	1906	2	AD2443	hypothetical prote
31	32	65.3	2514	2	T37320	ataxia telangiecta
32	32	65.3	2619	2	T24588	hypothetical prote
33	31	63.3	87	2	A97842	hypothetical prote
34	31	63.3	155	2	F75040	hypothetical prote
35	31	63.3	178	2	C64168	hypothetical prote
36	31	63.3	182	2	AC0449	conserved hypothet
37	31	63.3	183	2	S56460	probable alpha hel
38	31	63.3	183	2	AD1056	conserved hypothet
39	31	63.3	183	2	C86121	probable alpha hel
40	31	63.3	183	2	C91280	probable alpha hel
41	31	63.3	198	2	S48290	OX40 ligand - mous
42	31	63.3	199	2	F72060	conserved hypothet
43	31	63.3	199	2	C86564	CT471 hypothetical
44	31	63.3	226	2	G69129	hypothetical prote
45	31	63.3	279	2	T41124	single-stranded DN

ALIGNMENTS

RESULT 1

E60045

Alzheimer's disease amyloid beta/A4 protein precursor - sheep (fragment)

C;Species: Ovis sp. (sheep)

C;Date: 01-Dec-1992 #sequence_revision 01-Dec-1992 #text_change 28-Jul-1995

C;Accession: E60045

R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.

Brain Res. Mol. Brain Res. 10, 299-305, 1991

A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis.

A;Reference number: A60045; MUID:92017079; PMID:1656157

A;Accession: E60045

A;Molecule type: mRNA

A;Residues: 1-57 <JOH>

A;Cross-references: EMBL:X56130

C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor homology

C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 49; DB 2; Length 57;
Best Local Similarity 100.0%; Pred. No. 0.0018;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||||||
Db 1 SEVKMDAEFR 10

RESULT 2

F60045

Alzheimer's disease amyloid beta/A4 protein precursor - pig (fragment)
C;Species: Sus scrofa domestica (domestic pig)
C;Date: 01-Dec-1992 #sequence_revision 01-Dec-1992 #text_change 13-Aug-1999
C;Accession: F60045
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide
in dog, polar bear and five other mammals by cross-species polymerase chain
reaction analysis.
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: F60045
A;Molecule type: mRNA
A;Residues: 1-57 <JOH>
A;Cross-references: EMBL:X56127; NID:g1895; PIDN:CAA39592.1; PID:g1896
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type
proteinase inhibitor homology
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 49; DB 2; Length 57;
Best Local Similarity 100.0%; Pred. No. 0.0018;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||||||
Db 1 SEVKMDAEFR 10

RESULT 3

G60045

Alzheimer's disease amyloid beta/A4 protein precursor - guinea pig (fragment)
C;Species: Cavia porcellus (guinea pig)
C;Date: 01-Dec-1992 #sequence_revision 01-Dec-1992 #text_change 28-Jul-1995
C;Accession: G60045
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide
in dog, polar bear and five other mammals by cross-species polymerase chain
reaction analysis.
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: G60045
A;Molecule type: mRNA
A;Residues: 1-57 <JOH>
A;Cross-references: EMBL:X56126
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type
proteinase inhibitor homology
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 49; DB 2; Length 57;
Best Local Similarity 100.0%; Pred. No. 0.0018;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||||||
Db 1 SEVKMDAEFR 10

RESULT 4

D60045

Alzheimer's disease amyloid beta/A4 protein precursor - bovine (fragment)

C;Species: Bos primigenius taurus (cattle)

C;Date: 01-Dec-1992 #sequence_revision 01-Dec-1992 #text_change 28-Jul-1995

C;Accession: D60045

R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.

Brain Res. Mol. Brain Res. 10, 299-305, 1991

A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis.

A;Reference number: A60045; MUID:92017079; PMID:1656157

A;Accession: D60045

A;Molecule type: mRNA

A;Residues: 1-57 <JOH>

A;Cross-references: EMBL:X56124

C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor homology

C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 49; DB 2; Length 57;
Best Local Similarity 100.0%; Pred. No. 0.0018;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||||||
Db 1 SEVKMDAEFR 10

RESULT 5

A60045

Alzheimer's disease amyloid beta/A4 protein precursor - dog (fragment)

C;Species: Canis lupus familiaris (dog)

C;Date: 01-Dec-1992 #sequence_revision 01-Dec-1992 #text_change 28-Jul-1995

C;Accession: A60045

R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.

Brain Res. Mol. Brain Res. 10, 299-305, 1991

A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis.

A;Reference number: A60045; MUID:92017079; PMID:1656157

A;Accession: A60045

A;Molecule type: mRNA

A;Residues: 1-57 <JOH>

A;Cross-references: EMBL:X56125

C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor homology

C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 49; DB 2; Length 57;
Best Local Similarity 100.0%; Pred. No. 0.0018;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||||
Db 1 SEVKMDAEFR 10

RESULT 6

B60045

Alzheimer's disease amyloid beta/A4 protein precursor - polar bear (fragment)

C;Species: Ursus maritimus (polar bear)

C;Date: 01-Dec-1992 #sequence_revision 01-Dec-1992 #text_change 13-Aug-1999

C;Accession: B60045

R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.

Brain Res. Mol. Brain Res. 10, 299-305, 1991

A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis.

A;Reference number: A60045; MUID:92017079; PMID:1656157

A;Accession: B60045

A;Molecule type: mRNA

A;Residues: 1-57 <JOH>

A;Cross-references: EMBL:X56128; NID:g2165; PIDN:CAA39593.1; PID:g2166

C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor homology

C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 49; DB 2; Length 57;
Best Local Similarity 100.0%; Pred. No. 0.0018;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||||
Db 1 SEVKMDAEFR 10

RESULT 7

PQ0438

Alzheimer's disease amyloid A4 protein precursor - rabbit (fragment)

C;Species: Oryctolagus cuniculus (domestic rabbit)

C;Date: 30-Sep-1993 #sequence_revision 19-Oct-1995 #text_change 19-Oct-1995

C;Accession: PQ0438; C60045

R;Davidson, J.S.; West, R.L.; Kotikalapudi, P.; Maroun, L.E.

Biochem. Biophys. Res. Commun. 188, 905-911, 1992

A;Title: Sequence and methylation in the beta/A4 region of the rabbit amyloid precursor protein gene.

A;Reference number: PQ0438; MUID:93075180; PMID:1445331

A;Accession: PQ0438

A;Molecule type: DNA

A;Residues: 1-82 <DAV>

A;Cross-references: GB:M83558; GB:M83657

R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.

Brain Res. Mol. Brain Res. 10, 299-305, 1991

A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis.

A;Reference number: A60045; MUID:92017079; PMID:1656157

A;Accession: C60045

A;Molecule type: mRNA

A;Residues: 12-68 <JOH>

A;Cross-references: EMBL:X56129

C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor homology

C;Keywords: alternative splicing; Alzheimer's disease; amyloid; Down's syndrome

Query Match 100.0%; Score 49; DB 2; Length 82;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 12 SEVKMDAEFR 21

RESULT 8

A49795

Alzheimer's disease amyloid beta protein precursor - crab-eating macaque

C;Species: Macaca fascicularis (crab-eating macaque)

C;Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 10-Sep-1999

C;Accession: A49795

R;Podlisny, M.B.; Tolan, D.R.; Selkoe, D.J.

Am. J. Pathol. 138, 1423-1435, 1991

A;Title: Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease.

A;Reference number: A49795; MUID:91273117; PMID:1905108

A;Accession: A49795

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-695 <POD>

A;Cross-references: GB:M58727; NID:g342062; PIDN:AAA36829.1; PID:g342063

C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor homology

C;Keywords: alternative splicing

Query Match 100.0%; Score 49; DB 1; Length 695;
Best Local Similarity 100.0%; Pred. No. 0.028;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 592 SEVKMDAEFR 601

RESULT 9

QRHUA4

Alzheimer's disease amyloid beta protein precursor [validated] - human

N;Alternate names: Alzheimer's disease amyloid A4 protein; coagulation factor XIa inhibitor; proteinase nexin II (PN-II)

N;Contains: amyloid beta protein long, plaque form; amyloid beta protein short, vascular form; amyloid protein precursor splice form APP(695); amyloid protein precursor splice form APP(751); amyloid protein precursor splice form APP(770)
C;Species: Homo sapiens (man)
C;Date: 30-Jun-1987 #sequence_revision 28-Jul-1995 #text_change 15-Sep-2000
C;Accession: S02260; S05194; A32277; A33260; A35486; I39452; I39451; I39453; I59562; A44017; B44017; A03134; A29030; A47584; A47585; S02638; S00707; S00925; A38949; A30320; B30320; C30320; A31087; A24668; A28583; A29302; A60805; JL0038; S06121; A60355; A59011; A38384; S29076; S38252; S32539; S48148; S48692; S51186; S51185; S51184; S51183; A54238; I58075; I52250; S09010; S10737; S24127; S43644
R;Lemaire, H.G.; Salbaum, J.M.; Multhaup, G.; Kang, J.; Bayney, R.M.; Unterbeck, A.; Beyreuther, K.; Mueller-Hill, B.
Nucleic Acids Res. 17, 517-522, 1989
A;Title: The PreA4(695) precursor protein of Alzheimer's disease A4 amyloid is encoded by 16 exons.
A;Reference number: S02260; MUID:89128427; PMID:2783775
A;Accession: S02260
A;Molecule type: DNA
A;Residues: 1-288,'V',365-770 <LEM1>
A;Cross-references: EMBL:X13466
A;Note: alternative splice form APP(695)
R;Lemaire, H.G.
submitted to the EMBL Data Library, November 1988
A;Reference number: S05194
A;Accession: S05194
A;Molecule type: DNA
A;Residues: 1-14,'VW',17-288,'V',365-770 <LEM2>
A;Cross-references: EMBL:X13466; NID:g35598; PIDN:CAA31830.1; PID:g871360
A;Note: alternative splice form APP(695)
R;La Fauci, G.; Lahiri, D.K.; Salton, S.R.J.; Robakis, N.K.
Biochem. Biophys. Res. Commun. 159, 297-304, 1989
A;Title: Characterization of the 5'-end region and the first two exons of the beta-protein precursor gene.
A;Reference number: A32277; MUID:89165870; PMID:2538123
A;Accession: A32277
A;Molecule type: DNA
A;Residues: 1-75 <LAF>
A;Cross-references: GB:M24546; GB:M24547; NID:g341202; PIDN:AAC13654.1; PID:g516074
R;Johnstone, E.M.; Chaney, M.O.; Moore, R.E.; Ward, K.E.; Norris, F.H.; Little, S.P.
Biochem. Biophys. Res. Commun. 163, 1248-1255, 1989
A;Title: Alzheimer's disease amyloid peptide is encoded by two exons and shows similarity to soybean trypsin inhibitor.
A;Reference number: A33260; MUID:89392030; PMID:2675837
A;Accession: A33260
A;Molecule type: DNA
A;Residues: 656-737 <JOH>
A;Cross-references: GB:M29270; NID:g178863; PIDN:AAA51768.1; PID:g178865
R;Prelli, F.; Levy, E.; van Duinen, S.G.; Bots, G.T.A.M.; Luyendijk, W.; Frangione, B.
Biochem. Biophys. Res. Commun. 170, 301-307, 1990
A;Title: Expression of a normal and variant Alzheimer's beta-protein gene in amyloid of hereditary cerebral hemorrhage, Dutch type: DNA and protein diagnostic assays.
A;Reference number: A35486; MUID:90321244; PMID:2196878
A;Accession: A35486

A;Molecule type: DNA
 A;Residues: 672-710 <PRE1>
 A;Note: 693-Gln was found in DNA isolated from HCHWA-D patients
 R;Yoshikai, S.I.; Sasaki, H.; Doh-ura, K.; Furuya, H.; Sakaki, Y.
 Gene 87, 257-263, 1990
 A;Title: Genomic organization of the human amyloid beta-protein precursor gene.
 A;Reference number: I39451; MUID:90236318; PMID:2110105
 A;Accession: I39452
 A;Status: nucleic acid sequence not shown; translation not shown; translated
 from GB/EMBL/DDBJ
 A;Molecule type: DNA
 A;Residues: 1-770 <YOS1>
 A;Cross-references: GB:M33112; NID:g178613; PIDN:AAB59502.1; PID:g178616
 A;Accession: I39451
 A;Status: nucleic acid sequence not shown; translation not shown; translated
 from GB/EMBL/DDBJ
 A;Molecule type: DNA
 A;Residues: 1-530,'QWLMPVIPAFWEAKVGR' <YOS2>
 A;Cross-references: GB:M34875; NID:g178608; PIDN:AAB59501.1; PID:g178615
 R;Yoshikai, S.I.; Sasaki, H.; Doh-ura, K.; Furuya, H.; Sakaki, Y.
 Gene 102, 291-292, 1991
 A;Reference number: A59020; MUID:91340168; PMID:1908403
 A;Contents: annotation; erratum
 A;Note: revised physical map for reference I39451
 R;Levy, E.; Carman, M.D.; Fernandez-Madrid, I.J.; Power, M.D.; Lieberburg, I.;
 van Duinen, S.G.; Bots, G.T.; Luyendijk, W.; Frangione, B.
 Science 248, 1124-1126, 1990
 A;Title: Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral
 hemorrhage, Dutch type.
 A;Reference number: I39453; MUID:90260663; PMID:2111584
 A;Accession: I39453
 A;Status: translated from GB/EMBL/DDBJ
 A;Molecule type: DNA
 A;Residues: 656-737 <LEV>
 A;Cross-references: GB:M37896; NID:g178618; PIDN:AAA51727.1; PID:g178620
 A;Note: a mutation with 693-Gln is presented
 R;Murrell, J.; Farlow, M.; Ghetti, B.; Benson, M.D.
 Science 254, 97-99, 1991
 A;Title: A mutation in the amyloid precursor protein associated with hereditary
 Alzheimer's disease.
 A;Reference number: I59562; MUID:92022553; PMID:1925564
 A;Accession: I59562
 A;Status: translated from GB/EMBL/DDBJ
 A;Molecule type: DNA
 A;Residues: 689-716,'F',718-737 <MUR>
 A;Cross-references: GB:S57665; NID:g236720; PIDN:AAB19991.1; PID:g236721
 R;Kamino, K.; Orr, H.T.; Payami, H.; Wijsman, E.M.; Alonso, M.E.; Pulst, S.M.;
 Anderson, L.; O'dahl, S.; Nemens, E.; White, J.A.; Sadovnick, A.D.; Ball, M.J.;
 Kaye, J.; Warren, A.; McInnis, M.; Antonarakis, S.E.; Korenberg, J.R.; Sharma,
 V.; Kukull, W.; Larson, E.; Heston, L.L.; Martin, G.M.; Bird, T.D.;
 Schellenberg, G.D.
 Am. J. Hum. Genet. 51, 998-1014, 1992
 A;Title: Linkage and mutational analysis of familial Alzheimer disease kindreds
 for the APP gene region.
 A;Reference number: A44017; MUID:93035397; PMID:1415269
 A;Accession: A44017
 A;Molecule type: DNA

A;Residues: 687-692,'G',694-718 <KAM1>
 A;Cross-references: GB:S45135; NID:g257377; PIDN:AAB23645.1; PID:g257378
 A;Experimental source: familial Alzheimer disease family SB
 A;Note: sequence extracted from NCBI backbone (NCBIP:115374)
 A;Accession: B44017
 A;Molecule type: DNA
 A;Residues: 687-718 <KAM2>
 A;Cross-references: GB:S45136; NID:g257379; PIDN:AAB23646.1; PID:g257380
 A;Experimental source: familial Alzheimer disease family LIT
 A;Note: sequence extracted from NCBI backbone (NCBIP:115376)
 A;Note: this sequence has a silent mutation
 R;Kang, J.; Lemaire, H.G.; Unterbeck, A.; Salbaum, J.M.; Masters, C.L.; Grzeschik, K.H.; Multhaup, G.; Beyreuther, K.; Muller-Hill, B.
 Nature 325, 733-736, 1987
 A;Title: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor.
 A;Reference number: A03134; MUID:87144572; PMID:2881207
 A;Accession: A03134
 A;Molecule type: mRNA
 A;Residues: 1-288,'V',365-770 <KAN>
 A;Cross-references: GB:Y00264; NID:g28525; PIDN:CAA68374.1; PID:g28526
 A;Note: alternative splice form APP(695)
 R;Robakis, N.K.; Ramakrishna, N.; Wolfe, G.; Wisniewski, H.M.
 Proc. Natl. Acad. Sci. U.S.A. 84, 4190-4194, 1987
 A;Title: Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides.
 A;Reference number: A29030; MUID:87231971; PMID:3035574
 A;Accession: A29030
 A;Molecule type: mRNA
 A;Residues: 284-288,'V',365-646,'E',648-770 <ROB>
 A;Cross-references: GB:M16765; NID:g178539; PIDN:AAA51722.1; PID:g178540
 A;Note: the authors translated the codon GAG for residue 647 as Asp
 R;Goldgaber, D.; Lerman, M.I.; McBride, O.W.; Saffiotti, U.; Gajdusek, D.C.
 Science 235, 877-880, 1987
 A;Title: Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease.
 A;Reference number: A47584; MUID:87120328; PMID:3810169
 A;Accession: A47584
 A;Molecule type: mRNA
 A;Residues: 674-756,'S',758-770 <GOL>
 A;Cross-references: GB:M15533; NID:g178706; PIDN:AAA35540.1; PID:g178707
 A;Experimental source: brain
 R;Tanzi, R.E.; Gusella, J.F.; Watkins, P.C.; Bruns, G.A.P.; St George-Hyslop, P.; Van Keuren, M.L.; Patterson, D.; Pagan, S.; Kurnit, D.M.; Neve, R.L.
 Science 235, 880-884, 1987
 A;Title: Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus.
 A;Reference number: A47585; MUID:87120329; PMID:2949367
 A;Accession: A47585
 A;Molecule type: mRNA
 A;Residues: 674-703 <TAN1>
 A;Cross-references: GB:M15532; NID:g177957; PIDN:AAA51564.1; PID:g177958
 R;Dyrks, T.; Weidemann, A.; Multhaup, G.; Salbaum, J.M.; Lemaire, H.G.; Kang, J.; Mueller-Hill, B.; Masters, C.L.; Beyreuther, K.
 EMBO J. 7, 949-957, 1988
 A;Title: Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease.

A;Reference number: S02638; MUID:88296437; PMID:2900137
 A;Accession: S02638
 A;Molecule type: mRNA
 A;Residues: 672-678 <DYZ>
 R;Tanzi, R.E.; McClatchey, A.I.; Lamperti, E.D.; Villa-Komaroff, L.; Gusella, J.F.; Neve, R.L.
 Nature 331, 528-530, 1988
 A;Title: Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease.
 A;Reference number: S00707; MUID:88122640; PMID:2893290
 A;Accession: S00707
 A;Molecule type: mRNA
 A;Residues: 286-344,'I',365-366 <TAN2>
 A;Cross-references: EMBL:X06982; NID:g28817; PIDN:CAA30042.1; PID:g929612
 A;Experimental source: promyelocytic leukemia cell line HL60
 A;Note: alternative splice form APP(751)
 R;Ponte, P.; Gonzalez-DeWhitt, P.; Schilling, J.; Miller, J.; Hsu, D.; Greenberg, B.; Davis, K.; Wallace, W.; Lieberburg, I.; Fuller, F.; Cordell, B.
 Nature 331, 525-527, 1988
 A;Title: A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors.
 A;Reference number: S00925; MUID:88122639; PMID:2893289
 A;Accession: S00925
 A;Molecule type: mRNA
 A;Residues: 1-344,'I',365-770 <PO2>
 A;Cross-references: GB:X06989; EMBL:Y00297; NID:g28720; PIDN:CAA30050.1; PID:g28721
 A;Note: alternative splice form APP(751)
 R;Kitaguchi, N.; Takahashi, Y.; Tokushima, Y.; Shiojiri, S.; Ito, H.
 Nature 331, 530-532, 1988
 A;Title: Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity.
 A;Reference number: A38949; MUID:88122641; PMID:2893291
 A;Accession: A38949
 A;Molecule type: mRNA
 A;Residues: 287-367 <KIT>
 A;Cross-references: GB:X06981; NID:g28816; PIDN:CAA30041.1; PID:g929611
 A;Experimental source: glioblastoma cell line
 A;Note: alternative splice form APP(770)
 R;Vitek, M.P.; Rasool, C.G.; de Sauvage, F.; Vitek, S.M.; Bartus, R.T.; Beer, B.; Ashton, R.A.; Macq, A.F.; Maloteaux, J.M.; Blume, A.J.; Octave, J.N.
 Brain Res. Mol. Brain Res. 4, 121-131, 1988
 A;Title: Absence of mutation in the beta-amyloid cDNAs cloned from the brains of three patients with sporadic Alzheimer's disease.
 A;Reference number: A30320
 A;Accession: A30320
 A;Status: not compared with conceptual translation
 A;Molecule type: mRNA
 A;Residues: 284-288,'V',365-770 <VIT1>
 A;Accession: B30320
 A;Status: not compared with conceptual translation
 A;Molecule type: mRNA
 A;Residues: 122-288,'V',365-770 <VIT2>
 A;Accession: C30320
 A;Status: not compared with conceptual translation
 A;Molecule type: mRNA
 A;Residues: 606-770 <VIT3>

R;Zain, S.B.; Salim, M.; Chou, W.G.; Sajdel-Sulkowska, E.M.; Majocha, R.E.; Marotta, C.A.
 Proc. Natl. Acad. Sci. U.S.A. 85, 929-933, 1988
 A;Title: Molecular cloning of amyloid cDNA derived from mRNA of the Alzheimer disease brain: coding and noncoding regions of the fetal precursor mRNA are expressed in the cortex.
 A;Reference number: A31087; MUID:88124954; PMID:2893379
 A;Accession: A31087
 A;Molecule type: mRNA
 A;Residues: 507-770 <ZAI>
 A;Cross-references: GB:M18734; NID:g178572; PIDN:AAA51726.1; PID:g178573
 A;Note: the authors translated the codon GAA for residue 599 as Gly, ACC for residue 603 as Val, GTG for residue 604 as Glu, GAG for residue 605 as Leu, CTT for residue 607 as Pro, CCC for residue 608 as Val, GTG for residue 609 as Asn, AAT for residue 610 as Gly, and GGT for residue 655 as Ser
 A;Note: the cited Genbank accession number, J03594, is not in release 101.0
 R;Masters, C.L.; Multhaup, G.; Simms, G.; Pottgiesser, J.; Martins, R.N.; Beyreuther, K.

Query Match 100.0%; Score 49; DB 1; Length 770;
 Best Local Similarity 100.0%; Pred. No. 0.032;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 667 SEVKMDAEFR 676

RESULT 10

S23094

beta-amyloid protein precursor - rat

C;Species: Rattus norvegicus (Norway rat)

C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 03-May-1996

C;Accession: S23094

R;Kojima, S.; Omori, M.

FEBS Lett. 304, 57-60, 1992

A;Title: Two-way cleavage of beta-amyloid protein precursor by multicatalytic proteinase.

A;Reference number: S23094; MUID:92316198; PMID:1618299

A;Accession: S23094

A;Molecule type: protein

A;Residues: 1-33 <KOJ>

C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor homology

Query Match 89.8%; Score 44; DB 2; Length 33;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEF 9
 |||||
 Db 1 SEVKMDAEF 9

RESULT 11

A27485

Alzheimer's disease amyloid beta/A4 protein homolog precursor - mouse

N;Alternate names: proteinase nexin II
 C;Species: Mus musculus (house mouse)
 C;Date: 31-Mar-1989 #sequence_revision 31-Mar-1989 #text_change 13-Aug-1999
 C;Accession: A27485; S19727; I49485
 R;Yamada, T.; Sasaki, H.; Furuya, H.; Miyata, T.; Goto, I.; Sakaki, Y.
 Biochem. Biophys. Res. Commun. 149, 665-671, 1987
 A;Title: Complementary DNA for the mouse homolog of the human amyloid beta protein precursor.
 A;Reference number: A27485; MUID:88106489; PMID:3322280
 A;Accession: A27485
 A;Molecule type: mRNA
 A;Residues: 1-695 <YAM>
 A;Cross-references: GB:M18373; NID:gl91568; PIDN:AAA37139.1; PID:g309085
 A;Experimental source: brain
 R;de Strooper, B.; van Leuven, F.; van den Berghe, H.
 Biochim. Biophys. Acta 1129, 141-143, 1991
 A;Title: The amyloid beta protein precursor or proteinase nexin II from mouse is closer related to its human homolog than previously reported.
 A;Reference number: S19727; MUID:92096458; PMID:1756177
 A;Accession: S19727
 A;Molecule type: mRNA
 A;Residues: 1-210,'G',212-220,'S',222-396,'A',398-402,'T',404-448,'A',450-695 <STR>
 A;Cross-references: EMBL:X59379
 R;Izumi, R.; Yamada, T.; Yoshikai, S.; Sasaki, H.; Hattori, M.; Sakaki, Y.
 Gene 112, 189-195, 1992
 A;Title: Positive and negative regulatory elements for the expression of the Alzheimer's disease amyloid precursor-encoding gene in mouse.
 A;Reference number: I49485; MUID:92209998; PMID:1555768
 A;Accession: I49485
 A;Status: translated from GB/EMBL/DDBJ
 A;Molecule type: DNA
 A;Residues: 1-19 <RES>
 A;Cross-references: GB:D10603; NID:g220328; PIDN:BAA01456.1; PID:g220329
 C;Genetics:
 A;Map position: 16C3
 C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor homology
 C;Keywords: alternative splicing; amyloid; transmembrane protein

Query Match 89.8%; Score 44; DB 2; Length 695;
 Best Local Similarity 100.0%; Pred. No. 0.33;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEF 9
 |||||
 Db 592 SEVKMDAEF 600

RESULT 12
 S00550

Alzheimer's disease amyloid beta protein precursor - rat
 N;Alternate names: beta-A4 amyloid protein
 C;Species: Rattus norvegicus (Norway rat)
 C;Date: 30-Jun-1989 #sequence_revision 30-Jun-1989 #text_change 13-Aug-1999
 C;Accession: S00550; A41245; A39820; S46251

R;Shivers, B.D.; Hilbich, C.; Multhaup, G.; Salbaum, M.; Beyreuther, K.; Seeburg, P.H.
 EMBO J. 7, 1365-1370, 1988
 A;Title: Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact.
 A;Reference number: S00550; MUID:88312583; PMID:2900758
 A;Accession: S00550
 A;Molecule type: mRNA
 A;Residues: 1-695 <SHI>
 A;Cross-references: EMBL:X07648; NID:g55616; PIDN:CAA30488.1; PID:g55617
 R;Schubert, D.; Schroeder, R.; LaCorbiere, M.; Saitoh, T.; Cole, G.
 Science 241, 223-226, 1988
 A;Title: Amyloid beta protein precursor is possibly a heparan sulfate proteoglycan core protein.
 A;Reference number: A41245; MUID:88264430; PMID:2968652
 A;Accession: A41245
 A;Molecule type: protein
 A;Residues: 18-37,'X',39-40,'X',42-44 <SCH>
 A;Note: evidence for heparan sulfate attachment
 R;Hesse, L.; Beher, D.; Masters, C.L.; Multhaup, G.
 FEBS Lett. 349, 109-116, 1994
 A;Title: The beta-A4 amyloid precursor protein binding to copper.
 A;Reference number: S46251; MUID:94320627; PMID:7913895
 A;Contents: annotation; copper binding sites
 A;Note: rat peptides were isolated but not sequenced
 R;Potempska, A.; Styles, J.; Mehta, P.; Kim, K.S.; Miller, D.L.
 J. Biol. Chem. 266, 8464-8469, 1991
 A;Title: Purification and tissue level of the beta-amyloid peptide precursor of rat brain.
 A;Reference number: A39820; MUID:91217087; PMID:1673681
 A;Accession: A39820
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 18-32 <POT>
 A;Experimental source: brain
 C;Comment: Deposition of amyloid protein as neurofibrillary tangles and/or plaques is characteristic of both Alzheimer's disease and Down's syndrome.
 C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor homology
 C;Keywords: alternative splicing; amyloid; glycoprotein; transmembrane protein
 F;625-648/Domain: transmembrane #status predicted <TMM>

Query Match 89.8%; Score 44; DB 2; Length 695;
 Best Local Similarity 100.0%; Pred. No. 0.33;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEF 9
 |||||
 Db 592 SEVKMDAEF 600

RESULT 13

JH0773

Alzheimer's disease amyloid beta protein precursor - African clawed frog

C;Species: Xenopus laevis (African clawed frog)

C;Date: 10-Jun-1993 #sequence_revision 10-Jun-1993 #text_change 13-Aug-1999

C;Accession: JH0773

R;Okado, H.; Okamoto, H.
 Biochem. Biophys. Res. Commun. 189, 1561-1568, 1992
 A;Title: A Xenopus homologue of the human beta-amyloid precursor protein:
 developmental regulation of its gene expression.
 A;Reference number: JH0773; MUID:93129227; PMID:1282805
 A;Accession: JH0773
 A;Molecule type: mRNA
 A;Residues: 1-747 <OKA>
 A;Cross-references: GB:S52417; NID:g263150; PIDN:AAB24853.1; PID:g263151
 A;Experimental source: larva
 C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type
 proteinase inhibitor homology
 C;Keywords: alternative splicing; amyloid
 F;287-337/Domain: animal Kunitz-type proteinase inhibitor homology <BPI>

Query Match 87.8%; Score 43; DB 2; Length 747;
 Best Local Similarity 80.0%; Pred. No. 0.59;
 Matches 8; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||:|:|
 Db 644 SEVKMDSEYR 653

RESULT 14
 E89026
 protein Fl3A2.1 [imported] - Caenorhabditis elegans
 C;Species: Caenorhabditis elegans
 C;Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 10-May-2001
 C;Accession: E89026
 R;anonymous, The C. elegans Sequencing Consortium.
 Science 282, 2012-2018, 1998
 A;Title: Genome sequence of the nematode C. elegans: a platform for
 investigating biology.
 A;Reference number: A75000; MUID:99069613; PMID:9851916
 A;Note: see websites genome.wustl.edu/gsc/C_elegans/ and
 www_sanger.ac.uk/Projects/C_elegans/ for a list of authors
 A;Note: published errata appeared in Science 283, 35, 1999; Science 283, 2103,
 1999; and Science 285, 1493, 1999
 A;Accession: E89026
 A;Status: preliminary
 A;Molecule type: DNA
 A;Residues: 1-142 <STO>
 A;Cross-references: GB:chr_V; PIDN:AAB69895.1; PID:g2384795; GSPDB:GN00023;
 CESP:Fl3A2.1
 C;Genetics:
 A;Gene: Fl3A2.1
 A;Map position: 5

Query Match 79.6%; Score 39; DB 2; Length 142;
 Best Local Similarity 77.8%; Pred. No. 0.67;
 Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 EVKMDAEFR 10
 |:| |||||
 Db 56 EIKQDAEFR 64

RESULT 15

AG1565

autolysin (amidase) homolog lin1064 [imported] - *Listeria innocua* (strain Clip11262)

C;Species: *Listeria innocua*

C;Date: 27-Nov-2001 #sequence_revision 27-Nov-2001 #text_change 27-Nov-2001

C;Accession: AG1565

R;Glaser, P.; Frangeul, L.; Buchrieser, C.; Amend, A.; Baquero, F.; Berche, P.; Bloecker, H.; Brandt, P.; Chakraborty, T.; Charbit, A.; Chetouani, F.; Couve, E.; de Daruvar, A.; Dehoux, P.; Domann, E.; Dominguez-Bernal, G.; Duchaud, E.; Durand, L.; Dussurget, O.; Entian, K.D.; Fsihi, H.; Garcia-Del Portillo, F.; Garrido, P.; Gautier, L.; Goebel, W.; Gomez-Lopez, N.; Hain, T.; Hauf, J.; Jackson, D.; Jones, L.M.; Karst, U.

Science 294, 849-852, 2001

A;Authors: Kreft, J.; Kuhn, M.; Kunst, F.; Kurapkat, G.; Madueno, E.; Maitournam, A.; Mata Vicente, J.; Ng, E.; Nordsiek, G.; Novella, S.; de Pablos, B.; Perez-Diaz, J.C.; Remmel, B.; Rose, M.; Rusniok, C.; Schlueter, T.; Simoes, N.; Tierrez, A.; Vazquez-Boland, J.A.; Voss, H.; Wehland, J.; Cossart, P.

A;Title: Comparative genomics of *Listeria* species.

A;Reference number: AB1077; MUID:21537279; PMID:11679669

A;Accession: AG1565

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-774 <GLA>

A;Cross-references: GB:AL592022; PIDN:CAC96295.1; PID:g16413523; GSPDB:GN00178

A;Experimental source: strain Clip11262

C;Genetics:

A;Gene: lin1064

Query Match 71.4%; Score 35; DB 2; Length 774;

Best Local Similarity 75.0%; Pred. No. 32;

Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 3 VKMDAEFR 10

:|:||||

Db 123 IKIDAEFR 130

Search completed: January 21, 2004, 09:26:08

Job time : 1.91778 secs

OM protein - protein search, using sw model

Run on: January 21, 2004, 09:25:15 ; Search time 2.00765 Seconds
 (without alignments)
 1018.511 Million cell updates/sec

Title: US-09-869-414A-64
 Perfect score: 49
 Sequence: 1 SEVKMDAEFR 10

Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 762491 seqs, 204481190 residues

Total number of hits satisfying chosen parameters: 762491

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : Published Applications_AA:*
 1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
 2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*
 3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
 4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*
 5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
 6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*
 7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
 8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
 9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:*
 10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep:*
 11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*
 12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*
 13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*
 14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*
 15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*
 16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
 17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*
 18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result		Query				Description
No.	Score	Match	Length	DB	ID	

1	49	100.0	10	9	US-09-794-927-64	Sequence 64, Appl
2	49	100.0	10	9	US-09-795-847-64	Sequence 64, Appl
3	49	100.0	10	9	US-09-794-743-64	Sequence 64, Appl
4	49	100.0	10	9	US-09-794-748-64	Sequence 64, Appl
5	49	100.0	10	9	US-09-796-264-4	Sequence 4, Appli
6	49	100.0	10	9	US-09-794-925-64	Sequence 64, Appl
7	49	100.0	10	9	US-09-681-442-64	Sequence 64, Appl
8	49	100.0	10	10	US-09-845-226-4	Sequence 4, Appli
9	49	100.0	10	10	US-09-795-903A-4	Sequence 4, Appli
10	49	100.0	10	11	US-09-869-414-64	Sequence 64, Appl
11	49	100.0	10	11	US-09-548-366-64	Sequence 64, Appl
12	49	100.0	10	12	US-10-427-208-53	Sequence 53, Appl
13	49	100.0	10	15	US-10-032-818-7	Sequence 7, Appli
14	49	100.0	11	12	US-10-354-955-1	Sequence 1, Appli
15	49	100.0	11	12	US-10-354-955-3	Sequence 3, Appli
16	49	100.0	12	9	US-09-896-874-2	Sequence 2, Appli
17	49	100.0	12	10	US-09-896-139-2	Sequence 2, Appli
18	49	100.0	12	10	US-09-895-843-2	Sequence 2, Appli
19	49	100.0	12	11	US-09-895-871-2	Sequence 2, Appli
20	49	100.0	12	12	US-10-427-208-54	Sequence 54, Appl
21	49	100.0	13	12	US-10-160-777-2	Sequence 2, Appli
22	49	100.0	13	12	US-10-337-075-2	Sequence 2, Appli
23	49	100.0	13	15	US-10-084-380A-7	Sequence 7, Appli
24	49	100.0	13	15	US-10-192-625-2	Sequence 2, Appli
25	49	100.0	13	15	US-10-192-424-2	Sequence 2, Appli
26	49	100.0	13	15	US-10-183-126A-2	Sequence 2, Appli
27	49	100.0	13	15	US-10-171-343-2	Sequence 2, Appli
28	49	100.0	13	15	US-10-264-707-2	Sequence 2, Appli
29	49	100.0	14	12	US-10-427-208-55	Sequence 55, Appl
30	49	100.0	16	12	US-10-427-208-56	Sequence 56, Appl
31	49	100.0	23	12	US-10-354-955-6	Sequence 6, Appli
32	49	100.0	67	12	US-10-437-706-1	Sequence 1, Appli
33	49	100.0	82	11	US-09-848-616-173	Sequence 173, App
34	49	100.0	82	12	US-10-050-898-219	Sequence 219, App
35	49	100.0	82	12	US-10-050-902-219	Sequence 219, App
36	49	100.0	534	12	US-09-998-491-2	Sequence 2, Appli
37	49	100.0	695	9	US-09-794-927-10	Sequence 10, Appl
38	49	100.0	695	9	US-09-794-927-14	Sequence 14, Appl
39	49	100.0	695	9	US-09-795-847-10	Sequence 10, Appl
40	49	100.0	695	9	US-09-795-847-14	Sequence 14, Appl
41	49	100.0	695	9	US-09-794-743-10	Sequence 10, Appl
42	49	100.0	695	9	US-09-794-743-14	Sequence 14, Appl
43	49	100.0	695	9	US-09-794-748-10	Sequence 10, Appl
44	49	100.0	695	9	US-09-794-748-14	Sequence 14, Appl
45	49	100.0	695	9	US-09-794-925-10	Sequence 10, Appl

ALIGNMENTS

RESULT 1
 US-09-794-927-64
 ; Sequence 64, Application US/09794927
 ; Patent No. US20010016324A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Gurney, Mark E.

```

; APPLICANT: Bienkowski, Michael J.
; APPLICANT: Heinrikson, Robert L.
; APPLICANT: Parodi, Luis A.
; APPLICANT: Yan, Riqiang
; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR,
AND
; TITLE OF INVENTION: USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: 28341/6280FG
; CURRENT APPLICATION NUMBER: US/09/794,927
; CURRENT FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: 09/416,901
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/155,493
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 09/404,133
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: PCT/US99/20881
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 60/101,594
; PRIOR FILING DATE: 1998-09-24
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 64
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-794-927-64

```

```

Query Match          100.0%; Score 49; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 SEVKMDAEFR 10
        |||||
Db      1 SEVKMDAEFR 10

```

RESULT 2

```

US-09-795-847-64
; Sequence 64, Application US/09795847
; Patent No. US20010018208A1
; GENERAL INFORMATION:
; APPLICANT: Gurney, Mark E.
; APPLICANT: Bienkowski, Michael J.
; APPLICANT: Heinrikson, Robert L.
; APPLICANT: Parodi, Luis A.
; APPLICANT: Yan, Riqiang
; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR,
AND
; TITLE OF INVENTION: USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: 28341/6280DE
; CURRENT APPLICATION NUMBER: US/09/795,847
; CURRENT FILING DATE: 2001-02-28

```

```
; PRIOR APPLICATION NUMBER: 09/416,901
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/155,493
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 09/404,133
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: PCT/US99/20881
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 60/101,594
; PRIOR FILING DATE: 1998-09-24
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 64
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-795-847-64
```

```
Query Match          100.0%; Score 49; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 SEVKMDAEFR 10
        |||||
Db      1 SEVKMDAEFR 10
```

RESULT 3

```
US-09-794-743-64
; Sequence 64, Application US/09794743
; Patent No. US20010021391A1
; GENERAL INFORMATION:
; APPLICANT: Gurney, Mark E.
; APPLICANT: Bienkowski, Michael J.
; APPLICANT: Heinrikson, Robert L.
; APPLICANT: Parodi, Luis A.
; APPLICANT: Yan, Riqiang
; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR,
AND
; TITLE OF INVENTION: USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: 28341/6280BC
; CURRENT APPLICATION NUMBER: US/09/794,743
; CURRENT FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: 09/416,901
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/155,493
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 09/404,133
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: PCT/US99/20881
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 60/101,594
; PRIOR FILING DATE: 1998-09-24
; NUMBER OF SEQ ID NOS: 73
```

; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 64
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-794-743-64

Query Match 100.0%; Score 49; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 1 SEVKMDAEFR 10

RESULT 4

US-09-794-748-64

; Sequence 64, Application US/09794748
; Patent No. US20020037315A1
; GENERAL INFORMATION:
; APPLICANT: Gurney, Mark E.
; APPLICANT: Bienkowski, Michael J.
; APPLICANT: Heinrikson, Robert L.
; APPLICANT: Parodi, Luis A.
; APPLICANT: Yan, Riqiang
; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR,
AND

; TITLE OF INVENTION: USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: 28341/6280JL
; CURRENT APPLICATION NUMBER: US/09/794,748
; CURRENT FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: 09/416,901
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/155,493
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 09/404,133
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: PCT/US99/20881
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 60/101,594
; PRIOR FILING DATE: 1998-09-24
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 64
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-794-748-64

Query Match 100.0%; Score 49; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0017;

```

Matches    10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 SEVKMDAEFR 10
            |||||
Db          1 SEVKMDAEFR 10

```

RESULT 5

```

US-09-796-264-4
; Sequence 4, Application US/09796264
; Patent No. US20020049303A1
; GENERAL INFORMATION:
; APPLICANT: Tang, Jordan J.N.
; APPLICANT: Lin, Xinli
; APPLICANT: Koelsch, Gerald
; TITLE OF INVENTION: Catalytically Active Recombinant Memapsin and Methods
; TITLE OF INVENTION: of Use Thereof
; FILE REFERENCE: OMRF 179
; CURRENT APPLICATION NUMBER: US/09/796,264
; CURRENT FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 09/604,608
; PRIOR FILING DATE: 2000-06-27
; PRIOR APPLICATION NUMBER: 60/168,060
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: 60/177,836
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 60/178,368
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: 60/210,292
; PRIOR FILING DATE: 2000-06-08
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-796-264-4

```

```

Query Match          100.0%;  Score 49;  DB 9;  Length 10;
Best Local Similarity 100.0%;  Pred. No. 0.0017;
Matches    10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 SEVKMDAEFR 10
            |||||
Db          1 SEVKMDAEFR 10

```

RESULT 6

```

US-09-794-925-64
; Sequence 64, Application US/09794925
; Patent No. US20020064819A1
; GENERAL INFORMATION:
; APPLICANT: Gurney, Mark E.
; APPLICANT: Bienkowski, Michael J.
; APPLICANT: Heinrikson, Robert L.

```

```

; APPLICANT: Parodi, Luis A.
; APPLICANT: Yan, Riqiang
; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR,
AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: 28341/6280HI
; CURRENT APPLICATION NUMBER: US/09/794,925
; CURRENT FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: 09/416,901
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/155,493
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 09/404,133
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: PCT/US99/20881
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 60/101,594
; PRIOR FILING DATE: 1998-09-24
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 64
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-794-925-64

```

```

Query Match          100.0%; Score 49; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 SEVKMDAEFR 10
        |||||
Db      1 SEVKMDAEFR 10

```

RESULT 7

```

US-09-681-442-64
; Sequence 64, Application US/09681442
; Patent No. US20020081634A1
; GENERAL INFORMATION:
; APPLICANT: Gurney, Mark E.
; APPLICANT: Bienkowski, Michael J.
; APPLICANT: Heinrikson, Robert L.
; APPLICANT: Parodi, Luis A.
; APPLICANT: Yan, Riqiang
; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR,
AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: 28341/6280FG
; CURRENT APPLICATION NUMBER: US/09/681,442
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/416,901
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/155,493
; PRIOR FILING DATE: 1999-09-23

```

; PRIOR APPLICATION NUMBER: 09/404,133
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: PCT/US99/20881
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 60/101,594
; PRIOR FILING DATE: 1998-09-24
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 64
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-681-442-64

Query Match 100.0%; Score 49; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 1 SEVKMDAEFR 10

RESULT 8

US-09-845-226-4

; Sequence 4, Application US/09845226
; Patent No. US20020115600A1
; GENERAL INFORMATION:
; APPLICANT: Tang, Jordan J.N.
; APPLICANT: Hong, Lin
; APPLICANT: Ghosh, Arun K.
; TITLE OF INVENTION: Inhibitors of Memapsin 2 and Use Thereof
; FILE REFERENCE: OMRF 182
; CURRENT APPLICATION NUMBER: US/09/845,226
; CURRENT FILING DATE: 2001-04-30
; PRIOR APPLICATION NUMBER: 09/603,713
; PRIOR FILING DATE: 2000-06-27
; PRIOR APPLICATION NUMBER: 60/168,060
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: 60/177,836
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 60/178,368
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: 60/210,292
; PRIOR FILING DATE: 2000-06-08
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-845-226-4

Query Match 100.0%; Score 49; DB 10; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||||
Db 1 SEVKMDAEFR 10

RESULT 9

US-09-795-903A-4

; Sequence 4, Application US/09795903A
; Patent No. US20020164760A1
; GENERAL INFORMATION:
; APPLICANT: Tang, Jordan J.N.
; APPLICANT: Lin, Xinli
; APPLICANT: Koelsch, Gerald
; TITLE OF INVENTION: Catalytically Active Recombinant Memapsin and Methods
; TITLE OF INVENTION: of Use Thereof
; FILE REFERENCE: OMRF 179
; CURRENT APPLICATION NUMBER: US/09/795,903A
; CURRENT FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 09/604,608
; PRIOR FILING DATE: 2000-06-27
; PRIOR APPLICATION NUMBER: 60/168,060
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: 60/177,836
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 60/178,368
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: 60/210,292
; PRIOR FILING DATE: 2000-06-08
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-795-903A-4

Query Match 100.0%; Score 49; DB 10; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||||
Db 1 SEVKMDAEFR 10

RESULT 10

US-09-869-414-64

; Sequence 64, Application US/09869414
; Publication No. US20030077226A1
; GENERAL INFORMATION:
; APPLICANT: Beinkowski et al.

```

; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR,
AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: 28341/6280M
; CURRENT APPLICATION NUMBER: US/09/869,414
; CURRENT FILING DATE: 2001-06-27
; PRIOR APPLICATION NUMBER: 09/416,901
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/155,493
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 09/404,133
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: PCT/US99/20881
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 60/101,594
; PRIOR FILING DATE: 1998-09-24
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 64
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-869-414-64

```

```

Query Match          100.0%; Score 49; DB 11; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 SEVKMDAEFR 10
        |||||
Db      1 SEVKMDAEFR 10

```

RESULT 11

US-09-548-366-64

```

; Sequence 64, Application US/09548366
; Publication No. US20030104365A1
; GENERAL INFORMATION:
; APPLICANT: Gurney, Mark E.
; APPLICANT: Bienkowski, Michael J.
; APPLICANT: Heinrikson, Robert L.
; APPLICANT: Parodi, Luis A.
; APPLICANT: Yan, Riqiang
; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR,
AND
; TITLE OF INVENTION: USES THEREFOR
; FILE REFERENCE: 28341/6280A
; CURRENT APPLICATION NUMBER: US/09/548,366
; CURRENT FILING DATE: 2000-04-12
; PRIOR APPLICATION NUMBER: 60/155,493
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 09/404,133
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: PCT/US99/20881
; PRIOR FILING DATE: 1999-09-23

```

; PRIOR APPLICATION NUMBER: 60/101,594
; PRIOR FILING DATE: 1998-09-24
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 64
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-548-366-64

Query Match 100.0%; Score 49; DB 11; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 1 SEVKMDAEFR 10

RESULT 12

US-10-427-208-53

; Sequence 53, Application US/10427208
; Publication No. US20030200555A1
; GENERAL INFORMATION:
; APPLICANT: Merck & Co., Inc.
; APPLICANT: Hazuda, Daria J
; APPLICANT: Chen Dodson, Elizabeth
; APPLICANT: Lai, Ming-Tain
; APPLICANT: Xu, Min
; APPLICANT: Shi, Xiao-Ping
; APPLICANT: Simon, Adam J.
; APPLICANT: Wu, Guoxin
; APPLICANT: Li, Yueming
; APPLICANT: Register, Robert B.
; TITLE OF INVENTION: ASSAYS USING AMYLOID PRECURSOR PROTEINS WITH MODIFIED
; TITLE OF INVENTION: BETA-SECRETASE CLEAVAGE SITES TO MONITOR BETA-SECRETASE
ACTIVITY

; FILE REFERENCE: 21052
; CURRENT APPLICATION NUMBER: US/10/427,208
; CURRENT FILING DATE: 2003-04-30
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 53
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-427-208-53

Query Match 100.0%; Score 49; DB 12; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 1 SEVKMDAEFR 10

RESULT 13

US-10-032-818-7

; Sequence 7, Application US/10032818
 ; Publication No. US20030092629A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Tang, Jordan J.N.
 ; APPLICANT: Koelsch, Gerald
 ; APPLICANT: Ghosh, Arun K.
 ; TITLE OF INVENTION: Inhibitors of Memapsin 2 and Use Thereof
 ; FILE REFERENCE: 2932.1006-007
 ; CURRENT APPLICATION NUMBER: US/10/032,818
 ; CURRENT FILING DATE: 2001-12-28
 ; PRIOR APPLICATION NUMBER: US 60/275,756
 ; PRIOR FILING DATE: 2001-03-14
 ; PRIOR APPLICATION NUMBER: US 60/258,705
 ; PRIOR FILING DATE: 2000-12-28
 ; NUMBER OF SEQ ID NOS: 83
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO 7
 ; LENGTH: 10
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic peptide
 US-10-032-818-7

Query Match 100.0%; Score 49; DB 15; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.0017;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 1 SEVKMDAEFR 10

RESULT 14

US-10-354-955-1

; Sequence 1, Application US/10354955
 ; Publication No. US20030171291A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Gary Christie
 ; APPLICANT: Ishrut Hussain
 ; APPLICANT: David J. Powell
 ; TITLE OF INVENTION: No. US20030171291A1el Treatment
 ; FILE REFERENCE: P32448
 ; CURRENT APPLICATION NUMBER: US/10/354,955
 ; CURRENT FILING DATE: 2003-01-30
 ; PRIOR APPLICATION NUMBER: 09/693,744
 ; PRIOR FILING DATE: 2000-10-20
 ; PRIOR APPLICATION NUMBER: 9925136.5
 ; PRIOR FILING DATE: 1999-10-22
 ; NUMBER OF SEQ ID NOS: 9
 ; SOFTWARE: FastSEQ for Windows Version 3.0
 ; SEQ ID NO 1
 ; LENGTH: 11

; TYPE: PRT
; ORGANISM: human
US-10-354-955-1

Query Match 100.0%; Score 49; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.0019;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 2 SEVKMDAEFR 11

RESULT 15

US-10-354-955-3

; Sequence 3, Application US/10354955
; Publication No. US20030171291A1
; GENERAL INFORMATION:
; APPLICANT: Gary Christie
; APPLICANT: Ishrut Hussain
; APPLICANT: David J. Powell
; TITLE OF INVENTION: No. US20030171291A1el Treatment
; FILE REFERENCE: P32448
; CURRENT APPLICATION NUMBER: US/10/354,955
; CURRENT FILING DATE: 2003-01-30
; PRIOR APPLICATION NUMBER: 09/693,744
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 9925136.5
; PRIOR FILING DATE: 1999-10-22
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: fusion protein with maltose binding protein attached at residue 1'

US-10-354-955-3

Query Match 100.0%; Score 49; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.0019;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 2 SEVKMDAEFR 11

Search completed: January 21, 2004, 09:41:42
Job time : 3.00765 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 21, 2004, 09:16:19 ; Search time 2.06501 Seconds
(without alignments)
1249.644 Million cell updates/sec

Title: US-09-869-414A-64
Perfect score: 49
Sequence: 1 SEVKMDAEFR 10

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 830525 seqs, 258052604 residues

Total number of hits satisfying chosen parameters: 830525

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SPTREMBL_23:*
1: sp_archaea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_rodent:*
12: sp_virus:*
13: sp_vertibrate:*
14: sp_unclassified:*
15: sp_rvirus:*
16: sp_bacteriap:*
17: sp_archeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

%
Result Query
No. Score Match Length DB ID Description

1	49	100.0	35	4	Q8WZ99	Q8wz99 homo sapien
2	49	100.0	82	4	Q16020	Q16020 homo sapien
3	49	100.0	82	4	Q16014	Q16014 homo sapien
4	49	100.0	82	4	Q16019	Q16019 homo sapien
5	49	100.0	113	13	Q8JH58	Q8jh58 chelydra se
6	49	100.0	534	13	O93296	O93296 gallus gall
7	49	100.0	569	13	Q9PVL1	Q9pvl1 gallus gall
8	49	100.0	695	11	Q60496	Q60496 cavia sp. p
9	49	100.0	695	13	Q9DGJ8	Q9dgj8 gallus gall
10	49	100.0	751	13	Q9DGJ7	Q9dgj7 gallus gall
11	49	100.0	770	6	Q9TUI0	Q9tui0 sus scrofa
12	44	89.8	79	11	O35463	O35463 cricetus
13	44	89.8	218	11	Q8BPV5	Q8bpv5 mus musculu
14	44	89.8	384	11	Q8BPC7	Q8bpc7 mus musculu
15	44	89.8	607	11	Q99K32	Q99k32 mus musculu
16	44	89.8	695	11	P97487	P97487 mus musculu
17	43	87.8	693	13	Q98SG0	Q98sg0 xenopus lae
18	43	87.8	695	13	Q98SF9	Q98sf9 xenopus lae
19	43	87.8	747	13	Q91963	Q91963 xenopus. ap
20	42	85.7	423	2	O52379	O52379 ralstonia s
21	42	85.7	423	2	Q45693	Q45693 burkholderi
22	39	79.6	142	5	O16896	O16896 caenorhabdi
23	36	73.5	630	2	Q93IK4	Q93ik4 vibrio sp.
24	35	71.4	317	17	Q96ZT2	Q96zt2 sulfolobus
25	35	71.4	419	2	Q8GHI9	Q8ghi9 pigmentipha
26	35	71.4	774	16	Q92CV7	Q92cv7 listeria in
27	35	71.4	2148	5	Q8IPL5	Q8ipl5 drosophila
28	34	69.4	239	10	Q9FNG2	Q9fng2 arabidopsis
29	34	69.4	254	5	Q8IK90	Q8ik90 plasmodium
30	34	69.4	605	16	Q9L1F6	Q9l1f6 streptomyce
31	34	69.4	626	16	Q8ZCN4	Q8zcn4 yersinia pe
32	34	69.4	1192	10	Q94BS1	Q94bs1 arabidopsis
33	34	69.4	1261	10	Q9LU30	Q9lu30 arabidopsis
34	34	69.4	3262	4	Q13788	Q13788 homo sapien
35	33	67.3	302	9	Q37840	Q37840 bacterioph
36	33	67.3	438	2	Q9AIK4	Q9aik4 bilophila w
37	33	67.3	449	16	Q8D1Z2	Q8dlz2 wiggleswort
38	33	67.3	582	16	Q8KFP0	Q8kfp0 chlorobium
39	33	67.3	621	4	Q9H9Y1	Q9h9y1 homo sapien
40	33	67.3	711	16	Q8EFW4	Q8efw4 shewanella
41	33	67.3	1027	4	Q9BWZ2	Q9bwz2 homo sapien
42	33	67.3	1245	10	Q9C7F8	Q9c7f8 arabidopsis
43	32	65.3	143	4	Q9H935	Q9h935 homo sapien
44	32	65.3	161	16	Q98FZ2	Q98fz2 rhizobium l
45	32	65.3	286	2	Q8VNV1	Q8vnv1 chlorobium

ALIGNMENTS

RESULT 1

Q8WZ99

ID	Q8WZ99	PRELIMINARY;	PRT;	35 AA.
AC	Q8WZ99;			
DT	01-MAR-2002	(TrEMBLrel. 20, Created)		
DT	01-MAR-2002	(TrEMBLrel. 20, Last sequence update)		
DT	01-MAR-2002	(TrEMBLrel. 20, Last annotation update)		

DE Amyloid protein (Fragment).
 GN APP.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Wakutani Y., Ninomiya H., Iwata H., Tanaka S., Urakami K., Adachi Y.,
 RA Wada-Isoe K., Yamagata K., Ohono K., Tsubuki S., Saido T.,
 RA Hashimoto T., Iwatsubo T., Nakashima K.;
 RT "Novel missense mutation (D678N) of amyloid precursor protein gene in
 RT a Japanese pedigree of familial Alzheimer's disease.";
 RL Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AB066441; BAB71958.1; -.
 FT NON_TER 1 1
 FT NON_TER 35 35
 SQ SEQUENCE 35 AA; 4084 MW; 49D7D17289743B71 CRC64;

Query Match 100.0%; Score 49; DB 4; Length 35;
 Best Local Similarity 100.0%; Pred. No. 0.0045;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 12 SEVKMDAEFR 21

RESULT 2

Q16020

ID Q16020 PRELIMINARY; PRT; 82 AA.
 AC Q16020;
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
 DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
 DE Beta-amyloid peptide (Fragment).
 GN BETA APP.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=93236601; PubMed=8476439;
 RA Denman R.B., Rosenzwaig R., Miller D.L.;
 RT "A system for studying the effect(s) of familial Alzheimer disease
 RT mutations on the processing of the beta-amyloid peptide precursor.";
 RL Biochem. Biophys. Res. Commun. 192:96-103(1993).
 DR EMBL; S61383; AAB26265.2; -.
 DR HSSP; P05067; 1BA4.
 DR InterPro; IPR001255; Beta-APP.
 DR Pfam; PF03494; Beta-APP; 1.
 FT NON_TER 1 1
 FT NON_TER 82 82
 SQ SEQUENCE 82 AA; 8882 MW; F534AA5AE5D9230A CRC64;

Query Match 100.0%; Score 49; DB 4; Length 82;

Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||||
Db 13 SEVKMDAEFR 22

RESULT 3

Q16014

ID Q16014 PRELIMINARY; PRT; 82 AA.
AC Q16014;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Beta-amyloid peptide (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=93236601; PubMed=8476439;
RA Denman R.B., Rosenzwaig R., Miller D.L.;
RT "A system for studying the effect(s) of familial Alzheimer disease
RT mutations on the processing of the beta-amyloid peptide precursor."
RL Biochem. Biophys. Res. Commun. 192:96-103(1993).
DR EMBL; S60721; AAB26263.2; -.
DR HSSP; P05067; 1BA4.
DR InterPro; IPR001255; Beta-APP.
DR Pfam; PF03494; Beta-APP; 1.
FT NON_TER 1 1
FT NON_TER 82 82
SQ SEQUENCE 82 AA; 8972 MW; F534AA5B3EA9230A CRC64;

Query Match 100.0%; Score 49; DB 4; Length 82;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||||
Db 13 SEVKMDAEFR 22

RESULT 4

Q16019

ID Q16019 PRELIMINARY; PRT; 82 AA.
AC Q16019;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Beta-amyloid peptide (Fragment).
GN BETA APP.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;

RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=93236601; PubMed=8476439;
 RA Denman R.B., Rosenzwaig R., Miller D.L.;
 RT "A system for studying the effect(s) of familial Alzheimer disease
 RT mutations on the processing of the beta-amyloid peptide precursor."
 RL Biochem. Biophys. Res. Commun. 192:96-103(1993).
 DR EMBL; S61380; AAB26264.2; -.
 DR HSSP; P05067; 1BA4.
 DR InterPro; IPR001255; Beta-APP.
 DR Pfam; PF03494; Beta-APP; 1.
 FT NON_TER 1 1
 FT NON_TER 82 82
 SQ SEQUENCE 82 AA; 8938 MW; F534AA50E579230A CRC64;

 Query Match 100.0%; Score 49; DB 4; Length 82;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 13 SEVKMDAEFR 22

RESULT 5

Q8JH58

ID Q8JH58 PRELIMINARY; PRT; 113 AA.
 AC Q8JH58;
 DT 01-OCT-2002 (TrEMBLrel. 22, Created)
 DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
 DE Amyloid beta protein (Fragment).
 OS Chelydra serpentina serpentina (common snapping turtle).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Testudines; Cryptodira; Testudinoidea; Chelydridae; Chelydra.
 OX NCBI_TaxID=134619;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21876906; PubMed=11882478;
 RA Trudeau V.L., Chiu S., Kennedy S.W., Brooks R.J.;
 RT "Octylphenol (OP) alters the expression of members of the amyloid
 RT protein family in the hypothalamus of the snapping turtle, Chelydra
 RT serpentina serpentina."
 RL Environ. Health Perspect. 110:269-275(2002).
 DR EMBL; AF541917; AAN04908.1; -.
 DR InterPro; IPR001868; A4_APP.
 DR InterPro; IPR001255; Beta-APP.
 DR Pfam; PF03494; Beta-APP; 1.
 DR PRINTS; PR00203; AMYLOIDA4.
 DR PROSITE; PS00320; A4_INTRA; 1.
 FT NON_TER 1 1
 SQ SEQUENCE 113 AA; 12750 MW; 72515C930496E053 CRC64;

Query Match 100.0%; Score 49; DB 13; Length 113;
 Best Local Similarity 100.0%; Pred. No. 0.015;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | |
Db 10 SEVKMDAEFR 19

RESULT 6

O93296

ID O93296 PRELIMINARY; PRT; 534 AA.
AC O93296;
DT 01-NOV-1998 (TrEMBLrel. 08, Created)
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Amyloid protein (Fragment).
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=98337885; PubMed=9671674;
RA Barnes N.Y., Li L., Yoshikawa K., Schwartz L.M., Oppenheim R.W.,
RA Milligan C.E.;
RT "Increased production of amyloid precursor protein provides a
RT substrate for caspase-3 in dying motoneurons.";
RL J. Neurosci. 18:5869-5880(1998).
DR EMBL; AF042098; AAC25052.1; -.
DR HSSP; P05067; 1BA4.
DR InterPro; IPR001868; A4_APP.
DR InterPro; IPR001255; Beta-APP.
DR Pfam; PF02177; A4_EXTRA; 1.
DR Pfam; PF03494; Beta-APP; 1.
DR PRINTS; PR00203; AMYLOIDA4.
DR PROSITE; PS00319; A4_EXTRA; 1.
DR PROSITE; PS00320; A4_INTRA; 1.
FT NON TER 1 1
SQ SEQUENCE 534 AA; 60597 MW; FB53ECC2E66D4C92 CRC64;

Query Match 100.0%; Score 49; DB 13; Length 534;
Best Local Similarity 100.0%; Pred. No. 0.075;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | |
Db 431 SEVKMDAEFR 440

RESULT 7

Q9PVL1

ID Q9PVL1 PRELIMINARY; PRT; 569 AA.
AC Q9PVL1;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Amyloid protein (Fragment).
GN APP.
OS Gallus gallus (Chicken).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
 OC Gallus.
 OX NCBI_TaxID=9031;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Brain;
 RA Coulson E.J., Paliga K., Beyreuther K., Masters C.L.;
 RT "What the evolution of the amyloid protein precursor supergene family
 RT tells us about its function.";
 RL Neurochem. Int. 0:0-0(2000).
 DR EMBL; AF030341; AAF12698.1; -.
 DR HSSP; P05067; 1BA4.
 DR InterPro; IPR001868; A4_APP.
 DR InterPro; IPR001255; Beta-APP.
 DR Pfam; PF02177; A4_EXTRA; 1.
 DR Pfam; PF03494; Beta-APP; 1.
 DR PRINTS; PR00203; AMYLOIDA4.
 DR PROSITE; PS00319; A4_EXTRA; 1.
 DR PROSITE; PS00320; A4_INTRA; 1.
 FT NON_TER 1 1
 SQ SEQUENCE 569 AA; 64753 MW; 0AB8BB851863A19D CRC64;

 Query Match 100.0%; Score 49; DB 13; Length 569;
 Best Local Similarity 100.0%; Pred. No. 0.08;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 467 SEVKMDAEFR 476

RESULT 8

Q60496

ID Q60496 PRELIMINARY; PRT; 695 AA.
 AC Q60496;
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
 DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
 DE Putative amyloid precursor protein.
 OS Cavia sp.
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Hystricognathi; Caviidae; Cavia.
 OX NCBI_TaxID=10143;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Brain;
 RX MEDLINE=97236426; PubMed=9116031;
 RA Beck M., Mueller D., Bigl V.;
 RT "Amyloid precursor protein in Guinea pigs - complete cDNA sequence and
 RT alternative splicing.";
 RL Biochim. Biophys. Acta 1351:17-21(1997).
 DR EMBL; X97631; CAA66230.1; -.
 DR HSSP; P05067; 1BA4.
 DR InterPro; IPR001868; A4_APP.
 DR InterPro; IPR001255; Beta-APP.
 DR Pfam; PF02177; A4_EXTRA; 1.

DR Pfam; PF03494; Beta-APP; 1.
DR PRINTS; PR00203; AMYLOIDA4.
DR SMART; SM00006; A4_EXTRA; 1.
DR PROSITE; PS00319; A4_EXTRA; 1.
DR PROSITE; PS00320; A4_INTRA; 1.
SQ SEQUENCE 695 AA; 78701 MW; 5196A0C4017F16AB CRC64;

Query Match 100.0%; Score 49; DB 11; Length 695;
Best Local Similarity 100.0%; Pred. No. 0.099;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 592 SEVKMDAEFR 601

RESULT 9

Q9DGJ8

ID Q9DGJ8 PRELIMINARY; PRT; 695 AA.
AC Q9DGJ8;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Beta-amyloid precursor protein 695 isoform.
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RA Sarasa M., Rodolosse A., Sorribas V.;
RT "Cloning of full-length chicken beta-amyloid precursor protein
RT isoforms.";
RL Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
DR EMBL; AF289218; AAG00593.1; -.
DR HSSP; P05067; 1BA4.
DR InterPro; IPR001868; A4_APP.
DR InterPro; IPR001255; Beta-APP.
DR Pfam; PF02177; A4_EXTRA; 1.
DR Pfam; PF03494; Beta-APP; 1.
DR PRINTS; PR00203; AMYLOIDA4.
DR SMART; SM00006; A4_EXTRA; 1.
DR PROSITE; PS00319; A4_EXTRA; 1.
DR PROSITE; PS00320; A4_INTRA; 1.
SQ SEQUENCE 695 AA; 78565 MW; F201ED02AEC86D95 CRC64;

Query Match 100.0%; Score 49; DB 13; Length 695;
Best Local Similarity 100.0%; Pred. No. 0.099;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 592 SEVKMDAEFR 601

RESULT 10

Q9DGJ7

ID Q9DGJ7 PRELIMINARY; PRT; 751 AA.
 AC Q9DGJ7;
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
 DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
 DE Beta-amyloid precursor protein 751 isoform.
 OS Gallus gallus (Chicken).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
 OC Gallus.
 OX NCBI_TaxID=9031;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Sarasa M., Rodolosse A., Sorribas V.;
 RT "Cloning of full-length chicken beta-amyloid precursor protein
 RT isoforms."
 RL Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF289219; AAG00594.1; -.
 DR HSSP; P05067; 1BA4.
 DR InterPro; IPR001868; A4_APP.
 DR InterPro; IPR001255; Beta-APP.
 DR InterPro; IPR002223; Kunitz_BPTI.
 DR Pfam; PF02177; A4_EXTRA; 1.
 DR Pfam; PF03494; Beta-APP; 1.
 DR Pfam; PF00014; Kunitz_BPTI; 1.
 DR PRINTS; PR00203; AMYLOIDA4.
 DR PRINTS; PR00759; BASICPTASE.
 DR ProDom; PD000222; Kunitz_BPTI; 1.
 DR SMART; SM00006; A4_EXTRA; 1.
 DR SMART; SM00131; KU; 1.
 DR PROSITE; PS00319; A4_EXTRA; 1.
 DR PROSITE; PS00320; A4_INTRA; 1.
 DR PROSITE; PS00280; BPTI_KUNITZ_1; 1.
 DR PROSITE; PS50279; BPTI_KUNITZ_2; 1.
 KW Protease inhibitor; Serine protease inhibitor.
 SQ SEQUENCE 751 AA; 84705 MW; E78E9413A8033D84 CRC64;

Query Match 100.0%; Score 49; DB 13; Length 751;
 Best Local Similarity 100.0%; Pred. No. 0.11;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 648 SEVKMDAEFR 657

RESULT 11

Q9TUI0

ID Q9TUI0 PRELIMINARY; PRT; 770 AA.
 AC Q9TUI0;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
 DE Amyloid precursor protein.
 OS Sus scrofa (Pig).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
 OX NCBI_TaxID=9823;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Kimura A., Takahashi T.;
 RT "Amyloid Precursor Protein 770."
 RL Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AB032550; BAA84580.1; -.
 DR HSSP; P05067; 1AAP.
 DR InterPro; IPR001868; A4_APP.
 DR InterPro; IPR001255; Beta-APP.
 DR InterPro; IPR002223; Kunitz_BPTI.
 DR Pfam; PF02177; A4_EXTRA; 1.
 DR Pfam; PF03494; Beta-APP; 1.
 DR Pfam; PF00014; Kunitz_BPTI; 1.
 DR PRINTS; PR00203; AMYLOIDA4.
 DR PRINTS; PR00759; BASICPTASE.
 DR ProDom; PD000222; Kunitz_BPTI; 1.
 DR SMART; SM00006; A4_EXTRA; 1.
 DR SMART; SM00131; KU; 1.
 DR PROSITE; PS00319; A4_EXTRA; 1.
 DR PROSITE; PS00320; A4_INTRA; 1.
 DR PROSITE; PS00280; BPTI_KUNITZ_1; 1.
 DR PROSITE; PS50279; BPTI_KUNITZ_2; 1.
 KW Protease inhibitor; Serine protease inhibitor.
 SQ SEQUENCE 770 AA; 86961 MW; 5F7A1DCB2BCC583E CRC64;

Query Match 100.0%; Score 49; DB 6; Length 770;
 Best Local Similarity 100.0%; Pred. No. 0.11;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 667 SEVKMDAEFR 676

RESULT 12

O35463

ID O35463 PRELIMINARY; PRT; 79 AA.
 AC O35463;
 DT 01-JAN-1998 (TrEMBLrel. 05, Created)
 DT 01-JAN-1998 (TrEMBLrel. 05, Last sequence update)
 DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
 DE Alzheimer's amyloid beta protein (Fragment).
 GN BETA APP.
 OS Cricetulus griseus (Chinese hamster).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Cricetinae;
 OC Cricetulus.
 OX NCBI_TaxID=10029;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Sambamurti K., Pinnix I., Gandhi S.;
 RL Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF030413; AAB86608.1; -.
 DR HSSP; P05067; 1BA4.
 DR InterPro; IPR001255; Beta-APP.

DR Pfam; PF03494; Beta-APP; 1.

FT NON_TER 1 1

FT NON_TER 79 79

SQ SEQUENCE 79 AA; 8538 MW; 37F2C6C3BFF3F597 CRC64;

Query Match 89.8%; Score 44; DB 11; Length 79;

Best Local Similarity 100.0%; Pred. No. 0.12;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEF 9

|||||

Db 16 SEVKMDAEF 24

RESULT 13

Q8BPV5

ID Q8BPV5 PRELIMINARY; PRT; 218 AA.

AC Q8BPV5;

DT 01-MAR-2003 (TrEMBLrel. 23, Created)

DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)

DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)

DE Amyloid beta (Fragment).

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=C57BL/6J; TISSUE=Lung;

RX MEDLINE=22354683; PubMed=12466851;

RA The FANTOM Consortium,

RA the RIKEN Genome Exploration Research Group Phase I & II Team;

RT "Analysis of the mouse transcriptome based on functional annotation of

RT 60,770 full-length cDNAs.";

RL Nature 420:563-573(2002).

DR EMBL; AK052448; BAC34997.1; -.

FT NON_TER 1 1

SQ SEQUENCE 218 AA; 24118 MW; 95B55AFDAE1D0EF5 CRC64;

Query Match 89.8%; Score 44; DB 11; Length 218;

Best Local Similarity 100.0%; Pred. No. 0.34;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEF 9

|||||

Db 115 SEVKMDAEF 123

RESULT 14

Q8BPC7

ID Q8BPC7 PRELIMINARY; PRT; 384 AA.

AC Q8BPC7;

DT 01-MAR-2003 (TrEMBLrel. 23, Created)

DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)

DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)

DE Amyloid beta (Fragment).

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Head;
 RX MEDLINE=22354683; PubMed=12466851;
 RA The FANTOM Consortium,
 RA the RIKEN Genome Exploration Research Group Phase I & II Team;
 RT "Analysis of the mouse transcriptome based on functional annotation of
 RT 60,770 full-length cDNAs."
 RL Nature 420:563-573(2002).
 DR EMBL; AK076506; BAC36369.1; -.
 FT NON_TER 1 1
 SQ SEQUENCE 384 AA; 43990 MW; A81B1AD8AE683173 CRC64;

Query Match 89.8%; Score 44; DB 11; Length 384;
 Best Local Similarity 100.0%; Pred. No. 0.61;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEF 9
 |||||
 Db 281 SEVKMDAEF 289

RESULT 15

Q99K32

ID Q99K32 PRELIMINARY; PRT; 607 AA.
 AC Q99K32;
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
 DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
 DE Hypothetical 68.4 kDa protein (Fragment).
 GN APP.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Strausberg R.;
 RL Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; BC005490; AAH05490.1; -.
 DR HSSP; P05067; 1AAP.
 DR MGD; MGI:88059; App.
 DR InterPro; IPR001868; A4_APP.
 DR InterPro; IPR001255; Beta-APP.
 DR InterPro; IPR002223; Kunitz_BPTI.
 DR Pfam; PF02177; A4_EXTRA; 1.
 DR Pfam; PF03494; Beta-APP; 1.
 DR Pfam; PF00014; Kunitz_BPTI; 1.
 DR PRINTS; PR00203; AMYLOIDA4.
 DR PRINTS; PR00759; BASICPTASE.
 DR ProDom; PD000222; Kunitz_BPTI; 1.
 DR SMART; SM00131; KU; 1.
 DR PROSITE; PS00319; A4_EXTRA; 1.
 DR PROSITE; PS00320; A4_INTRA; 1.

DR PROSITE; PS00280; BPTI_KUNITZ_1; 1.
DR PROSITE; PS50279; BPTI_KUNITZ_2; 1.
KW Hypothetical protein; Protease inhibitor; Serine protease inhibitor.
FT NON_TER 1 1
SQ SEQUENCE 607 AA; 68391 MW; BF802214CBA7D172 CRC64;

Query Match 89.8%; Score 44; DB 11; Length 607;
Best Local Similarity 100.0%; Pred. No. 0.98;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEF 9
| | | | | | | |
Db 504 SEVKMDAEF 512

Search completed: January 21, 2004, 09:25:08
Job time : 3.06501 secs

OM protein - protein search, using sw model

Run on: January 21, 2004, 09:15:44 ; Search time 0.497132 Seconds
(without alignments)
945.960 Million cell updates/sec

Title: US-09-869-414A-64
Perfect score: 49
Sequence: 1 SEVKMDAEFR 10

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 127863 seqs, 47026705 residues

Total number of hits satisfying chosen parameters: 127863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SwissProt_41:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	% Query		Match Length	DB	ID	Description
	Score	Match				
1	49	100.0	57	1	A4_URSMA	Q29149 ursus marit
2	49	100.0	58	1	A4_CANFA	Q28280 canis famil
3	49	100.0	58	1	A4_RABIT	Q28748 oryctolagus
4	49	100.0	58	1	A4_SHEEP	Q28757 ovis aries
5	49	100.0	59	1	A4_BOVIN	Q28053 bos taurus
6	49	100.0	751	1	A4_SAIISC	Q95241 s amyloid b
7	49	100.0	770	1	A4_CAVPO	Q60495 c amyloid b
8	49	100.0	770	1	A4_HUMAN	P05067 h amyloid b
9	49	100.0	770	1	A4_MACFA	P53601 m amyloid b
10	49	100.0	770	1	A4_PIG	P79307 s amyloid b
11	44	89.8	770	1	A4_MOUSE	P12023 m amyloid b
12	44	89.8	770	1	A4_RAT	P08592 r amyloid b
13	37	75.5	269	1	T2S1_STRFI	O52512 streptomyce
14	34	69.4	3562	1	PGCV_CHICK	Q90953 gallus gall
15	34	69.4	4563	1	APB_HUMAN	P04114 homo sapien
16	33	67.3	927	1	CC15_SCHPO	Q09822 schizosacch
17	32	65.3	263	1	Y683_HALN1	Q9hri2 halobacteri

18	32	65.3	354	1	BCPA_CHLLT	Q46135	chlorobium
19	32	65.3	365	1	BCPA_CHLTE	Q46393	chlorobium
20	32	65.3	776	1	OSTA_VIBVU	Q8ded5	vibrio vuln
21	32	65.3	1906	1	YFA0_ANASP	Q8ym40	anabaena sp
22	31	63.3	81	1	RS16_CLOPE	Q8xjp4	clostridium
23	31	63.3	178	1	YJGA_HAEIN	P45076	haemophilus
24	31	63.3	183	1	YJGA_ECOLI	P26650	escherichia
25	31	63.3	198	1	TNF4_MOUSE	P43488	mus musculu
26	31	63.3	279	1	RFA2_SCHPO	Q92373	schizosacch
27	31	63.3	346	1	PA6A_HUMAN	Q9npb6	homo sapien
28	31	63.3	346	1	PA6A_MOUSE	Q9z101	mus musculu
29	31	63.3	416	1	TRPB_RHILO	Q98cn7	rhizobium l
30	31	63.3	479	1	Y098_MYCPN	P75535	mycoplasma
31	31	63.3	1024	1	Y075_MYCGE	P47321	mycoplasma
32	30	61.2	78	1	RL31_RICCN	Q92jd0	rickettsia
33	30	61.2	78	1	RL31_RICPR	Q9ze47	rickettsia
34	30	61.2	197	1	OM26_HAEIN	Q57483	haemophilus
35	30	61.2	351	1	HI82_RHIME	Q92121	rhizobium m
36	30	61.2	356	1	RF1_BACSU	P45872	bacillus su
37	30	61.2	394	1	EFTU_BUCAI	O31297	buchnera ap
38	30	61.2	400	1	YF74_ARCFU	O28698	archaeoglob
39	30	61.2	419	1	P47K_PSECL	P31521	pseudomonas
40	30	61.2	463	1	YDI4_SCHPO	Q92342	schizosacch
41	30	61.2	464	1	SPN5_SCHPO	P48010	schizosacch
42	30	61.2	595	1	SYK_MOUSE	Q99mn1	mus musculu
43	30	61.2	656	1	V091_FOWPV	O72896	fowlpox vir
44	30	61.2	666	1	ZP2_RABIT	P48829	oryctolagus
45	30	61.2	681	1	THIC_YERPE	Q8zaq2	yersinia pe

ALIGNMENTS

RESULT 1

A4_URSMA

ID A4_URSMA STANDARD; PRT; 57 AA.
AC Q29149;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE Alzheimer's disease amyloid A4 protein homolog [Contains: Beta-amyloid
DE protein (Beta-APP) (A-beta)] (Fragment).
GN APP.
OS Ursus maritimus (Polar bear) (Thalarctos maritimus).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Ursidae; Ursus.
OX NCBI_TaxID=29073;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=92017079; PubMed=1656157;
RA Johnstone E.M., Chaney M.O., Norris F.H., Pascual R., Little S.P.;
RT "Conservation of the sequence of the Alzheimer's disease amyloid
RT peptide in dog, polar bear and five other mammals by cross-species
RT polymerase chain reaction analysis."
RL Brain Res. Mol. Brain Res. 10:299-305(1991).
CC -!- FUNCTION: FUNCTIONAL NEURONAL RECEPTOR WHICH COUPLES TO

CC INTRACELLULAR SIGNALING PATHWAY THROUGH THE GTP-BINDING PROTEIN
 CC G(O) (BY SIMILARITY).
 CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
 CC -!- SIMILARITY: BELONGS TO THE APP FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; X56128; CAA39593.1; -.
 DR PIR; B60045; B60045.
 DR HSSP; P05067; 1BA4.
 DR InterPro; IPR001868; A4_APP.
 DR InterPro; IPR001255; Beta-APP.
 DR Pfam; PF03494; Beta-APP; 1.
 DR PROSITE; PS00319; A4_EXTRA; PARTIAL.
 DR PROSITE; PS00320; A4_INTRA; PARTIAL.
 KW Glycoprotein; Amyloid; Neurone; Transmembrane.
 FT NON_TER 1 1
 FT CHAIN 6 48 BETA-AMYLOID PROTEIN (POTENTIAL).
 FT DOMAIN <1 33 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 34 57 POTENTIAL.
 FT NON_TER 57 57
 SQ SEQUENCE 57 AA; 6172 MW; 84209D88EBA82DFA CRC64;

Query Match 100.0%; Score 49; DB 1; Length 57;
 Best Local Similarity 100.0%; Pred. No. 0.0019;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 1 SEVKMDAEFR 10

RESULT 2

A4_CANFA

ID A4_CANFA STANDARD; PRT; 58 AA.
 AC Q28280;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 01-NOV-1997 (Rel. 35, Last sequence update)
 DT 30-MAY-2000 (Rel. 39, Last annotation update)
 DE Alzheimer's disease amyloid A4 protein homolog [Contains: Beta-amyloid
 DE protein (Beta-APP) (A-beta)] (Fragment).
 GN APP.
 OS Canis familiaris (Dog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
 OX NCBI_TaxID=9615;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Kidney;
 RX MEDLINE=92017079; PubMed=1656157;
 RA Johnstone E.M., Chaney M.O., Norris F.H., Pascual R., Little S.P.;

RT "Conservation of the sequence of the Alzheimer's disease amyloid
 RT peptide in dog, polar bear and five other mammals by cross-species
 RT polymerase chain reaction analysis.";
 RL Brain Res. Mol. Brain Res. 10:299-305(1991).
 CC -!- FUNCTION: FUNCTIONAL NEURONAL RECEPTOR WHICH COUPLES TO
 CC INTRACELLULAR SIGNALING PATHWAY THROUGH THE GTP-BINDING PROTEIN
 CC G(O) (BY SIMILARITY).
 CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
 CC -!- SIMILARITY: BELONGS TO THE APP FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; X56125; CAA39590.1; -.
 DR HSSP; P05067; 1BA4.
 DR InterPro; IPR001868; A4_APP.
 DR InterPro; IPR001255; Beta-APP.
 DR Pfam; PF03494; Beta-APP; 1.
 DR PROSITE; PS00319; A4_EXTRA; PARTIAL.
 DR PROSITE; PS00320; A4_INTRA; PARTIAL.
 KW Glycoprotein; Amyloid; Neurone; Transmembrane.
 FT NON_TER 1 1
 FT CHAIN 7 49 BETA-AMYLOID PROTEIN (POTENTIAL).
 FT DOMAIN <1 34 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 35 58 POTENTIAL.
 FT NON_TER 58 58
 SQ SEQUENCE 58 AA; 6285 MW; 8469D488A2E12DFA CRC64;

Query Match 100.0%; Score 49; DB 1; Length 58;
 Best Local Similarity 100.0%; Pred. No. 0.0019;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 2 SEVKMDAEFR 11

RESULT 3

A4_RABIT

ID A4_RABIT STANDARD; PRT; 58 AA.
 AC Q28748;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 01-NOV-1997 (Rel. 35, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Alzheimer's disease amyloid A4 protein homolog [Contains: Beta-amyloid
 DE protein (Beta-APP) (A-beta)] (Fragment).
 GN APP.
 OS Oryctolagus cuniculus (Rabbit).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
 OX NCBI_TaxID=9986;
 RN [1]

RP SEQUENCE FROM N.A.
 RC TISSUE=Brain;
 RX MEDLINE=92017079; PubMed=1656157;
 RA Johnstone E.M., Chaney M.O., Norris F.H., Pascual R., Little S.P.;
 RT "Conservation of the sequence of the Alzheimer's disease amyloid
 RT peptide in dog, polar bear and five other mammals by cross-species
 RT polymerase chain reaction analysis.";
 RL Brain Res. Mol. Brain Res. 10:299-305(1991).
 CC -!- FUNCTION: FUNCTIONAL NEURONAL RECEPTOR WHICH COUPLES TO
 CC INTRACELLULAR SIGNALING PATHWAY THROUGH THE GTP-BINDING PROTEIN
 CC G(O) (BY SIMILARITY).
 CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
 CC -!- SIMILARITY: BELONGS TO THE APP FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; X56129; CAA39594.1; -.
 DR HSSP; P05067; 1BA4.
 DR InterPro; IPR001868; A4_APP.
 DR InterPro; IPR001255; Beta-APP.
 DR Pfam; PF03494; Beta-APP; 1.
 DR PROSITE; PS00319; A4_EXTRA; PARTIAL.
 DR PROSITE; PS00320; A4_INTRA; PARTIAL.
 KW Glycoprotein; Amyloid; Neurone; Transmembrane.
 FT NON_TER 1 1
 FT CHAIN 6 48 BETA-AMYLOID PROTEIN (POTENTIAL).
 FT DOMAIN <1 33 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 34 57 POTENTIAL.
 FT DOMAIN 58 >58 CYTOPLASMIC (POTENTIAL).
 FT NON_TER 58 58
 SQ SEQUENCE 58 AA; 6300 MW; F434209D88EBA82D CRC64;

Query Match 100.0%; Score 49; DB 1; Length 58;
 Best Local Similarity 100.0%; Pred. No. 0.0019;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 1 SEVKMDAEFR 10

RESULT 4

A4_SHEEP

ID A4_SHEEP STANDARD; PRT; 58 AA.
 AC Q28757;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 01-NOV-1997 (Rel. 35, Last sequence update)
 DT 30-MAY-2000 (Rel. 39, Last annotation update)
 DE Alzheimer's disease amyloid A4 protein homolog [Contains: Beta-amyloid
 DE protein (Beta-APP) (A-beta)] (Fragment).
 GN APP.

OS *Ovis aries* (Sheep).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;
 OC Bovidae; Caprinae; Ovis.
 OX NCBI_TaxID=9940;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Heart;
 RX MEDLINE=92017079; PubMed=1656157;
 RA Johnstone E.M., Chaney M.O., Norris F.H., Pascual R., Little S.P.;
 RT "Conservation of the sequence of the Alzheimer's disease amyloid
 RT peptide in dog, polar bear and five other mammals by cross-species
 RT polymerase chain reaction analysis."
 RL Brain Res. Mol. Brain Res. 10:299-305(1991).
 CC -!- FUNCTION: FUNCTIONAL NEURONAL RECEPTOR WHICH COUPLES TO
 CC INTRACELLULAR SIGNALING PATHWAY THROUGH THE GTP-BINDING PROTEIN
 CC G(O) (BY SIMILARITY).
 CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
 CC -!- SIMILARITY: BELONGS TO THE APP FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; X56130; CAA39595.1; -.
 DR HSSP; P05067; 1BA4.
 DR InterPro; IPR001868; A4_APP.
 DR InterPro; IPR001255; Beta-APP.
 DR Pfam; PF03494; Beta-APP; 1.
 DR PROSITE; PS00319; A4_EXTRA; PARTIAL.
 DR PROSITE; PS00320; A4_INTRA; PARTIAL.
 KW Glycoprotein; Amyloid; Neurone; Transmembrane.
 FT NON_TER 1 1
 FT CHAIN 6 48 BETA-AMYLOID PROTEIN (POTENTIAL).
 FT DOMAIN <1 33 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 34 57 POTENTIAL.
 FT DOMAIN 58 >58 CYTOPLASMIC (POTENTIAL).
 FT NON_TER 58 58
 SQ SEQUENCE 58 AA; 6300 MW; F434209D88EBA82D CRC64;

Query Match 100.0%; Score 49; DB 1; Length 58;
 Best Local Similarity 100.0%; Pred. No. 0.0019;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 1 SEVKMDAEFR 10

RESULT 5
 A4_BOVIN
 ID A4_BOVIN STANDARD; PRT; 59 AA.
 AC Q28053;

DT 01-NOV-1997 (Rel. 35, Created)
 DT 01-NOV-1997 (Rel. 35, Last sequence update)
 DT 30-MAY-2000 (Rel. 39, Last annotation update)
 DE Alzheimer's disease amyloid A4 protein homolog [Contains: Beta-amyloid
 DE protein (Beta-APP) (A-beta)] (Fragment).
 GN APP.
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;
 OC Bovidae; Bovinae; Bos.
 OX NCBI_TaxID=9913;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Brain;
 RX MEDLINE=92017079; PubMed=1656157;
 RA Johnstone E.M., Chaney M.O., Norris F.H., Pascual R., Little S.P.;
 RT "Conservation of the sequence of the Alzheimer's disease amyloid
 RT peptide in dog, polar bear and five other mammals by cross-species
 RT polymerase chain reaction analysis."
 RL Brain Res. Mol. Brain Res. 10:299-305(1991).
 CC -!- FUNCTION: FUNCTIONAL NEURONAL RECEPTOR WHICH COUPLES TO
 CC INTRACELLULAR SIGNALING PATHWAY THROUGH THE GTP-BINDING PROTEIN
 CC G(O) (BY SIMILARITY).
 CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
 CC -!- SIMILARITY: BELONGS TO THE APP FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; X56124; CAA39589.1; -.
 DR EMBL; X56126; CAA39591.1; -.
 DR HSSP; P05067; 1BA4.
 DR InterPro; IPR001868; A4_APP.
 DR InterPro; IPR001255; Beta-APP.
 DR Pfam; PF03494; Beta-APP; 1.
 DR PROSITE; PS00319; A4_EXTRA; PARTIAL.
 DR PROSITE; PS00320; A4_INTRA; PARTIAL.
 KW Glycoprotein; Amyloid; Neurone; Transmembrane.
 FT NON_TER 1 1
 FT CHAIN 7 49 BETA-AMYLOID PROTEIN (POTENTIAL).
 FT DOMAIN <1 34 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 35 58 POTENTIAL.
 FT DOMAIN 59 >59 CYTOPLASMIC (POTENTIAL).
 FT NON_TER 59 59
 SQ SEQUENCE 59 AA; 6414 MW; F43469D488A2E12D CRC64;

Query Match 100.0%; Score 49; DB 1; Length 59;
 Best Local Similarity 100.0%; Pred. No. 0.0019;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||

RESULT 6

A4_SAISC

ID A4_SAISC STANDARD; PRT; 751 AA.
AC Q95241;
DT 15-DEC-1998 (Rel. 37, Created)
DT 15-DEC-1998 (Rel. 37, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Amyloid beta A4 protein precursor (APP) (Alzheimer's disease amyloid
DE protein homolog) [Contains: Soluble APP-alpha (S-APP-alpha); Soluble
DE APP-beta (S-APP-beta); C99; Beta-amyloid protein 42 (Beta-APP42);
DE Beta-amyloid protein 40 (Beta-APP40); C83; P3(42); P3(40); Gamma-
DE CTF(59) (Gamma-secretase C-terminal fragment 59); Gamma-CTF(57)
DE (Gamma-secretase C-terminal fragment 57); Gamma-CTF(50) (Gamma-
DE secretase C-terminal fragment 50); C31].
GN APP.
OS Saimiri sciureus (Common squirrel monkey).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Platyrrhini; Cebidae; Cebinae; Saimiri.
OX NCBI_TaxID=9521;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Kidney, and Liver;
RX MEDLINE=96108492; PubMed=8532114;
RA Levy E., Amorim A., Frangione B., Walker L.C.;
RT "Beta-amyloid precursor protein gene in squirrel monkeys with
RT cerebral amyloid angiopathy."
RL Neurobiol. Aging 16:805-808(1995).
CC -!- FUNCTION: Functions as a cell surface receptor and performs
CC physiological functions on the surface of neurons relevant to
CC neurite growth, neuronal adhesion and axonogenesis. Involved in
CC cell mobility and transcription regulation through protein-protein
CC interactions (By similarity). Can promote transcription activation
CC through binding to APBB1/Tip60 and inhibit Notch signaling through
CC interaction with Numb (By similarity). Couples to apoptosis-
CC inducing pathways such as those mediated by G(0) and JIP (By
CC similarity). Inhibits G(0) alpha ATPase activity (By similarity).
CC Acts as a kinesin I membrane receptor, mediating the axonal
CC transport of beta-secretase and presenilin 1 (By similarity). May
CC be involved in copper homeostasis/oxidative stress through copper
CC ion reduction. In vitro, copper-metallated APP induces neuronal
CC death directly or is potentiated through Cu(II)-mediated low-
CC density lipoprotein oxidation (By similarity). Can regulate
CC neurite outgrowth through binding to components of the
CC extracellular matrix such as heparin and collagen I and IV (By
CC similarity). The splice isoforms that contain the BPTI domain
CC possess protease inhibitor activity (By similarity).
CC -!- FUNCTION: Beta-amyloid peptides are lipophilic metal chelators
CC with metal-reducing activity. Bind transient metals such as
CC copper, zinc and iron (By similarity).
CC -!- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved
CC peptides, including C31, are potent enhancers of neuronal
CC apoptosis (By similarity).
CC -!- SUBUNIT: Binds, via its C-terminal, to the PID domain of several
CC cytoplasmic proteins, including APBB family members, the APBA

family, MAPK8IP1, and SHC1, Numb and Dab1 (By similarity). Binding to Dab1 inhibits its serine phosphorylation (By similarity). Also interacts with GPCR-like protein BPP, FPRL1, APPBP1, IB1, KNS2 (via its TPR domains) (By similarity), APPBP2 (via BaSS) and DDB1. In vitro, it binds MAPT via the MT-binding domains (By similarity). Associates with microtubules in the presence of ATP and in a kinesin-dependent manner (By similarity).

-!- SUBCELLULAR LOCATION: Type I membrane protein. Cell surface protein that rapidly becomes internalized via clatherin-coated pits. During maturation, the immature APP (N-glycosylated in the endoplasmic reticulum) moves to the Golgi complex where complete maturation occurs (O-glycosylated and sulfated). After alpha-secretase cleavage, soluble APP is released into the extracellular space and the C-terminal is internalized to endosomes and lysosomes. Some APP accumulates in secretory transport vesicles leaving the late Golgi compartment and returns to the cell surface. GammaCTF(59) peptide is located to both the cytoplasm and nuclei of neurons (By similarity).

-!- ALTERNATIVE PRODUCTS:

- Event=Alternative splicing; Named isoforms=2;
- Comment=Additional isoforms seem to exist;
- Name=APP770;
- IsoId=Q95241-1; Sequence=Displayed;
- Name=APP695;
- IsoId=Q95241-2; Sequence=Not described;

-!- DOMAIN: The basolateral sorting signal (BaSS) is required for sorting of membrane proteins to the basolateral surface of epithelial cells (By similarity).

-!- DOMAIN: The NPXY sequence motif found in many tyrosine-phosphorylated proteins is required for the specific binding of the PID domain. However additional amino acids either N- or C-terminal to the NPXY motif are often required for complete interaction. The PID domain-containing proteins which bind APP require the YENPTY motif for full interaction. These interactions are independent of phosphorylation on the terminal tyrosine residue. The NPXY site is also involved in clatherin-mediated endocytosis (By similarity).

-!- PTM: Proteolytically processed under normal cellular conditions. Cleavage by alpha-secretase or alternatively by beta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, respectively, and the retention of corresponding membrane-anchored C-terminal fragments, C83 and C99. Subsequent processing of C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is nonamyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gammaCTF(50), gammaCTF(57) and gammaCTF(59) (By similarity).

-!- PTM: Proteolytically cleaved by caspases during neuronal apoptosis (By similarity). Cleavage at Asp-720 by either caspase-3, -8 or -9 results in the production of the neurotoxic C31 peptide and the increased production of beta-amyloid peptides (By similarity).

-!- PTM: N- and O-linked glycosylated (By similarity).

-!- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and serine residues is neuron-specific. Phosphorylation can affect APP

CC processing, neuronal differentiation and interaction with other
 CC proteins (By similarity).
 CC -!- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and
 CC zinc, can induce histidine-bridging between beta-amyloid molecules
 CC resulting in beta-amyloid-metal aggregates (By similarity).
 CC Extracellular zinc-binding increases binding of heparin to APP and
 CC inhibits collagen-binding (By similarity).
 CC -!- SIMILARITY: BELONGS TO THE APP FAMILY.
 CC -!- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; S81024; AAD14347.1; -.
 DR HSSP; P05067; 1AAP.
 DR InterPro; IPR001868; A4_APP.
 DR InterPro; IPR001255; Beta-APP.
 DR InterPro; IPR002223; Kunitz_BPTI.
 DR Pfam; PF02177; A4_EXTRA; 1.
 DR Pfam; PF03494; Beta-APP; 1.
 DR Pfam; PF00014; Kunitz_BPTI; 1.
 DR PRINTS; PR00203; AMYLOIDA4.
 DR PRINTS; PR00759; BASICPTASE.
 DR ProDom; PD000222; Kunitz_BPTI; 1.
 DR SMART; SM00006; A4_EXTRA; 1.
 DR SMART; SM00131; KU; 1.
 DR PROSITE; PS00319; A4_EXTRA; 1.
 DR PROSITE; PS00320; A4_INTRA; 1.
 DR PROSITE; PS00280; BPTI_KUNITZ_1; 1.
 DR PROSITE; PS50279; BPTI_KUNITZ_2; 1.
 KW Apoptosis; Endocytosis; Cell adhesion; Serine protease inhibitor;
 KW Coated pits; Neurone; Heparin-binding; Metal-binding; Copper; Iron;
 KW Zinc; Signal; Transmembrane; Glycoprotein; Phosphorylation;
 KW Proteoglycan; Amyloid; Alternative splicing.
 FT SIGNAL 1 17 BY SIMILARITY.
 FT CHAIN 18 751 A4 PROTEIN.
 FT CHAIN 18 668 SOLUBLE APP-ALPHA (POTENTIAL).
 FT CHAIN 18 652 SOLUBLE APP-BETA (POTENTIAL).
 FT CHAIN 653 751 C99 (POTENTIAL).
 FT CHAIN 653 694 BETA-AMYLOID PROTEIN 42 (POTENTIAL).
 FT CHAIN 653 692 BETA-AMYLOID PROTEIN 40 (POTENTIAL).
 FT CHAIN 669 751 C83 (POTENTIAL).
 FT CHAIN 669 694 P3(42) (POTENTIAL).
 FT CHAIN 669 692 P3(40) (POTENTIAL).
 FT CHAIN 693 751 GAMMA-CTF(59) (POTENTIAL).
 FT CHAIN 695 751 GAMMA-CTF(57) (POTENTIAL).
 FT CHAIN 702 751 GAMMA-CTF(50) (POTENTIAL).
 FT CHAIN 721 751 C31 (POTENTIAL).
 FT DOMAIN 18 680 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 681 704 POTENTIAL.
 FT DOMAIN 705 751 CYTOPLASMIC (POTENTIAL).
 FT DOMAIN 96 110 HEPARIN-BINDING (BY SIMILARITY).

FT	DOMAIN	181	188	ZINC-BINDING (BY SIMILARITY).
FT	DOMAIN	291	341	BPTI/KUNITZ INHIBITOR.
FT	DOMAIN	316	344	HEPARIN-BINDING (BY SIMILARITY).
FT	DOMAIN	363	428	HEPARIN-BINDING (BY SIMILARITY).
FT	DOMAIN	504	521	COLLAGEN-BINDING (BY SIMILARITY).
FT	DOMAIN	713	732	INTERACTION WITH G(O)-ALPHA
FT				(BY SIMILARITY).
FT	DOMAIN	230	260	ASP/GLU-RICH (ACIDIC).
FT	DOMAIN	274	280	POLY-THR.
FT	SITE	144	144	REQUIRED FOR COPPER(II) REDUCTION
FT				(BY SIMILARITY).
FT	ACT_SITE	301	302	REACTIVE BOND.
FT	SITE	652	653	CLEAVAGE (BY BETA-SECRETASE)
FT				(BY SIMILARITY).
FT	SITE	653	654	CLEAVAGE (BY CASPASE-6) (BY SIMILARITY).
FT	SITE	668	669	CLEAVAGE (BY ALPHA-SECRETASE)
FT				(BY SIMILARITY).
FT	SITE	685	685	INVOLVED IN FREE RADICAL PROPAGATION
FT				(BY SIMILARITY).
FT	SITE	687	687	INVOLVED IN OXIDATIVE REACTIONS
FT				(BY SIMILARITY).
FT	SITE	692	693	CLEAVAGE (BY GAMMA-SECRETASE; SITE 1)
FT				(BY SIMILARITY).
FT	SITE	694	695	CLEAVAGE (BY GAMMA-SECRETASE; SITE 2)
FT				(BY SIMILARITY).
FT	SITE	701	702	CLEAVAGE (BY GAMMA-SECRETASE; SITE 3)
FT				(BY SIMILARITY).
FT	SITE	705	715	BASOLATERAL SORTING SIGNAL
FT				(BY SIMILARITY).
FT	SITE	720	721	CLEAVAGE (BY CASPASES-3,-6,-8 OR -9)
FT				(BY SIMILARITY).
FT	SITE	738	741	ENDOCYTOSIS SIGNAL.
FT	SITE	740	743	NPXY MOTIF.
FT	METAL	137	137	COPPER (BY SIMILARITY).

Query Match 100.0%; Score 49; DB 1; Length 751;
 Best Local Similarity 100.0%; Pred. No. 0.024;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 648 SEVKMDAEFR 657

RESULT 7

A4_CAVPO

ID A4_CAVPO STANDARD; PRT; 770 AA.
 AC Q60495; Q60496;
 DT 15-SEP-2003 (Rel. 42, Created)
 DT 15-SEP-2003 (Rel. 42, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Amyloid beta A4 protein precursor (APP) (ABPP) (Alzheimer's disease
 DE amyloid protein homolog) [Contains: Soluble APP-alpha (S-APP-alpha);
 DE Soluble APP-beta (S-APP-beta); CTF-alpha; CTF-beta; Beta-amyloid
 DE protein 42 (Beta-APP42); Beta-amyloid protein 40 (Beta-APP40); P3(42);
 DE P3(40); CTF(59) (Gamma-secretase C-terminal fragment 59); Gamma-
 DE CTF(57) (Gamma-secretase C-terminal fragment 57); C31].

GN APP.
 OS *Cavia porcellus* (Guinea pig).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Hystricognathi; Caviidae; *Cavia*.
 OX NCBI_TaxID=10141;
 RN [1]
 RP SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.
 RC TISSUE=Brain, and Liver;
 RX MEDLINE=97236426; PubMed=9116031;
 RA Beck M., Mueller D., Bigl V.;
 RT "Amyloid precursor protein in Guinea pigs - complete cDNA sequence and
 RT alternative splicing.";
 RL Biochim. Biophys. Acta 1351:17-21(1997).
 RN [2]
 RP INTERACTION OF BETA-APP40 WITH APOE.
 RX MEDLINE=98007700; PubMed=9349544;
 RA Martel C.L., Mackic J.B., Matsubara E., Governale S., Miguel C.,
 RA Miao W., McComb J.G., Frangione B., Ghiso J., Zlokovic B.V.;
 RT "Isoform-specific effects of apolipoproteins E2, E3, and E4 on
 RT cerebral capillary sequestration and blood-brain barrier transport of
 RT circulating Alzheimer's amyloid beta.";
 RL J. Neurochem. 69:1995-2004(1997).
 RN [3]
 RP PROCESSING.
 RX MEDLINE=20084499; PubMed=10619481;
 RA Beck M., Brueckner M.K., Holzer M., Kaap S., Pannicke T., Arendt T.,
 RA Bigl V.;
 RT "Guinea-pig primary cell cultures provide a model to study expression
 RT and amyloidogenic processing of endogenous amyloid precursor
 RT protein.";
 RL Neuroscience 95:243-254(2000).
 RN [4]
 RP GAMMA-SECRETASE PROCESSING.
 RX MEDLINE=20576391; PubMed=11035007;
 RA Pinnix I., Musunuru U., Tun H., Sridharan A., Golde T., Eckman C.,
 RA Ziani-Cherif C., Onstead L., Sambamurti K.;
 RT "A novel gamma -secretase assay based on detection of the putative
 RT C-terminal fragment-gamma of amyloid beta protein precursor.";
 RL J. Biol. Chem. 276:481-487(2001).
 CC -!- FUNCTION: Functions as a cell surface receptor and performs
 CC physiological functions on the surface of neurons relevant to
 CC neurite growth, neuronal adhesion and axonogenesis. Involved in
 CC cell mobility and transcription regulation through protein-protein
 CC interactions (By similarity). Can promote transcription activation
 CC through binding to APBB1/Tip60 and inhibit Notch signaling through
 CC interaction with Numb (By similarity). Couples to apoptosis-
 CC inducing pathways such as those mediated by G(0) and JIP (By
 CC similarity). Inhibits G(0) alpha ATPase activity (By similarity).
 CC Acts as a kinesin I membrane receptor, mediating the axonal
 CC transport of beta-secretase and presenilin 1 (By similarity). May
 CC be involved in copper homeostasis/oxidative stress through copper
 CC ion reduction (By similarity). In vitro, copper-metallated APP
 CC induces neuronal death directly or is potentiated through Cu(II)-
 CC mediated low-density lipoprotein oxidation (By similarity). Can
 CC regulate neurite outgrowth through binding to components of the
 CC extracellular matrix such as heparin and collagen I and IV (By
 CC similarity). The splice isoforms that contain the BPTI domain

possess protease inhibitor activity (By similarity).

-!- FUNCTION: Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. Beta-amyloid peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins.

-!- FUNCTION: Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain (By similarity).

-!- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis (By similarity).

-!- SUBUNIT: Binds, via its C-terminal, to the PID domain of several cytoplasmic proteins, including APBB family members, the APBA family, MAPK8IP1, SHC1 and Numb and Dab1 (By similarity). Also interacts with GPCR-like protein BPP, FPRL1, APPBP1, IB1, KNS2 (via its TPR domains), APPBP2 (via BaSS) and DDB1 (By similarity). Associates with microtubules in the presence of ATP and in a kinesin-dependent manner (By similarity). Soluble Abeta40 binds all three isoforms of APOE, in vitro and in vivo. When lipidated, ApoE3 appears to be the preferred amyloid binding isoform, while the apoE4 isoform-beta-APP40 complex is capable of being transported across the blood-brain barrier.

-!- SUBCELLULAR LOCATION: Type I membrane protein. Cell surface protein that rapidly becomes internalized via clathrin-coated pits (By similarity). During maturation, the immature APP (N-glycosylated in the endoplasmic reticulum) moves to the Golgi complex where complete maturation occurs (O-glycosylated and sulfated) (By similarity). After alpha-secretase cleavage, soluble APP is released into the extracellular space and the C-terminal is internalized to endosomes and lysosomes (By similarity). Some APP accumulates in secretory transport vesicles leaving the late Golgi compartment and returns to the cell surface (By similarity). APP sorts to the basolateral surface in epithelial cells (By similarity).

-!- ALTERNATIVE PRODUCTS:
 Event=Alternative splicing; Named isoforms=2;
 Comment=Additional isoforms, missing exons 7,8 and 15, seem to exist. The L-isoforms, missing exon 15, are referred to as appicans;
 Name=APP770;
 IsoId=Q60495-1; Sequence=Displayed;
 Name=APP695;
 IsoId=Q60495-2; Sequence=VSP_007221, VSP_007222;

-!- TISSUE SPECIFICITY: Isoform APP695 is the major isoform found in brain. The longer isoforms containing the BPTI domain are predominantly expressed in peripheral organs such as muscle and liver.

-!- INDUCTION: Increased levels during neuronal differentiation.

-!- DOMAIN: The basolateral sorting signal (BaSS) is required for sorting of membrane proteins to the basolateral surface of epithelial cells.

-!- DOMAIN: The NPXY sequence motif found in many tyrosine-phosphorylated proteins is required for the specific binding of the PID domain. However additional amino acids either N- or C-terminal to the NPXY motif are often required for complete interaction. The PID domain-containing proteins which bind APP

CC require the YENPTY motif for full interaction. These interactions
 CC are independent of phosphorylation on the terminal tyrosine
 CC residue (By similarity). The NPXY site is also involved in
 CC clatherin-mediated endocytosis.
 CC -!- PTM: Proteolytically processed under normal cellular conditions.
 CC Cleavage by alpha-secretase or alternatively by beta-secretase
 CC leads to generation and extracellular release of soluble APP
 CC peptides, S-APP-alpha and S-APP-beta, respectively, and the
 CC retention of corresponding membrane-anchored C-terminal fragments,
 CC CTF-alpha and CTF-beta. Subsequent processing of CTF-alpha by
 CC gamma-secretase yields P3 peptides. This is the major secretory
 CC pathway and is nonamyloidogenic. Alternatively,
 CC presenilin/nicastrin-mediated gamma-secretase processing of CTF-
 CC beta releases the amyloid beta proteins, amyloid-beta 40 (Abeta40)
 CC and amyloid-beta 42 (Abeta42), major components of amyloid
 CC plaques, and the corresponding cytotoxic C-terminal fragments
 CC (CTFs).
 CC -!- PTM: Proteolytically cleaved by caspase-3 during neuronal
 CC apoptosis (By similarity).
 CC -!- PTM: N- and O-linked glycosylated. O-linkage of chondroitin
 CC sulfate to the L-APP isoforms produces the APP proteoglycan core
 CC proteins, the appicans (By similarity).
 CC -!- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and
 CC serine residues is neuron-specific (By similarity).
 CC Phosphorylation can affect APP processing, neuronal
 CC differentiation and interaction with other proteins.
 CC -!- PTM: Extracellular binding and reduction of copper, results in a
 CC corresponding oxidation of Cys-144 and Cys-158, and the formation
 CC of a disulfide bond (By similarity).
 CC -!- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and
 CC zinc, can induce histidine-bridging between beta-amyloid molecules
 CC resulting in beta-amyloid-metal aggregates.
 CC -!- SIMILARITY: BELONGS TO THE APP FAMILY.
 CC -!- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.

CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----

DR EMBL; X97631; CAA66230.1; -.
 DR EMBL; X99198; CAA67589.1; -.
 DR HSSP; P05067; 1BA4.
 DR InterPro; IPR008155; A4_APP.
 DR InterPro; IPR008154; A4_extra.
 DR InterPro; IPR001255; Beta-APP.
 DR Pfam; PF00014; Kunitz_BPTI; 1.
 DR PRINTS; PR00203; AMYLOIDA4.
 DR ProDom; PD000222; Kunitz_BPTI; 1.
 DR SMART; SM00006; A4_EXTRA; 1.
 DR SMART; SM00131; KU; 1.
 DR PROSITE; PS00319; A4_EXTRA; 1.
 DR PROSITE; PS00320; A4_INTRA; 1.
 DR PROSITE; PS00280; BPTI_KUNITZ_1; 1.

DR PROSITE; PS50279; BPTI_KUNITZ_2; 1.
KW Apoptosis; Endocytosis; Cell adhesion; Serine protease inhibitor;
KW Coated pits; Neurone; Heparin-binding; Metal-binding; Copper; Iron;
KW Zinc; Signal; Transmembrane; Glycoprotein; Phosphorylation;
KW Proteoglycan; Alternative splicing; Amyloid.
FT SIGNAL 1 17 BY SIMILARITY.
FT CHAIN 18 770 AMYLOID BETA A4 PROTEIN.
FT CHAIN 18 687 SOLUBLE APP-ALPHA (BY SIMILARITY).
FT CHAIN 18 671 SOLUBLE APP-BETA (BY SIMILARITY).
FT CHAIN 672 770 CTF-ALPHA (BY SIMILARITY).
FT CHAIN 672 713 BETA-AMYLOID PROTEIN 42 (BY SIMILARITY).
FT CHAIN 672 711 BETA-AMYLOID PROTEIN 40 (BY SIMILARITY).
FT CHAIN 688 770 CTF-BETA (BY SIMILARITY).
FT CHAIN 688 713 P3(42) (BY SIMILARITY).
FT CHAIN 688 711 P3(40) (BY SIMILARITY).
FT CHAIN 712 770 GAMMA-CTF(59) (BY SIMILARITY).
FT CHAIN 714 770 GAMMA-CTF(57) (BY SIMILARITY).
FT CHAIN 740 770 C31 (BY SIMILARITY).

Query Match 100.0%; Score 49; DB 1; Length 770;
Best Local Similarity 100.0%; Pred. No. 0.025;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
| | | | | | | | | |
Db 667 SEVKMDAEFR 676

RESULT 8

A4_HUMAN
ID A4_HUMAN STANDARD; PRT; 770 AA.
AC P05067; P09000; P78438; Q13764; Q13778; Q13793; Q16011; Q9BT38;
AC Q9UCB6; Q9UQ58;
DT 13-AUG-1987 (Rel. 05, Created)
DT 01-NOV-1991 (Rel. 20, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Amyloid beta A4 protein precursor (APP) (ABPP) (Alzheimer's disease
DE amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (Protease
DE nexin-II) (PN-II) (APPI) (PreA4) [Contains: Soluble APP-alpha (S-APP-
DE alpha); Soluble APP-beta (S-APP-beta); C99; Beta-amyloid protein 42
DE (Beta-APP42); Beta-amyloid protein 40 (Beta-APP40); C83; P3(42);
DE P3(40); Gamma-CTF(59) (Gamma-secretase C-terminal fragment 59)
DE (Amyloid intracellular domain 59) (AID(59)); Gamma-CTF(57) (Gamma-
DE secretase C-terminal fragment 57) (Amyloid intracellular domain 57)
DE (AID(57)); Gamma-CTF(50) (Gamma-secretase C-terminal fragment 50)
DE (Amyloid intracellular domain 50) (AID(50)); C31].
GN APP OR A4 OR AD1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM APP695).
RC TISSUE=Brain;
RX MEDLINE=87144572; PubMed=2881207;
RA Kang J., Lemaire H.-G., Unterbeck A., Salbaum J.M., Masters C.L.,
RA Grzeschik K.-H., Multhaup G., Beyreuther K., Mueller-Hill B.;

RT "The precursor of Alzheimer's disease amyloid A4 protein resembles a
 RT cell-surface receptor.";
 RL Nature 325:733-736(1987).
 RN [2]
 RP SEQUENCE FROM N.A. (ISOFORM APP751).
 RC TISSUE=Brain;
 RX MEDLINE=88122639; PubMed=2893289;
 RA Ponte P., Gonzalez-Dewhitt P., Schilling J., Miller J., Hsu D.,
 RA Greenberg B., Davis K., Wallace W., Lieberburg I., Fuller F.,
 RA Cordell B.;
 RT "A new A4 amyloid mRNA contains a domain homologous to serine
 RT proteinase inhibitors.";
 RL Nature 331:525-527(1988).
 RN [3]
 RP SEQUENCE FROM N.A. (ISOFORM APP695).
 RX MEDLINE=89128427; PubMed=2783775;
 RA Lemaire H.-G., Salbaum J.M., Multhaup G., Kang J., Bayney R.M.,
 RA Unterbeck A., Beyreuther K., Mueller-Hill B.;
 RT "The PreA4(695) precursor protein of Alzheimer's disease A4 amyloid
 RT is encoded by 16 exons.";
 RL Nucleic Acids Res. 17:517-522(1989).
 RN [4]
 RP SEQUENCE FROM N.A. (ISOFORM APP770).
 RX MEDLINE=90236318; PubMed=2110105;
 RA Yoshikai S.-I., Sasaki H., Doh-Ura K., Furuya H., Sakaki Y.;
 RT "Genomic organization of the human amyloid beta-protein precursor
 RT gene.";
 RL Gene 87:257-263(1990).
 RN [5]
 RP ERRATUM, AND REVISIONS.
 RA Yoshikai S.-I., Sasaki H., Doh-ura K., Furuya H., Sakaki Y.;
 RL Gene 102:291-292(1991).
 RN [6]
 RP SEQUENCE FROM N.A. (ISOFORM L-APP733).
 RC TISSUE=Leukocyte;
 RX MEDLINE=92268136; PubMed=1587857;
 RA Koenig G., Moenning U., Czech C., Prior R., Banati R.,
 RA Schreiter-Gasser U., Bauer J., Masters C.L., Beyreuther K.;
 RT "Identification and differential expression of a novel alternative
 RT splice isoform of the beta A4 amyloid precursor protein (APP) mRNA in
 RT leukocytes and brain microglial cells.";
 RL J. Biol. Chem. 267:10804-10809(1992).
 RN [7]
 RP SEQUENCE FROM N.A. (ISOFORM APP770).
 RX MEDLINE=97263807; PubMed=9108164;
 RA Hattori M., Tsukahara F., Furuhashi Y., Tanahashi H., Hirose M.,
 RA Saito M., Tsukuni S., Sakaki Y.;
 RT "A novel method for making nested deletions and its application for
 RT sequencing of a 300 kb region of human APP locus.";
 RL Nucleic Acids Res. 25:1802-1808(1997).
 RN [8]
 RP SEQUENCE FROM N.A. (ISOFORM APP305).
 RC TISSUE=Pancreas;
 RX MEDLINE=22388257; PubMed=12477932;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,

RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length
 RT human and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [9]
 RP SEQUENCE OF 1-10 FROM N.A.
 RC TISSUE=Liver;
 RX MEDLINE=89016647; PubMed=3140222;
 RA Schon E.A., Mita S., Sadlock J., Herbert J.;
 RT "A cDNA specifying the human amyloid beta precursor protein (ABPP)
 RT encodes a 95-kDa polypeptide.";
 RL Nucleic Acids Res. 16:9351-9351(1988).
 RN [10]
 RP ERRATUM, AND REVISIONS.
 RA Mita S., Sadlock J., Herbert J., Schon E.A.;
 RL Nucleic Acids Res. 16:11402-11402(1988).
 RN [11]
 RP SEQUENCE OF 1-75 FROM N.A.
 RX MEDLINE=89165870; PubMed=2538123;
 RA La Fauci G., Lahiri D.K., Salton S.R., Robakis N.K.;
 RT "Characterization of the 5'-end region and the first two exons of the
 RT beta-protein precursor gene.";
 RL Biochem. Biophys. Res. Commun. 159:297-304(1989).
 RN [12]
 RP SEQUENCE OF 18-50.
 RC TISSUE=Fibroblast;
 RX MEDLINE=87250462; PubMed=3597385;
 RA van Nostrand W.E., Cunningham D.D.;
 RT "Purification of protease nexin II from human fibroblasts.";
 RL J. Biol. Chem. 262:8508-8514(1987).
 RN [13]
 RP PARTIAL SEQUENCE FROM N.A. (ISOFORM APP751).
 RC TISSUE=Brain;
 RX MEDLINE=89346754; PubMed=2569763;
 RA de Sauvage F., Octave J.N.;
 RT "A novel mRNA of the A4 amyloid precursor gene coding for a possibly
 RT secreted protein.";
 RL Science 245:651-653(1989).
 RN [14]
 RP PARTIAL SEQUENCE FROM N.A. (ISOFORM APP695).
 RC TISSUE=Brain;
 RX MEDLINE=87231971; PubMed=3035574;
 RA Robakis N.K., Ramakrishna N., Wolfe G., Wisniewski H.M.;
 RT "Molecular cloning and characterization of a cDNA encoding the

RT cerebrovascular and the neuritic plaque amyloid peptides.";
 RL Proc. Natl. Acad. Sci. U.S.A. 84:4190-4194(1987).
 RN [15]
 RP SEQUENCE OF 286-366 FROM N.A.
 RX MEDLINE=88122640; PubMed=2893290;
 RA Tanzi R.E., McClatchey A.I., Lamperti E.D., Villa-Komaroff L.,
 RA Gusella J.F., Neve R.L.;
 RT "Protease inhibitor domain encoded by an amyloid protein precursor
 RT mRNA associated with Alzheimer's disease.";
 RL Nature 331:528-530(1988).
 RN [16]
 RP SEQUENCE OF 287-367 FROM N.A.
 RX MEDLINE=88122641; PubMed=2893291;
 RA Kitaguchi N., Takahashi Y., Tokushima Y., Shiojiri S., Ito H.;
 RT "Novel precursor of Alzheimer's disease amyloid protein shows
 RT protease inhibitory activity.";
 RL Nature 331:530-532(1988).
 RN [17]
 RP SEQUENCE OF 507-770 FROM N.A.
 RC TISSUE=Brain cortex;
 RX MEDLINE=88124954; PubMed=2893379;
 RA Zain S.B., Salim M., Chou W.G., Sajdel-Sulkowska E.M., Majocha R.E.,
 RA Marotta C.A.;
 RT "Molecular cloning of amyloid cDNA derived from mRNA of the Alzheimer
 RT disease brain: coding and noncoding regions of the fetal precursor
 RT mRNA are expressed in the cortex.";
 RL Proc. Natl. Acad. Sci. U.S.A. 85:929-933(1988).
 RN [18]
 RP SEQUENCE OF 523-555, AND COLLAGEN-BINDING DOMAIN.
 RX MEDLINE=96139497; PubMed=8576160;
 RA Beher D., Hesse L., Masters C.L., Multhaup G.;
 RT "Regulation of amyloid protein precursor (APP) binding to collagen and
 RT mapping of the binding sites on APP and collagen type I.";
 RL J. Biol. Chem. 271:1613-1620(1996).
 RN [19]
 RP SEQUENCE OF 656-737 FROM N.A.
 RX MEDLINE=89392030; PubMed=2675837;
 RA Johnstone E.M., Chaney M.O., Moore R.E., Ward K.E., Norris F.H.,
 RA Little S.P.;
 RT "Alzheimer's disease amyloid peptide is encoded by two exons and shows
 RT similarity to soybean trypsin inhibitor.";
 RL Biochem. Biophys. Res. Commun. 163:1248-1255(1989).
 RN [20]
 RP SEQUENCE OF 672-681.
 RC TISSUE=Brain cortex;
 RX MEDLINE=88035004; PubMed=3312495;
 RA Pardridge W.M., Vinters H.V., Yang J., Eisenberg J., Choi T.B.,
 RA Tourtellotte W.W., Huebner V., Shively J.E.;
 RT "Amyloid angiopathy of Alzheimer's disease: amino acid composition
 RT and partial sequence of a 4,200-dalton peptide isolated from cortical
 RT microvessels.";
 RL J. Neurochem. 49:1394-1401(1987).
 RN [21]
 RP SEQUENCE OF 674-770 FROM N.A.
 RC TISSUE=Brain;
 RX MEDLINE=87120328; PubMed=3810169;
 RA Goldgaber D., Lerman M.I., McBride O.W., Saffiotti U., Gajdusek D.C.;

RT "Characterization and chromosomal localization of a cDNA encoding
RT brain amyloid of Alzheimer's disease.";

Query Match 100.0%; Score 49; DB 1; Length 770;
Best Local Similarity 100.0%; Pred. No. 0.025;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|||||||
Db 667 SEVKMDAEFR 676

RESULT 9

A4_MACFA

ID A4_MACFA STANDARD; PRT; 770 AA.
AC P53601; Q95KN7;
DT 01-OCT-1996 (Rel. 34, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Amyloid beta A4 protein precursor (APP) (ABPP) (Alzheimer's disease
DE amyloid protein homolog) [Contains: Soluble APP-alpha (S-APP-alpha);
DE Soluble APP-beta (S-APP-beta); C99; Beta-amyloid protein 42 (Beta-
DE APP42); Beta-amyloid protein 40 (Beta-APP40); C83; P3(42); P3(40);
DE Gamma-CTF(59) (Gamma-secretase C-terminal fragment 59); Gamma-CTF(57)
DE (Gamma-secretase C-terminal fragment 57); Gamma-CTF(50) (Gamma-
DE secretase C-terminal fragment 50); C31].
GN APP.
OS Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae;
OC Cercopithecinae; Macaca.
OX NCBI_TaxID=9541;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORMS APP695 AND APP770).
RC TISSUE=Cerebellum;
RX MEDLINE=91273117; PubMed=1905108;
RA Podlisny M.B., Tolan D.R., Selkoe D.J.;
RT "Homology of the amyloid beta protein precursor in monkey and human
RT supports a primate model for beta amyloidosis in Alzheimer's
RT disease.";
RL Am. J. Pathol. 138:1423-1435(1991).
CC -!- FUNCTION: Functions as a cell surface receptor and performs
CC physiological functions on the surface of neurons relevant to
CC neurite growth, neuronal adhesion and axonogenesis. Involved in
CC cell mobility and transcription regulation through protein-protein
CC interactions (By similarity). Can promote transcription activation
CC through binding to APBB1/Tip60 and inhibit Notch signaling through
CC interaction with Numb (By similarity). Couples to apoptosis-
CC inducing pathways such as those mediated by G(0) and JIP (By
CC similarity). Inhibits G(0) alpha ATPase activity (By similarity).
CC Acts as a kinesin I membrane receptor, mediating the axonal
CC transport of beta-secretase and presenilin 1 (By similarity). May
CC be involved in copper homeostasis/oxidative stress through copper
CC ion reduction. In vitro, copper-metallated APP induces neuronal
CC death directly or is potentiated through Cu(II)-mediated low-
CC density lipoprotein oxidation (By similarity). Can regulate
CC neurite outgrowth through binding to components of the

CC extracellular matrix such as heparin and collagen I and IV (By
 CC similarity). The splice isoforms that contain the BPTI domain
 CC possess protease inhibitor activity (By similarity).
 CC -!- FUNCTION: Beta-amyloid peptides are lipophilic metal chelators
 CC with metal-reducing activity. Bind transient metals such as
 CC copper, zinc and iron (By similarity).
 CC -!- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved
 CC peptides, including C31, are potent enhancers of neuronal
 CC apoptosis (By similarity).
 CC -!- SUBUNIT: Binds, via its C-terminal, to the PID domain of several
 CC cytoplasmic proteins, including APBB family members, the APBA
 CC family, MAPK8IP1, and SHC1, Numb and Dab1 (By similarity). Binding
 CC to Dab1 inhibits its serine phosphorylation (By similarity). Also
 CC interacts with GPCR-like protein BPP, FPRL1, APPBP1, IB1, KNS2
 CC (via its TPR domains) (By similarity), APPBP2 (via BaSS) and DDB1.
 CC In vitro, it binds MAPT via the MT-binding domains (By
 CC similarity). Associates with microtubules in the presence of ATP
 CC and in a kinesin-dependent manner (By similarity).
 CC -!- SUBCELLULAR LOCATION: Type I membrane protein. Cell surface
 CC protein that rapidly becomes internalized via clatherin-coated
 CC pits. During maturation, the immature APP (N-glycosylated in the
 CC endoplasmic reticulum) moves to the Golgi complex where complete
 CC maturation occurs (O-glycosylated and sulfated). After alpha-
 CC secretase cleavage, soluble APP is released into the extracellular
 CC space and the C-terminal is internalized to endosomes and
 CC lysosomes. Some APP accumulates in secretory transport vesicles
 CC leaving the late Golgi compartment and returns to the cell
 CC surface. GammaCTF(59) peptide is located to both the cytoplasm and
 CC nuclei of neurons (By similarity).
 CC -!- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=2;
 CC Comment=Additional isoforms seem to exist;
 CC Name=APP770;
 CC IsoId=P53601-1; Sequence=Displayed;
 CC Name=APP695;
 CC IsoId=P53601-2; Sequence=VSP_000010, VSP_000011;
 CC -!- DOMAIN: The basolateral sorting signal (BaSS) is required for
 CC sorting of membrane proteins to the basolateral surface of
 CC epithelial cells (By similarity).
 CC -!- DOMAIN: The NPXY sequence motif found in many tyrosine-
 CC phosphorylated proteins is required for the specific binding of
 CC the PID domain. However additional amino acids either N- or C-
 CC terminal to the NPXY motif are often required for complete
 CC interaction. The PID domain-containing proteins which bind APP
 CC require the YENPTY motif for full interaction. These interactions
 CC are independent of phosphorylation on the terminal tyrosine
 CC residue. The NPXY site is also involved in clatherin-mediated
 CC endocytosis (By similarity).
 CC -!- PTM: Proteolytically processed under normal cellular conditions.
 CC Cleavage by alpha-secretase or alternatively by beta-secretase
 CC leads to generation and extracellular release of soluble APP
 CC peptides, S-APP-alpha and S-APP-beta, respectively, and the
 CC retention of corresponding membrane-anchored C-terminal fragments,
 CC C83 and C99. Subsequent processing of C83 by gamma-secretase
 CC yields P3 peptides. This is the major secretory pathway and is
 CC nonamyloidogenic. Alternatively, presenilin/nicastrin-mediated
 CC gamma-secretase processing of C99 releases the amyloid beta

CC proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42),
 CC major components of amyloid plaques, and the cytotoxic C-terminal
 CC fragments, gammaCTF(50), gammaCTF(57) and gammaCTF(59) (By
 CC similarity).
 CC -!- PTM: Proteolytically cleaved by caspases during neuronal apoptosis
 CC (By similarity). Cleavage at Asp-739 by either caspase-3, -8 or -9
 CC results in the production of the neurotoxic C31 peptide and the
 CC increased production of beta-amyloid peptides (By similarity).
 CC -!- PTM: N- and O-linked glycosylated (By similarity).
 CC -!- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and
 CC serine residues is neuron-specific. Phosphorylation can affect APP
 CC processing, neuronal differentiation and interaction with other
 CC proteins (By similarity).
 CC -!- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and
 CC zinc, can induce histidine-bridging between beta-amyloid molecules
 CC resulting in beta-amyloid-metal aggregates (By similarity).
 CC Extracellular zinc-binding increases binding of heparin to APP and
 CC inhibits collagen-binding (By similarity).
 CC -!- SIMILARITY: BELONGS TO THE APP FAMILY.
 CC -!- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; M58727; AAA36829.1; -.
 DR EMBL; M58726; AAA36828.1; -.
 DR HSSP; P05067; 1AAP.
 DR InterPro; IPR001868; A4_APP.
 DR InterPro; IPR002223; Kunitz_BPTI.
 DR Pfam; PF02177; A4_EXTRA; 1.
 DR Pfam; PF03494; Beta-APP; 1.
 DR Pfam; PF00014; Kunitz_BPTI; 1.
 DR PRINTS; PR00759; BASICPTASE.
 DR ProDom; PD000222; Kunitz_BPTI; 1.
 DR SMART; SM00006; A4_EXTRA; 1.
 DR SMART; SM00131; KU; 1.
 DR PROSITE; PS00319; A4_EXTRA; 1.
 DR PROSITE; PS00320; A4_INTRA; 1.
 DR PROSITE; PS00280; BPTI_KUNITZ_1; 1.
 DR PROSITE; PS50279; BPTI_KUNITZ_2; 1.
 KW Apoptosis; Endocytosis; Cell adhesion; Serine protease inhibitor;
 KW Coated pits; Neurone; Heparin-binding; Metal-binding; Copper; Iron;
 KW Zinc; Signal; Transmembrane; Glycoprotein; Phosphorylation;
 KW Proteoglycan; Alternative splicing; Amyloid.
 FT SIGNAL 1 17 BY SIMILARITY.
 FT CHAIN 18 770 AMYLOID BETA A4 PROTEIN.
 FT CHAIN 18 687 SOLUBLE APP-ALPHA (POTENTIAL).
 FT CHAIN 18 671 SOLUBLE APP-BETA (POTENTIAL).
 FT CHAIN 672 770 C99 (POTENTIAL).
 FT CHAIN 672 713 BETA-AMYLOID PROTEIN 42 (POTENTIAL).
 FT CHAIN 672 711 BETA-AMYLOID PROTEIN 40 (POTENTIAL).
 FT CHAIN 688 770 C83 (POTENTIAL).

FT	CHAIN	688	713	P3(42) (POTENTIAL).
FT	CHAIN	688	711	P3(40) (POTENTIAL).
FT	CHAIN	712	770	GAMMA-CTF(59) (POTENTIAL).
FT	CHAIN	714	770	GAMMA-CTF(57) (POTENTIAL).
FT	CHAIN	721	770	GAMMA-CTF(50) (POTENTIAL).
FT	CHAIN	740	770	C31 (POTENTIAL).
FT	DOMAIN	18	699	EXTRACELLULAR (POTENTIAL).
FT	TRANSMEM	700	723	POTENTIAL.
FT	DOMAIN	724	770	CYTOPLASMIC (POTENTIAL).
FT	DOMAIN	96	110	HEPARIN-BINDING (BY SIMILARITY).
FT	DOMAIN	181	188	ZINC-BINDING (BY SIMILARITY).
FT	DOMAIN	291	341	BPTI/KUNITZ INHIBITOR.
FT	DOMAIN	391	423	HEPARIN-BINDING (BY SIMILARITY).
FT	DOMAIN	491	522	HEPARIN-BINDING (BY SIMILARITY).
FT	DOMAIN	523	540	COLLAGEN-BINDING (BY SIMILARITY).
FT	DOMAIN	732	751	INTERACTION WITH G(O)-ALPHA
FT				(BY SIMILARITY).
FT	DOMAIN	230	260	ASP/GLU-RICH (ACIDIC).
FT	DOMAIN	274	280	POLY-THR.
FT	SITE	144	144	REQUIRED FOR COPPER(II) REDUCTION
FT				(BY SIMILARITY).
FT	ACT_SITE	301	302	REACTIVE BOND (BY SIMILARITY).
FT	SITE	671	672	CLEAVAGE (BY BETA-SECRETASE)
FT				(BY SIMILARITY).
FT	SITE	672	673	CLEAVAGE (BY CASPASE-6) (BY SIMILARITY).
FT	SITE	687	688	CLEAVAGE (BY ALPHA-SECRETASE)
FT				(BY SIMILARITY).
FT	SITE	704	704	IMPLICATED IN FREE RADICAL PROPAGATION
FT				(BY SIMILARITY).
FT	SITE	706	706	INVOLVED IN OXIDATIVE REACTIONS
FT				(BY SIMILARITY).
FT	SITE	711	712	CLEAVAGE (BY GAMMA-SECRETASE; SITE 1)
FT				(BY SIMILARITY).
FT	SITE	713	714	CLEAVAGE (BY GAMMA-SECRETASE; SITE 2)
FT				(BY SIMILARITY).
FT	SITE	720	721	CLEAVAGE (BY GAMMA-SECRETASE; SITE 3)
FT				(BY SIMILARITY).
FT	SITE	724	734	BASOLATERAL SORTING SIGNAL
FT				(BY SIMILARITY).
FT	SITE	739	740	CLEAVAGE (BY CASPASES-3,-6,-8 OR -9)
FT				(BY SIMILARITY).
FT	SITE	757	760	ENDOCYTOSIS SIGNAL.
FT	SITE	759	762	NPXY MOTIF.

Query Match 100.0%; Score 49; DB 1; Length 770;
 Best Local Similarity 100.0%; Pred. No. 0.025;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 667 SEVKMDAEFR 676

RESULT 10

A4_PIG

ID A4_PIG STANDARD; PRT; 770 AA.

AC P79307; Q29023; Q9TUI0;

DT 01-NOV-1997 (Rel. 35, Created)
 DT 15-SEP-2003 (Rel. 42, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Amyloid beta A4 protein precursor (APP) (ABPP) (Alzheimer's disease
 DE amyloid protein homolog) [Contains: Soluble APP-alpha (S-APP-alpha);
 DE Soluble APP-beta (S-APP-beta); C99; Beta-amyloid protein 42 (Beta-
 DE APP42); Beta-amyloid protein 40 (Beta-APP40); C83; P3(42); P3(40);
 DE Gamma-CTF(59) (Gamma-secretase C-terminal fragment 59); Gamma-CTF(57)
 DE (Gamma-secretase C-terminal fragment 57); Gamma-CTF(50) (Gamma-
 DE secretase C-terminal fragment 50); C31].
 OS Sus scrofa (Pig).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
 OX NCBI_TaxID=9823;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Kimura A., Takahashi T.;
 RT "Amyloid precursor protein 770.";
 RL Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
 RN [2]
 RP SEQUENCE OF 1-136 FROM N.A.
 RC TISSUE=Small intestine;
 RA Winteroe A.K., Fredholm M.;
 RT "Evaluation and characterization of a porcine small intestine cDNA
 RT library.";
 RL Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
 RN [3]
 RP SEQUENCE OF 667-723 FROM N.A.
 RC TISSUE=Brain;
 RX MEDLINE=92017079; PubMed=1656157;
 RA Johnstone E.M., Chaney M.O., Norris F.H., Pascual R., Little S.P.;
 RT "Conservation of the sequence of the Alzheimer's disease amyloid
 RT peptide in dog, polar bear and five other mammals by cross-species
 RT polymerase chain reaction analysis.";
 RL Brain Res. Mol. Brain Res. 10:299-305(1991).
 CC -!- FUNCTION: Functions as a cell surface receptor and performs
 CC physiological functions on the surface of neurons relevant to
 CC neurite growth, neuronal adhesion and axonogenesis. Involved in
 CC cell mobility and transcription regulation through protein-protein
 CC interactions (By similarity). Can promote transcription activation
 CC through binding to APBB1/Tip60 and inhibit Notch signaling through
 CC interaction with Numb (By similarity). Couples to apoptosis-
 CC inducing pathways such as those mediated by G(0) and JIP (By
 CC similarity). Inhibits G(0) alpha ATPase activity (By similarity).
 CC Acts as a kinesin I membrane receptor, mediating the axonal
 CC transport of beta-secretase and presenilin 1 (By similarity). May
 CC be involved in copper homeostasis/oxidative stress through copper
 CC ion reduction (By similarity). In vitro, copper-metallated APP
 CC induces neuronal death directly or is potentiated through Cu(II)-
 CC mediated low-density lipoprotein oxidation (By similarity). Can
 CC regulate neurite outgrowth through binding to components of the
 CC extracellular matrix such as heparin and collagen I and IV (By
 CC similarity).
 CC -!- FUNCTION: Beta-amyloid peptides are lipophilic metal chelators
 CC with metal-reducing activity. Bind transient metals such as
 CC copper, zinc and iron (By similarity).
 CC -!- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved

CC peptides, including C31, are potent enhancers of neuronal
 CC apoptosis (By similarity).
 CC -!- SUBUNIT: Binds, via its C-terminal, to the PID domain of several
 CC cytoplasmic proteins, including APBB family members, the APBA
 CC family, MAPK8IP1, and SHC1, Numb and Dab1 (By similarity). Binding
 CC to Dab1 inhibits its serine phosphorylation (By similarity). Also
 CC interacts with GPCR-like protein BPP, FPRL1, APPBP1, IB1, KNS2
 CC (via its TPR domains) (By similarity), APPBP2 (via BaSS) and DDB1.
 CC In vitro, it binds MAPT via the MT-binding domains (By
 CC similarity). Associates with microtubules in the presence of ATP
 CC and in a kinesin-dependent manner (By similarity).
 CC -!- SUBCELLULAR LOCATION: Type I membrane protein. Cell surface
 CC protein that rapidly becomes internalized via clatherin-coated
 CC pits. During maturation, the immature APP (N-glycosylated in the
 CC endoplasmic reticulum) moves to the Golgi complex where complete
 CC maturation occurs (O-glycosylated and sulfated). After alpha-
 CC secretase cleavage, soluble APP is released into the extracellular
 CC space and the C-terminal is internalized to endosomes and
 CC lysosomes. Some APP accumulates in secretory transport vesicles
 CC leaving the late Golgi compartment and returns to the cell
 CC surface. GammaCTF(59) peptide is located to both the cytoplasm and
 CC nuclei of neurons (By similarity).
 CC -!- DOMAIN: The basolateral sorting signal (BaSS) is required for
 CC sorting of membrane proteins to the basolateral surface of
 CC epithelial cells (By similarity).
 CC -!- DOMAIN: The NPXY sequence motif found in many tyrosine-
 CC phosphorylated proteins is required for the specific binding of
 CC the PID domain. However additional amino acids either N- or C-
 CC terminal to the NPXY motif are often required for complete
 CC interaction. The PID domain-containing proteins which bind APP
 CC require the YENPTY motif for full interaction. These interactions
 CC are independent of phosphorylation on the terminal tyrosine
 CC residue. The NPXY site is also involved in clatherin-mediated
 CC endocytosis (By similarity).
 CC -!- PTM: Proteolytically processed under normal cellular conditions.
 CC Cleavage by alpha-secretase or alternatively by beta-secretase
 CC leads to generation and extracellular release of soluble APP
 CC peptides, S-APP-alpha and S-APP-beta, respectively, and the
 CC retention of corresponding membrane-anchored C-terminal fragments,
 CC C83 and C99. Subsequent processing of C83 by gamma-secretase
 CC yields P3 peptides. This is the major secretory pathway and is
 CC nonamyloidogenic. Alternatively, presenilin/nicastrin-mediated
 CC gamma-secretase processing of C99 releases the amyloid beta
 CC proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42),
 CC major components of amyloid plaques, and the cytotoxic C-terminal
 CC fragments, gammaCTF(50), gammaCTF(57) and gammaCTF(59) (By
 CC similarity).
 CC -!- PTM: Proteolytically cleaved by caspases during neuronal apoptosis
 CC (By similarity). Cleavage at Asp-739 by either caspase-3, -8 or -9
 CC results in the production of the neurotoxic C31 peptide and the
 CC increased production of beta-amyloid peptides (By similarity).
 CC -!- PTM: N- and O-linked glycosylated (By similarity).
 CC -!- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and
 CC serine residues is neuron-specific. Phosphorylation can affect APP
 CC processing, neuronal differentiation and interaction with other
 CC proteins (By similarity).
 CC -!- PTM: Extracellular binding and reduction of copper, results in a

CC corresponding oxidation of Cys-144 and Cys-158, and the formation
 CC of a disulfide bond (By similarity).
 CC -!- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and
 CC zinc, can induce histidine-bridging between beta-amyloid molecules
 CC resulting in beta-amyloid-metal aggregates (By similarity).
 CC Extracellular zinc-binding increases binding of heparin to APP and
 CC inhibits collagen-binding (By similarity).
 CC -!- SIMILARITY: BELONGS TO THE APP FAMILY.
 CC -!- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AB032550; BAA84580.1; -.
 DR EMBL; Z84022; CAB06313.1; -.
 DR EMBL; X56127; CAA39592.1; -.
 DR HSSP; P05067; 1AAP.
 DR InterPro; IPR008155; A4_APP.
 DR InterPro; IPR008154; A4_extra.
 DR InterPro; IPR001255; Beta-APP.
 DR InterPro; IPR002223; Kunitz_BPTI.
 DR Pfam; PF02177; A4_EXTRA; 1.
 DR PRINTS; PR00203; AMYLOIDA4.
 DR PRINTS; PR00759; BASICPTASE.
 DR ProDom; PD000222; Kunitz_BPTI; 1.
 DR SMART; SM00006; A4_EXTRA; 1.
 DR SMART; SM00131; KU; 1.
 DR PROSITE; PS00319; A4_EXTRA; 1.
 DR PROSITE; PS00320; A4_INTRA; 1.
 DR PROSITE; PS00280; BPTI_KUNITZ_1; 1.
 DR PROSITE; PS50279; BPTI_KUNITZ_2; 1.
 KW Apoptosis; Endocytosis; Cell adhesion; Serine protease inhibitor;
 KW Coated pits; Neurone; Heparin-binding; Metal-binding; Copper; Iron;
 KW Zinc; Signal; Transmembrane; Glycoprotein; Phosphorylation;
 KW Amyloid.
 FT SIGNAL 1 17 BY SIMILARITY.
 FT CHAIN 18 770 AMYLOID BETA A4 PROTEIN.
 FT CHAIN 18 687 SOLUBLE APP-ALPHA (POTENTIAL).
 FT CHAIN 18 671 SOLUBLE APP-BETA (POTENTIAL).
 FT CHAIN 672 770 C99 (BY SIMILARITY).
 FT CHAIN 672 713 BETA-AMYLOID PROTEIN 42 (BY SIMILARITY).
 FT CHAIN 672 711 BETA-AMYLOID PROTEIN 40 (BY SIMILARITY).
 FT CHAIN 688 770 C83 (BY SIMILARITY).
 FT CHAIN 688 713 P3(42) (BY SIMILARITY).
 FT CHAIN 688 711 P3(40) (BY SIMILARITY).
 FT CHAIN 712 770 GAMMA-CTF(59).
 FT CHAIN 714 770 GAMMA-CTF(57).
 FT CHAIN 721 770 GAMMA-CTF(50) (BY SIMILARITY).
 FT CHAIN 740 770 C31 (DURING APOPTOSIS) (BY SIMILARITY).
 FT DOMAIN 18 699 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 700 723 POTENTIAL.
 FT DOMAIN 724 770 CYTOPLASMIC (POTENTIAL).

FT	DOMAIN	96	110	HEPARIN-BINDING (BY SIMILARITY).
FT	DOMAIN	135	155	COPPER-BINDING (BY SIMILARITY).
FT	DOMAIN	181	188	ZINC-BINDING (BY SIMILARITY).
FT	DOMAIN	291	341	BPTI/KUNITZ INHIBITOR.
FT	DOMAIN	391	423	HEPARIN-BINDING (BY SIMILARITY).
FT	DOMAIN	491	522	HEPARIN-BINDING (BY SIMILARITY).
FT	DOMAIN	523	540	COLLAGEN-BINDING (BY SIMILARITY).
FT	DOMAIN	732	751	INTERACTION WITH G(O)-ALPHA (BY SIMILARITY).
FT				
FT	DOMAIN	230	260	ASP/GLU-RICH (ACIDIC).
FT	DOMAIN	274	280	POLY-THR.
FT	SITE	144	144	REQUIRED FOR COPPER(II) REDUCTION (BY SIMILARITY).
FT				
FT	ACT_SITE	301	302	REACTIVE BOND (BY SIMILARITY).
FT	SITE	671	672	CLEAVAGE (BY BETA-SECRETASE) (BY SIMILARITY).
FT				
FT	SITE	672	673	CLEAVAGE (BY CASPASE-6) (BY SIMILARITY).
FT	SITE	687	688	CLEAVAGE (BY ALPHA-SECRETASE) (BY SIMILARITY).
FT				
FT	SITE	704	704	IMPLICATED IN FREE RADICAL PROPAGATION (BY SIMILARITY).
FT				
FT	SITE	706	706	INVOLVED IN OXIDATIVE REACTIONS (BY SIMILARITY).
FT				
FT	SITE	711	712	CLEAVAGE (BY GAMMA-SECRETASE; SITE 1) (BY SIMILARITY).
FT				
FT	SITE	713	714	CLEAVAGE (BY GAMMA-SECRETASE; SITE 2) (BY SIMILARITY).
FT				

Query Match 100.0%; Score 49; DB 1; Length 770;
 Best Local Similarity 100.0%; Pred. No. 0.025;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
 |||||
 Db 667 SEVKMDAEFR 676

RESULT 11

A4_MOUSE

ID A4_MOUSE STANDARD; PRT; 770 AA.
 AC P12023; P97487; P97942; Q99K32;
 DT 01-OCT-1989 (Rel. 12, Created)
 DT 15-SEP-2003 (Rel. 42, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Amyloid beta A4 protein precursor (APP) (ABPP) (Alzheimer's disease
 DE amyloid protein homolog) (Amyloidogenic glycoprotein) (AG) [Contains:
 DE Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99
 DE (APP-C99); Beta-amyloid protein 42 (Beta-APP42); Beta-amyloid protein
 DE 40 (Beta-APP40); C83; P3(42); P3(40); Gamma-CTF(59) (Gamma-secretase
 DE C-terminal fragment 59) (Amyloid intracellular domain 59) (AID(59))
 DE (APP-C59); Gamma-CTF(57) (Gamma-secretase C-terminal fragment 57)
 DE (Amyloid intracellular domain 57) (AID(57)) (APP-C57); Gamma-CTF(50)
 DE (Gamma-secretase C-terminal fragment 50) (Amyloid intracellular domain
 DE 50) (AID(50)); C31].
 GN APP.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORM APP695).
 RC TISSUE=Brain;
 RX MEDLINE=88106489; PubMed=3322280;
 RA Yamada T., Sasaki H., Furuya H., Miyata T., Goto I., Sakaki Y.;
 RT "Complementary DNA for the mouse homolog of the human amyloid beta
 RT protein precursor.";
 RL Biochem. Biophys. Res. Commun. 149:665-671(1987).
 RN [2]
 RP REVISIONS.
 RA Yamada T.;
 RL Submitted (MAR-1988) to the EMBL/GenBank/DDBJ databases.
 RN [3]
 RP SEQUENCE FROM N.A. (ISOFORM APP695).
 RC STRAIN=BALB/c; TISSUE=Brain;
 RX MEDLINE=92096458; PubMed=1756177;
 RA de Strooper B., van Leuven F., van den Berghe H.;
 RT "The amyloid beta protein precursor or proteinase nexin II from mouse
 RT is closer related to its human homolog than previously reported.";
 RL Biochim. Biophys. Acta 1129:141-143(1991).
 RN [4]
 RP SEQUENCE FROM N.A. (ISOFORM APP695).
 RC STRAIN=SAMP8; TISSUE=Hippocampus;
 RX PubMed=11235921;
 RA Kumar V.B., Vyas K., Franko M., Choudhary V., Buddhiraju C.,
 RA Alvarez J., Morley J.E.;
 RT "Molecular cloning, expression, and regulation of hippocampal amyloid
 RT precursor protein of senescence accelerated mouse (SAMP8).";
 RL Biochem. Cell Biol. 79:57-67(2001).
 RN [5]
 RP SEQUENCE OF 1-19 FROM N.A.
 RX MEDLINE=92209998; PubMed=1555768;
 RA Izumi R., Yamada T., Yoshikai S.I., Sasaki H., Hattori M.,
 RA Sakai Y.;
 RT "Positive and negative regulatory elements for the expression of the
 RT Alzheimer's disease amyloid precursor-encoding gene in mouse.";
 RL Gene 112:189-195(1992).
 RN [6]
 RP PARTIAL SEQUENCE FROM N.A. (ISOFORM APP770).
 RC TISSUE=Breast tumor;
 RX MEDLINE=22388257; PubMed=12477932;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,

RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnierch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [7]
 RP SEQUENCE OF 281-380 FROM N.A., AND ALTERNATIVE SPLICING.
 RC TISSUE=Brain, and Kidney;
 RX MEDLINE=89149813; PubMed=2493250;
 RA Yamada T., Sasaki H., Dohura K., Goto I., Sakaki Y.;
 RT "Structure and expression of the alternatively-spliced forms of mRNA
 RT for the mouse homolog of Alzheimer's disease amyloid beta protein
 RT precursor.";
 RL Biochem. Biophys. Res. Commun. 158:906-912(1989).
 RN [8]
 RP SEQUENCE OF 289-364 FROM N.A.
 RC STRAIN=CD-1; TISSUE=Placenta;
 RX MEDLINE=89345111; PubMed=2569710;
 RA Fukuchi K., Martin G.M., Deeb S.S.;
 RT "Sequence of the protease inhibitor domain of the A4 amyloid protein
 RT precursor of Mus domesticus.";
 RL Nucleic Acids Res. 17:5396-5396(1989).
 RN [9]
 RP SEQUENCE OF 656-737 FROM N.A.
 RC STRAIN=129/Sv;
 RA Wragg M.A., Busfield F., Duff K., Korenblat K., Capecchi M.,
 RA Loring J.F., Goate A.M.;
 RT "Introduction of six mutations into the mouse genome using 'Hit and
 RT Run' gene-targeting: introduction of familial Alzheimer's disease
 RT mutations into the mouse amyloid precursor protein gene and
 RT humanization of the A-beta fragment.";
 RL Submitted (DEC-1996) to the EMBL/GenBank/DDBJ databases.
 RN [10]
 RP TISSUE SPECIFICITY OF ALTERNATIVE SPLICED FORMS.
 RX PubMed=8510506;
 RA Sola C., Mengod G., Ghetti B., Palacios J.M., Triarhou L.C.;
 RT "Regional distribution of the alternatively spliced isoforms of beta
 RT APP RNA transcript in the brain of normal, heterozygous and
 RT homozygous weaver mutant mice as revealed by in situ hybridization
 RT histochemistry.";
 RL Brain Res. Mol. Brain Res. 17:340-346(1993).
 RN [11]
 RP INTERACTION WITH KNS2.
 RX PubMed=11144355;
 RA Kamal A., Stokin G.B., Yang Z., Xia C.-H., Goldstein L.S.;
 RT "Axonal transport of amyloid precursor protein is mediated by direct
 RT binding to the kinesin light chain subunit of kinesin-I.";
 RL Neuron 28:449-459(2000).
 RN [12]
 RP C-TERMINAL PROTEIN-PROTEIN INTERACTIONS, AND MUTAGENESIS OF TYR-728;
 RP THR-743; TYR-757; ASN-759 AND TYR-762.
 RX MEDLINE=21408156; PubMed=11517249;
 RA Matsuda S., Yasukawa T., Homma Y., Ito Y., Niikura T., Hiraki T.,
 RA Hirai S., Ohno S., Kita Y., Kawasumi M., Kouyama K., Yamamoto T.,
 RA Kyriakis J.M., Nishimoto I.;
 RT "C-jun N-terminal kinase (JNK)-interacting protein-1b/islet-brain-1

RT scaffolds Alzheimer's amyloid precursor protein with JNK.";
 RL J. Neurosci. 21:6597-6607(2001).
 RN [13]
 RP INTERACTION WITH MAPK8IP1, AND PHOSPHORYLATION.
 RX MEDLINE=22028091; PubMed=11912189;
 RA Taru H., Iijima K.-I., Hase M., Kirino Y., Yagi Y., Suzuki T.;
 RT "Interaction of Alzheimer's beta-amyloid precursor family proteins
 RT with scaffold proteins of the JNK signaling cascade.";
 RL J. Biol. Chem. 277:20070-20078(2002).
 RN [14]
 RP INTERACTION OF CTF PEPTIDES WITH NUMB.
 RX PubMed=12011466;
 RA Roncarati R., Sestan N., Scheinfeld M.H., Berechid B.E., Lopez P.A.,
 RA Meucci O., McGlade J.C., Rakic P., D'Adamio L.;
 RT "The gamma-secretase-generated intracellular domain of beta-amyloid
 RT precursor protein binds Numb and inhibits Notch signaling.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:7102-7107(2002).
 RN [15]
 RP GAMMA-SECRETASE PROCESSING, AND INTERACTION WITH APBB1.
 RX PubMed=11553691;
 RA Cupers P., Orlans I., Craessaerts K., Annaert W., De Strooper B.;
 RT "The amyloid precursor protein (APP)-cytoplasmic fragment generated by
 RT gamma-secretase is rapidly degraded but distributes partially in a
 RT nuclear fraction of neurones in culture.";
 RL J. Neurochem. 78:1168-1178(2001).
 CC -!- FUNCTION: Functions as a cell surface receptor and performs
 CC physiological functions on the surface of neurons relevant to
 CC neurite growth, neuronal adhesion and axonogenesis. Involved in
 CC cell mobility and transcription regulation through protein-protein
 CC interactions. Can promote transcription activation through binding
 CC to APBB1/Tip60 and inhibit Notch signaling through interaction
 CC with Numb. Couples to apoptosis-inducing pathways such as those
 CC mediated by G(O) and JIP. Inhibits G(O) alpha ATPase activity (By
 CC similarity). Acts as a kinesin I membrane receptor, mediating the
 CC axonal transport of beta-secretase and presenilin 1. May be
 CC involved in copper homeostasis/oxidative stress through copper ion
 CC reduction. Can regulate neurite outgrowth through binding to
 CC components of the extracellular matrix such as heparin and
 CC collagen I and IV (By similarity). The splice isoforms that
 CC contain the BPTI domain possess protease inhibitor activity (By
 CC similarity).
 CC -!- FUNCTION: Beta-amyloid peptides are lipophilic metal chelators
 CC with metal-reducing activity. Bind transient metals such as
 CC copper, zinc and iron. Rat and mouse beta-amyloid peptides bind
 CC only weakly transient metals and have little reducing activity due
 CC to substitutions of transient metal chelating residues. Beta-APP42
 CC may activate mononuclear phagocytes in the brain and elicit
 CC inflammatory responses. Promotes both tau aggregation and TPK II-
 CC mediated phosphorylation (By similarity).
 CC -!- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved
 CC peptides, including C31, are potent enhancers of neuronal
 CC apoptosis.
 CC -!- SUBUNIT: Binds, via its C-terminal, to the PID domain of several
 CC cytoplasmic proteins, including APBB family members, the APBA
 CC family, MAPK8IP1, SHC1, Numb and Dab1. Binding to Dab1 inhibits
 CC its serine phosphorylation. Also interacts with GPCR-like protein
 CC BPP, FPRL1, APPBP1, IB1, KNS2 (via its TPR domains), APPBP2 (via

CC BaSS) and DDB1 (By similarity). In vitro, it binds MAPT via the
 CC MT-binding domains (By similarity). Associates with microtubules
 CC in the presence of ATP and in a kinesin-dependent manner (By
 CC similarity). Interacts, through a C-terminal domain, with GNAO1
 CC (By similarity). Amyloid beta-42 binds CHRNA7 in hippocampal
 CC neurons (By similarity). Beta-amyloid associates with HADH2 (By
 CC similarity).
 CC -!- SUBCELLULAR LOCATION: Type I membrane protein. Cell surface
 CC protein that rapidly becomes internalized via clatherin-coated
 CC pits. During maturation, the immature APP (N-glycosylated in the
 CC endoplasmic reticulum) moves to the Golgi complex where complete

Query Match 89.8%; Score 44; DB 1; Length 770;
 Best Local Similarity 100.0%; Pred. No. 0.26;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEF 9
 |||||
 Db 667 SEVKMDAEF 675

RESULT 12

A4_RAT

ID A4_RAT STANDARD; PRT; 770 AA.
 AC P08592;
 DT 01-AUG-1988 (Rel. 08, Created)
 DT 01-DEC-1992 (Rel. 24, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Amyloid beta A4 protein precursor (APP) (Alzheimer's disease amyloid
 DE protein homolog) (Amyloidogenic glycoprotein) (AG) [Contains: Soluble
 DE APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-
 DE amyloid protein 42 (Beta-APP42); Beta-amyloid protein 40 (Beta-APP40);
 DE C83; P3(42); P3(40); Gamma-CTF(59) (Gamma-secretase C-terminal
 DE fragment 59); Gamma-CTF(57) (Gamma-secretase C-terminal fragment 57);
 DE Gamma-CTF(50) (Gamma-secretase C-terminal fragment 50); C31].
 GN APP.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORM APP695).
 RC TISSUE=Brain;
 RX MEDLINE=88312583; PubMed=2900758;
 RA Shivers B.D., Hilbich C., Multhaup G., Salbaum J.M., Beyreuther K.,
 RA Seeburg P.H.;
 RT "Alzheimer's disease amyloidogenic glycoprotein: expression pattern
 RT in rat brain suggests a role in cell contact.";
 RL EMBO J. 7:1365-1370(1988).
 RN [2]
 RP SEQUENCE OF 289-364 FROM N.A.
 RC TISSUE=Liver;
 RX MEDLINE=89183625; PubMed=2648331;
 RA Kang J., Mueller-Hill B.;
 RT "The sequence of the two extra exons in rat preA4.";
 RL Nucleic Acids Res. 17:2130-2130(1989).
 RN [3]

RP SEQUENCE OF 720-730, AND MASS SPECTROMETRY.
 RX PubMed=11483588;
 RA Gu Y., Misonou H., Sato T., Dohmae N., Takio K., Ihara Y.;
 RT "Distinct intramembrane cleavage of the beta-amyloid precursor protein
 RT family resembling gamma-secretase-like cleavage of Notch.";
 RL J. Biol. Chem. 276:35235-35238(2001).
 RN [4]
 RP ALTERNATIVE SPLICING.
 RX PubMed=8624099;
 RA Sandbrink R., Masters C.L., Beyreuther K.;
 RT "APP gene family. Alternative splicing generates functionally related
 RT isoforms.";
 RL Ann. N.Y. Acad. Sci. 777:281-287(1996).
 RN [5]
 RP TISSUE SPECIFICITY OF APPICAN.
 RX PubMed=7744833;
 RA Shioi J., Pangalos M.N., Ripellino J.A., Vassilacopoulou D.,
 RA Mytilineou C., Margolis R.U., Robakis N.K.;
 RT "The Alzheimer amyloid precursor proteoglycan (appican) is present in
 RT brain and is produced by astrocytes but not by neurons in primary
 RT neural cultures.";
 RL J. Biol. Chem. 270:11839-11844(1995).
 RN [6]
 RP TISSUE SPECIFICITY OF ISOFORMS.
 RX PubMed=8996834;
 RA Sandbrink R., Monning U., Masters C.L., Beyreuther K.;
 RT "Expression of the APP gene family in brain cells, brain development
 RT and aging.";
 RL Gerontology 43:119-131(1997).
 RN [7]
 RP INTERACTION WITH DDB1, AND MUTAGENESIS OF TYR-757; ASN-759 AND
 RP TYR-762.
 RX PubMed=9930726;
 RA Watanabe T., Sukegawa J., Tomita S., Iijima K.-I., Oguchi S.,
 RA Suzuki T., Nairn A.C., Greengard P.;
 RT "A 127-kDa protein (UV-DDB) binds to the cytoplasmic domain of the
 RT Alzheimer's amyloid precursor protein.";
 RL J. Neurochem. 72:549-556(1999).
 RN [8]
 RP INTERACTION WITH GNAO1, AND MUTAGENESIS OF HIS-732 AND HIS-733.
 RX PubMed=10024358;
 RA Brouillet E., Trembleau A., Galanaud D., Volovitch M., Bouillot C.,
 RA Valenza C., Prochiantz A., Allinquant B.;
 RT "The amyloid precursor protein interacts with Go heterotrimeric
 RT protein within a cell compartment specialized in signal
 RT transduction.";
 RL J. Neurosci. 19:1717-1727(1999).
 RN [9]
 RP CHARACTERISTICS OF APPICAN, AND MUTAGENESIS OF SER-656.
 RX MEDLINE=95256193; PubMed=7737970;
 RA Pangalos M.N., Efthimiopoulos S., Shioi J., Robakis N.K.;
 RT "The chondroitin sulfate attachment site of appican is formed by
 RT splicing out exon 15 of the amyloid precursor gene.";
 RL J. Biol. Chem. 270:10388-10391(1995).
 RN [10]
 RP BETA-AMYLOID METAL-BINDING.
 RX PubMed=10386999;

RA Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E.,
 RA Scarpa R.C., Cuajungco M.P., Gray D.N., Lim J., Moir R.D., Tanzi R.E.,
 RA Bush A.I.;
 RT "The A beta peptide of Alzheimer's disease directly produces hydrogen
 RT peroxide through metal ion reduction.";
 RL Biochemistry 38:7609-7616(1999).
 RN [11]
 RP BETA-AMYLOID ZINC BINDING.
 RX MEDLINE=99343552; PubMed=10413512;
 RA Liu S.T., Howlett G., Barrow C.J.;
 RT "Histidine-13 is a crucial residue in the zinc ion-induced aggregation
 RT of the A beta peptide of Alzheimer's disease.";
 RL Biochemistry 38:9373-9378(1999).
 RN [12]
 RP IMPORTANCE OF GLY-704 IN FREE RADICAL PROPAGATION, AND MUTAGENESIS OF
 RP GLY-704.
 RX PubMed=11959460;
 RA Kanski J., Varadarajan S., Aksenova M., Butterfield D.A.;
 RT "Role of glycine-33 and methionine-35 in Alzheimer's amyloid beta-
 RT peptide 1-42-associated oxidative stress and neurotoxicity.";
 RL Biochim. Biophys. Acta 1586:190-198(2001).
 RN [13]
 RP PHOSPHORYLATION.
 RX PubMed=9085254;
 RA Oishi M., Nairn A.C., Czernik A.J., Lim G.S., Isohara T., Gandy S.E.,
 RA Greengard P., Suzuki T.;
 RT "The cytoplasmic domain of Alzheimer's amyloid precursor protein is
 RT phosphorylated at Thr654, Ser655, and Thr668 in adult rat brain and
 RT cultured cells.";
 RL Mol. Med. 3:111-123(1997).
 RN [14]
 RP PHOSPHORYLATION ON SER-730.
 RX PubMed=10329382;
 RA Isohara T., Horiuchi A., Watanabe T., Ando K., Czernik A.J., Uno I.,
 RA Greengard P., Nairn A.C., Suzuki T.;
 RT "Phosphorylation of the cytoplasmic domain of Alzheimer's beta-amyloid
 RT precursor protein at Ser655 by a novel protein kinase.";
 RL Biochem. Biophys. Res. Commun. 258:300-305(1999).
 RN [15]
 RP PHOSPHORYLATION, INDUCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
 RP THR-743.
 RX MEDLINE=99274744; PubMed=10341243;
 RA Ando K., Oishi M., Takeda S., Iijima K.-I., Isohara T., Nairn A.C.,
 RA Kirino Y., Greengard P., Suzuki T.;
 RT "Role of phosphorylation of Alzheimer's amyloid precursor protein
 RT during neuronal differentiation.";
 RL J. Neurosci. 19:4421-4427(1999).
 RN [16]
 RP PHOSPHORYLATION ON THR-743.
 RX PubMed=10936190;
 RA Iijima K.-I., Ando K., Takeda S., Satoh Y., Seki T., Itohara S.,
 RA Greengard P., Kirino Y., Nairn A.C., Suzuki T.;
 RT "Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor
 RT protein by cyclin-dependent kinase 5.";
 RL J. Neurochem. 75:1085-1091(2000).
 RN [17]
 RP CARBOHYDRATE STRUCTURE OF APPICAN.

RX PubMed=11479316;
RA Tsuchida K., Shioi J., Yamada S., Boghosian G., Wu A., Cai H.,
RA Sugahara K., Robakis N.K.;
RT "Appican, the proteoglycan form of the amyloid precursor protein,
RT contains chondroitin sulfate E in the repeating disaccharide region
RT and 4-O-sulfated galactose in the linkage region.";
RL J. Biol. Chem. 276:37155-37160(2001).
CC -!- FUNCTION: Functions as a cell surface receptor and performs
CC physiological functions on the surface of neurons relevant to
CC neurite growth, neuronal adhesion and axonogenesis. Involved in
CC cell mobility and transcription regulation through protein-protein
CC interactions (By similarity). Can promote transcription activation
CC through binding to APBB1/Tip60 and inhibit Notch signaling through
CC interaction with Numb (By similarity). Couples to apoptosis-
CC inducing pathways such as those mediated by G(0) and JIP. Inhibits
CC G(0) alpha ATPase activity. Acts as a kinesin I membrane receptor,
CC mediating the axonal transport of beta-secretase and presenilin 1
CC (By similarity). May be involved in copper homeostasis/oxidative
CC stress through copper ion reduction. Can regulate neurite
CC outgrowth through binding to components of the extracellular
CC matrix such as heparin and collagen I and IV (By similarity). The
CC splice isoforms that contain the BPTI domain possess protease
CC inhibitor activity (By similarity).
CC -!- FUNCTION: Beta-amyloid peptides are lipophilic metal chelators
CC with metal-reducing activity. Bind transient metals such as
CC copper, zinc and iron. Rat and mouse beta-amyloid peptides bind
CC only weakly transient metals and have little reducing activity due
CC to substitutions of transient metal chelating residues. Beta-APP42
CC may activate mononuclear phagocytes in the brain and elicit
CC inflammatory responses. Promotes both tau aggregation and TPK II-
CC mediated phosphorylation (By similarity).
CC -!- FUNCTION: Appicans elicit adhesion of neural cells to the
CC extracellular matrix and may regulate neurite outgrowth in the
CC brain.
CC -!- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved
CC peptides, including C31, are potent enhancers of neuronal
CC apoptosis (By similarity).
CC -!- SUBUNIT: Binds, via its C-terminal, to the PID domain of several
CC cytoplasmic proteins, including APBB family members, the APBA
CC family, MAPK8IP1, SHC1 and Numb and Dab1 (By similarity). Binding
CC to Dab1 inhibits its serine phosphorylation (By similarity). Also
CC interacts with GPCR-like protein BPP, FPRL1, APPBP1, IBL, KNS2
CC (via its TPR domains), APPBP2 (via BaSS) (By similarity) and DDB1.
CC In vitro, it binds MAPT via the MT-binding domains (By
CC similarity). Associates with microtubules in the presence of ATP
CC and in a kinesin-dependent manner (By similarity). Interacts,
CC through a C-terminal domain, with GNAO1. Amyloid beta-42 binds
CC CHRNA7 in hippocampal neurons (By similarity). Beta-amyloid
CC associates with HADH2 (By similarity).
CC -!- SUBCELLULAR LOCATION: Type I membrane protein. Cell surface
CC protein that rapidly becomes internalized via clatherin-coated
CC pits. During maturation, the immature APP (N-glycosylated in the

Query Match 89.8%; Score 44; DB 1; Length 770;
Best Local Similarity 100.0%; Pred. No. 0.26;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SEVKMDAEF 9
| | | | |
Db 667 SEVKMDAEF 675

RESULT 13

T2S1_STRFI

ID T2S1_STRFI STANDARD; PRT; 269 AA.
AC O52512;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Type II restriction enzyme SfiI (EC 3.1.21.4) (Endonuclease SfiI)
DE (R.SfiI).
GN SFIIR.
OS Streptomyces fimbriatus.
OC Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
OC Streptomycineae; Streptomycetaceae; Streptomyces.
OX NCBI_TaxID=68197;
RN [1]
RP SEQUENCE FROM N.A.
RA van Cott E.M., Moran L.S., Slatko B.E., Wilson G.G.;
RT "Characterization of the SfiI restriction and modification genes."
RL Submitted (DEC-1997) to the EMBL/GenBank/DDBJ databases.
CC -!- FUNCTION: Recognizes the double-stranded sequence GGCCNNNNNGGCC
CC and cleaves before N-9.
CC -!- CATALYTIC ACTIVITY: Endonucleolytic cleavage of DNA to give
CC specific double-stranded fragments with terminal 5'-phosphates.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF039750; AAB95365.1; -.
DR REBASE; 1655; SfiI.
KW Restriction system; Hydrolase; Nuclease; Endonuclease.
SQ SEQUENCE 269 AA; 31044 MW; 3C48499BAA5205EA CRC64;

Query Match 75.5%; Score 37; DB 1; Length 269;
Best Local Similarity 70.0%; Pred. No. 2.6;
Matches 7; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 SEVKMDAEFR 10
|::| | | | |
Db 115 SQLPMDAEFR 124

RESULT 14

PGCV_CHICK

ID PGCV_CHICK STANDARD; PRT; 3562 AA.
AC Q90953; Q90945;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)

DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Versican core protein precursor (Large fibroblast proteoglycan)
 DE (Chondroitin sulfate proteoglycan core protein 2) (PG-M).
 GN CPSG2.
 OS Gallus gallus (Chicken).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
 OC Gallus.
 OX NCBI_TaxID=9031;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORMS V0 AND V1).
 RC STRAIN=White leghorn; TISSUE=Limb bud;
 RX MEDLINE=93300846; PubMed=8314802;
 RA Shinomura T., Nishida Y., Ito K., Kimata K.;
 RT "cDNA cloning of PG-M, a large chondroitin sulfate proteoglycan
 RT expressed during chondrogenesis in chick limb buds. Alternative
 RT spliced multiforms of PG-M and their relationships to versican."
 RL J. Biol. Chem. 268:14461-14469(1993).
 CC -!- FUNCTION: May play a role in intercellular signaling and in
 CC connecting cells with the extracellular matrix. May take part in
 CC the regulation of cell motility, growth and differentiation. Binds
 CC hyaluronic acid.
 CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix.
 CC -!- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=2;
 CC Comment=Additional isoforms seem to exist;
 CC Name=V0;
 CC IsoId=Q90953-1; Sequence=Displayed;
 CC Name=V1;
 CC IsoId=Q90953-2; Sequence=VSP_003093;
 CC -!- TISSUE SPECIFICITY: Prechondrogenic condensation area of
 CC developing limb buds.
 CC -!- DEVELOPMENTAL STAGE: Disappears after the cartilage development
 CC (By similarity).
 CC -!- SIMILARITY: Contains 1 immunoglobulin-like V-type domain.
 CC -!- SIMILARITY: Contains 2 link domains.
 CC -!- SIMILARITY: Contains 2 EGF-like domains.
 CC -!- SIMILARITY: Contains 1 C-type lectin family domain.
 CC -!- SIMILARITY: Contains 1 Sushi (SCR) domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; X60226; CAA42787.1; -.
 DR EMBL; D13542; BAA02742.1; -.
 DR PIR; A47171; A47171.
 DR HSSP; P00740; 1EDM.
 DR InterPro; IPR000152; Asx_hydroxyl.
 DR InterPro; IPR000742; EGF_2.
 DR InterPro; IPR001881; EGF_Ca.
 DR InterPro; IPR006209; EGF_like.
 DR InterPro; IPR007110; Ig-like.

DR InterPro; IPR003599; Ig.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR001304; Lectin_C.
 DR InterPro; IPR000538; Link.
 DR InterPro; IPR000436; Sushi_SCR_CCP.
 DR Pfam; PF00008; EGF; 2.
 DR Pfam; PF00047; ig; 1.
 DR Pfam; PF00059; lectin_c; 1.
 DR Pfam; PF00084; sushi; 1.
 DR Pfam; PF00193; Xlink; 2.
 DR PRINTS; PR01265; LINKMODULE.
 DR ProDom; PD000918; Link; 2.
 DR SMART; SM00032; CCP; 1.
 DR SMART; SM00034; CLECT; 1.
 DR SMART; SM00179; EGF_CA; 1.
 DR SMART; SM00409; IG; 1.
 DR SMART; SM00445; LINK; 2.
 DR PROSITE; PS00010; ASX_HYDROXYL; 1.
 DR PROSITE; PS00615; C_TYPE_LLECTIN_1; 1.
 DR PROSITE; PS50041; C_TYPE_LLECTIN_2; 1.
 DR PROSITE; PS00022; EGF_1; 2.
 DR PROSITE; PS01186; EGF_2; 1.
 DR PROSITE; PS01187; EGF_CA; 1.
 DR PROSITE; PS50835; IG_LIKE; 1.
 DR PROSITE; PS01241; LINK; 2.
 KW Glycoprotein; Proteoglycan; Lectin; Extracellular matrix; Sushi;
 KW Signal; Repeat; EGF-like domain; Calcium; Immunoglobulin domain;
 KW Hyaluronic acid; Alternative splicing.
 FT SIGNAL 1 26 POTENTIAL.
 FT CHAIN 27 3562 VERSICAN CORE PROTEIN.
 FT DOMAIN 27 143 IG-LIKE V-TYPE.
 FT DOMAIN 166 243 LINK 1.
 FT DOMAIN 264 345 LINK 2.
 FT DOMAIN 3254 3290 EGF-LIKE 1.
 FT DOMAIN 3292 3328 EGF-LIKE 2, CALCIUM-BINDING (POTENTIAL).
 FT DOMAIN 3341 3455 C-TYPE LECTIN.
 FT DOMAIN 3460 3518 SUSHI.
 FT DISULFID 44 129 BY SIMILARITY.
 FT DISULFID 171 242 BY SIMILARITY.
 FT DISULFID 195 216 BY SIMILARITY.
 FT DISULFID 269 344 BY SIMILARITY.
 FT DISULFID 293 314 BY SIMILARITY.
 FT DISULFID 3258 3269 BY SIMILARITY.
 FT DISULFID 3263 3278 BY SIMILARITY.
 FT DISULFID 3280 3289 BY SIMILARITY.
 FT DISULFID 3296 3307 BY SIMILARITY.
 FT DISULFID 3301 3316 BY SIMILARITY.
 FT DISULFID 3318 3327 BY SIMILARITY.
 FT DISULFID 3334 3345 BY SIMILARITY.
 FT DISULFID 3362 3454 BY SIMILARITY.
 FT DISULFID 3430 3446 BY SIMILARITY.
 FT DISULFID 3461 3504 BY SIMILARITY.
 FT DISULFID 3490 3517 BY SIMILARITY.
 FT CARBOHYD 163 163 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 235 235 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 329 329 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 529 529 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT	CARBOHYD	709	709	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	948	948	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	1409	1409	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	1479	1479	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	1523	1523	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	1530	1530	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	1625	1625	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	1751	1751	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	1988	1988	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	2088	2088	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	2089	2089	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	2507	2507	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	2642	2642	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	2679	2679	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	2748	2748	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	2762	2762	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	3069	3069	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	3194	3194	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	3232	3232	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	3545	3545	N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	VARSPLIC	485	1411	Missing (in isoform V1).
FT				/FTId=VSP_003093.
SQ	SEQUENCE	3562 AA;	388078 MW;	9BC566E88C1602D2 CRC64;

Query Match 69.4%; Score 34; DB 1; Length 3562;
 Best Local Similarity 66.7%; Pred. No. 1.4e+02;
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 SEVKMDAEF 9
 | :|:||||
 Db 1709 STIKLDAEF 1717

RESULT 15

APB_HUMAN

ID APB_HUMAN STANDARD; PRT; 4563 AA.
 AC P04114; O00502; Q13787;
 DT 01-NOV-1986 (Rel. 03, Created)
 DT 01-NOV-1986 (Rel. 03, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Apolipoprotein B-100 precursor (Apo B-100) [Contains: Apolipoprotein
 DE B-48 (Apo B-48)].
 GN APOB.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=87016385; PubMed=3763409;
 RA Knott T.C., Wallis S.C., Powell I.M., Pease R.J., Lusis A.J.,
 RA Blackhart B., McCarthy B.J., Mahley R.W., Levy-Wilson B., Scott J.;
 RT "Complete cDNA and derived protein sequence of human apolipoprotein
 RT B-100.";
 RL Nucleic Acids Res. 14:7501-7503(1986).
 RN [2]
 RP SEQUENCE FROM N.A.

RX MEDLINE=88003974; PubMed=3652907;
 RA Ludwig E.H., Blackhart B.D., Pierotti V.R., Caiati L., Fortier C.,
 RA Knott T., Scott J., Mahley R.W., Levy-Wilson B., McCarthy B.J.;
 RT "DNA sequence of the human apolipoprotein B gene.";
 RL DNA 6:363-372(1987).
 RN [3]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=87008488; PubMed=3759943;
 RA Chen S.-H., Yang C.-Y., Chen P.-F., Setzer D., Tanimura M., Li W.-H.,
 RA Gotto A.M. Jr., Chan L.;
 RT "The complete cDNA and amino acid sequence of human apolipoprotein
 RT B-100.";
 RL J. Biol. Chem. 261:12918-12921(1986).
 RN [4]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=87041416; PubMed=3464946;
 RA Law S.W., Grant S.M., Higuchi K., Hospattankar A.V., Lackner K.J.,
 RA Lee N., Brewer H.B. Jr.;
 RT "Human liver apolipoprotein B-100 cDNA: complete nucleic acid and
 RT derived amino acid sequence.";
 RL Proc. Natl. Acad. Sci. U.S.A. 83:8142-8146(1986).
 RN [5]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=87161758; PubMed=3030729;
 RA Cladaras C., Hadzopoulou-Cladaras M., Nolte R.T., Atkinson D.,
 RA Zannis V.I.;
 RT "The complete sequence and structural analysis of human
 RT apolipoprotein B-100: relationship between apoB-100 and apoB-48
 RT forms.";
 RL EMBO J. 5:3495-3507(1986).
 RN [6]
 RP SEQUENCE OF 709-906 FROM N.A.
 RX MEDLINE=85270450; PubMed=3860836;
 RA Deeb S.S., Motulsky A.G., Albers J.J.;
 RT "A partial cDNA clone for human apolipoprotein B.";
 RL Proc. Natl. Acad. Sci. U.S.A. 82:4983-4986(1985).
 RN [7]
 RP SEQUENCE OF 3056-3159 FROM N.A.
 RX MEDLINE=86041888; PubMed=3903660;
 RA Mehrabian M., Schumaker V.N., Fareed G.C., West R., Johnson D.F.,
 RA Kirchgessner T.G., Lin H.-C., Wang X., Ma Y., Mendiaz E., Lusis A.J.;
 RT "Human apolipoprotein B: identification of cDNA clones and
 RT characterization of mRNA.";
 RL Nucleic Acids Res. 13:6937-6953(1985).
 RN [8]
 RP SEQUENCE OF 1937-2018 AND 3811-4334 FROM N.A.
 RX MEDLINE=86093680; PubMed=3841204;
 RA Carlsson P., Olofsson S.O., Bondjers G., Darnfors C., Wiklund O.,
 RA Bjursell G.;
 RT "Molecular cloning of human apolipoprotein B cDNA.";
 RL Nucleic Acids Res. 13:8813-8826(1985).
 RN [9]
 RP SEQUENCE OF 3109-4563 FROM N.A.
 RX MEDLINE=85300528; PubMed=2994225;
 RA Knott T.J., Rall S.C. Jr., Innerarity T.L., Jacobson S.F.,
 RA Urdea M.S., Levy-Wilson B., Powell L.M., Pease R.J., Eddy R.,
 RA Nakai H., Byers M., Priestley L.M., Robertson E., Rall L.B.,

RA Betsholtz C., Shows T.B., Mahley R.W., Scott J.;
 RT "Human apolipoprotein B: structure of carboxyl-terminal domains,
 RT sites of gene expression, and chromosomal localization.";
 RL Science 230:37-43(1985).
 RN [10]
 RP SEQUENCE OF 1-291 FROM N.A.
 RX MEDLINE=86149325; PubMed=3513177;
 RA Protter A.A., Hardman D.A., Schilling J.W., Miller J., Appleby V.,
 RA Chen G.C., Kirsher S.W., McEnroe G., Kane J.P.;
 RT "Isolation of a cDNA clone encoding the amino-terminal region of
 RT human apolipoprotein B.";
 RL Proc. Natl. Acad. Sci. U.S.A. 83:1467-1471(1986).
 RN [11]
 RP SEQUENCE OF 1-1670 FROM N.A.
 RX MEDLINE=86287319; PubMed=3461454;
 RA Protter A.A., Hardman D.A., Sato K.Y., Schilling J.W.,
 RA Yamanaka M., Hort Y.J., Hjerrild K.A., Chen G.C., Kane J.P.;
 RT "Analysis of cDNA clones encoding the entire B-26 region of human
 RT apolipoprotein B.";
 RL Proc. Natl. Acad. Sci. U.S.A. 83:5678-5682(1986).
 RN [12]
 RP PARTIAL SEQUENCE, AND IDENTIFICATION OF APO-B48.
 RX MEDLINE=88018019; PubMed=3659919;
 RA Chen S.-H., Habib G., Yang C.-H., Gu Z.-W., Lee B.R., Weng S.-H.,
 RA Silberman S.R., Cai S.-J., Deslypere J.P., Rosseneu M.,
 RA Gotto A.M. Jr., Li W.-H., Chan L.;
 RT "Apolipoprotein B-48 is the product of a messenger RNA with an organ-
 RT specific in-frame stop codon.";
 RL Science 238:363-366(1987).
 RN [13]
 RP DOMAINS.
 RX MEDLINE=87039351; PubMed=3773997;
 RA Knott T.C., Pease R.J., Powell L.M., Wallis S.C., Rall S.C. Jr.,
 RA Innerarity T.L., Blackhart B., Taylor W.R., Marcel Y., Milne R.,
 RA Johnson D., Fuller M., Lusis A.J., McCarthy B.J., Mahley R.W.,
 RA Levy-Wilson B., Scott J.;
 RT "Complete protein sequence and identification of structural domains
 RT of human apolipoprotein B.";
 RL Nature 323:734-738(1986).
 RN [14]
 RP DOMAINS.
 RA Yang C.-Y., Chen S.-H., Gianturco S.H., Bradley W.A., Sparrow J.T.,
 RA Tanimura M., Li W.-H., Sparrow D.A., Deloof H., Rosseneu M.,
 RA Lee F.-S., Gu Z.-W., Gotto A.M. Jr., Chan L.;
 RT "Sequence, structure, receptor-binding domains and internal repeats
 RT of human apolipoprotein B-100.";
 RL Nature 323:738-742(1986).
 RN [15]
 RP CALCIUM-BINDING DATA.
 RX MEDLINE=86242245; PubMed=3087360;
 RA Dashti N., Lee D.M., Mok T.;
 RT "Apolipoprotein B is a calcium binding protein.";
 RL Biochem. Biophys. Res. Commun. 137:493-499(1986).
 RN [16]
 RP PALMITOYLATION OF CYS-1112.
 RX MEDLINE=20143590; PubMed=10679026;
 RA Zhao Y., McCabe J.B., Vance J., Berthiaume L.G.;

RT "Palmitoylation of apolipoprotein B is required for proper
 RT intracellular sorting and transport of cholesteryl esters and
 RT triglycerides.";
 RL Mol. Biol. Cell 11:721-734(2000).
 RN [17]
 RP VARIANT SER-4338.
 RX MEDLINE=91071750; PubMed=1979313;
 RA Navajas M., Laurent A.-M., Moreel J.-F., Ragab A., Cambou J.-P.,
 RA Cuny G., Cambien F., Roizes G.;
 RT "Detection by denaturing gradient gel electrophoresis of a new
 RT polymorphism in the apolipoprotein B gene.";
 RL Hum. Genet. 86:91-93(1990).
 RN [18]
 RP VARIANT FDB GLN-3527.
 RX MEDLINE=89098975; PubMed=2563166;
 RA Soria L.F., Ludwig E.H., Clarke H.R.G., Vega G.L., Grundy S.M.,
 RA McCarthy B.J.;
 RT "Association between a specific apolipoprotein B mutation and
 RT familial defective apolipoprotein B-100.";
 RL Proc. Natl. Acad. Sci. U.S.A. 86:587-591(1989).
 RN [19]
 RP VARIANT LEU-2739.
 RX MEDLINE=91016974; PubMed=2216805;
 RA Huang L.-S., Gavish D., Breslow J.L.;
 RT "Sequence polymorphism in the human apoB gene at position 8344.";
 RL Nucleic Acids Res. 18:5922-5922(1990).
 RN [20]
 RP VARIANT FDB CYS-3558.
 RX MEDLINE=95190020; PubMed=7883971;
 RA Pullinger C.R., Hennessy L.K., Chatterton J.E., Liu W., Love J.A.,
 RA Mendel C.M., Frost P.H., Malloy M.J., Schumaker V.N., Kane J.P.;
 RT "Familial ligand-defective apolipoprotein B. Identification of a new
 RT mutation that decreases LDL receptor binding affinity.";
 RL J. Clin. Invest. 95:1225-1234(1995).
 RN [21]
 RP VARIANTS LEU-1437; SER-1914; LYS-2566; THR-3121; ALA-3945; MET-4128
 RP AND THR-4481.
 RX MEDLINE=97044521; PubMed=8889592;
 RA Poirier O., Ricard S., Behague I., Souriau C., Evans A.E.,
 RA Arveiler D., Marques-Vidal P., Luc G., Roizes G., Cambien F.;
 RT "Detection of new variants in the apolipoprotein B (Apo B) gene by
 RT PCR-SSCP.";
 RL Hum. Mutat. 8:282-285(1996).
 RN [22]
 RP VARIANTS FDB GLN-3527 AND CYS-3558.
 RX MEDLINE=97403938; PubMed=9259199;
 RA Rabes J.P., Varret M., Saint-Jore B., Erlich D., Jondeau G.,
 RA Krempf M., Giraudet P., Junien C., Boileau C.;
 RT "Familial ligand-defective apolipoprotein B-100: simultaneous
 RT detection of the ARG3500-->GLN and ARG3531-->CYS mutations in a
 RT French population.";
 RL Hum. Mutat. 10:160-163(1997).
 RN [23]
 RP VARIANTS SER-1914; ARG-1923; LEU-2739; ASP-3319; THR-3427; GLN-3432
 RP AND ILE-3921.
 RX MEDLINE=98141125; PubMed=9490296;
 RA Leren T.P., Bakken K.S., Hoel V., Hjermann I., Berg K.;

RT "Screening for mutations of the apolipoprotein B gene causing
RT hypocholesterolemia.";
RL Hum. Genet. 102:44-49(1998).
CC -!- FUNCTION: APOLIPOPROTEIN B IS A MAJOR PROTEIN CONSTITUENT OF
CC CHYLOMICRONS, VLDL AND LDL. IT FUNCTIONS AS A RECOGNITION SIGNAL
CC FOR THE CELLULAR BINDING AND INTERNALIZATION OF LDL PARTICLES BY
CC THE APOB/E RECEPTOR.

Query Match 69.4%; Score 34; DB 1; Length 4563;
Best Local Similarity 66.7%; Pred. No. 1.8e+02;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2 EVKMDAEFR 10
|||:| :||
Db 1483 EVKIDGQFR 1491

Search completed: January 21, 2004, 09:23:05
Job time : 2.49713 secs